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Abstract 
Introduction Cytochromes P450 (CYPs) are the major family of enzymes 
responsible for detoxification and metabolism of a wide range of both endogenous 
and xenobiotics chemicals in living organisms. The use of CYPs to activate prodrugs 
to cytotoxins selectively in tumours has been explored including AQ4N, Phortress 
and Aminoflavone. CYP1A1, CYP1B1, CYP2W1, and CYP4F11 have been 
identified as expressed in tumour tissue and surrounding stroma at high frequency 
compared to most normal tissues.  
Aim is to investigate the differential metabolism of novel chloromethylindoline by 
high frequency expressed CYPs in tumours. This differential may be exploited to 
elicit a selective chemotherapeutic effect by metabolising inert small molecules to 
potent cytotoxins within the tumour environment.   
Materials and Methods Sensitive and specific LC/MS/MS techniques have been 
developed to investigate the metabolism of chloromethylindolines. Recombinant 
enzymes and transfected cell lines were used to investigate the metabolic profiles 
with a focus on production of the cytotoxic derivatives of chloromethylindolines.   
Results Detailed metabolic studies show that (1-(Chloromethyl)-1,2-dihydropyrrolo 
[3,2-e]indol-3(6H)-yl)(5-methoxy-1H-indol-2-yl) methanone (ICT2700) and other 
chloromethylindolines are converted by CYP1A1 mediated hydroxylation at the C-5 
position leading to highly potent metabolites. In vitro cytotoxicity studies showed 
differentials of up to 1000-fold was achieved between CYP1A1 activated compared 
to the non-metabolised parent molecules. The reactivity of metabolites of ICT2700 
was also explored using glutathione as a nucleophile. The metabolites were identified 
by a combination of LC/MS and LC MS/MS techniques. Investigations using mouse 
and human liver microsomes show that a large number of metabolites are created 
though none were shown to be associated with a potential anticancer effect. Studies 
focused on CYP2W1 show that this isoform metabolised ICT2706 to a cytotoxic 
species and a pharmacokinetic study showed a good distribution of ICT2706 into 
mouse tissues including tumour. However metabolism of ICT2726 by CYP2W1 
resulted only in a non-toxic metabolite profile and may have potential as a biomarker 
for functional CYP2W1 in tissues. Preliminary studies show that palmitic acid 
hydroxylation is a useful marker of functional CYP4F11.  
Summary and conclusion The in vitro results show that the chloromethylindolines 
are a novel class of agent with potential as prodrugs that following specific 
hydroxylation by CYP1A1 and CYP2W1 are converted to ultra-potent cytotoxins. 
Other metabolites are also evident which are not cytotoxic. Studies in vivo show that 
selected chloromethylindolines possess a good pharmacokinetic profile and show 
potential as prodrug anticancer agents that require activation by CYP1A1 or 
CYP2W1. The methods, results, progress and suggestions for future work are 
presented in this thesis. 
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I.  Introduction 
I .1. Cancer  
Cancer is a cellular disease that arises from the loss of the ability of cells to 
respond normally to intracellular and/or extracellular signalling pathways that 
govern the balance between proliferation, differentiation and death (Tannock 
et al., 2005). 
This inability to control the cellular balance leads to abnormal and 
uncontrolled division of cells. Cells grow rapidly and form a mass or tumour 
(Becker, 2009; King, 2000). Tumours can be malignant when they grow, 
invade and spread (metastasise) to other tissues in the body. However, the 
primary tumour of the majority of cancers takes time to grow before 
metastasis occurs. This is considered to be good when the treatment is 
applied in the early stages of the disease to achieve a complete cure by total 
removal of the primary tumour (Knowles and Selby, 2005). 
In the UK, more than 300,000 individuals are diagnosed with cancer every 
year (excluding non- melanoma skin cancer). Despite remaining constant 
over the past decade, the incidence of cancer has increased by 28% in the 
last three decades and more than 1 in 3 people are expected to develop 
some form of cancer during their lifetime. In 2009, more than 156,000 deaths 
in the UK were due to cancer, comprising 28% of all deaths in the UK. There 
are more than 200 different types of cancer. The four most commonly 
observed are breast (16%), lung (13%), colorectal (13%) and prostate (12%). 
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With regard to mortality, lung cancer is the leading cause of death (22%), 
followed by colorectal cancer (10%) and breast cancer (8%) (Cancer 
Research UK, 2011). 
The main cancer treatment modalities are surgery, radiotherapy, 
chemotherapy and biological therapy. The treatment strategies for cancer 
depend on a number of factors including type of tumour, tumour location, and 
extent of invasion. Patients with limited metastatic disease may benefit from 
surgical therapy. Removing part of the tumour (biopsy) can give an accurate 
diagnosis and prognosis. Investigating a sample to determine tumour type, 
grade, and hormonal/ receptor status can influence the treatment regime. 
Similarly to surgical therapy, radiotherapy is used to treat localised tumours. 
The principle of radiotherapy is that ionising radiations easily transfer 
electrons to oxygen generating reactive oxygen species (ROS), which leads 
to DNA damage, and this damage cannot be repaired by tumour cells. 
Normal cells can survive because they still have working repair systems (King, 
2000). Unfortunately this therapy may affect other healthy cells such as blood 
cells. Moreover, lack of oxygen (hypoxic cells) in tumours results in 
resistance to radiation compared to normal oxygenated cancer cells (King, 
2000). Cytotoxic chemotherapy kills cancer cells mainly by damaging DNA, 
interfering with DNA synthesis and inhibiting cell division. Chemotherapeutics 
and hormonal therapy can face some problems with adverse symptoms and 
drug resistance (Dipirio, 2007).   
Instead of using cytotoxic systemic treatments for cancer, new specific 
agents for tumour targeting have been developed based on a better 
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understanding of tumour cellular biology and enzymology. In colorectal 
cancer, for example, a monoclonal antibody that inhibits the receptor for 
vascular endothelial growth factor, important in the process of angiogenesis, 
can improve survival for patients (Tannock et al., 2005). 
Over recent years, enzyme contributions to the metabolism of anticancer 
agents and drug-drug interactions have also been explored. Examples of 
such enzymes are the cytochrome P450s (CYPs) (Bruno and Njar, 2007) and 
proteases (Yang et al., 2009). More recently, the use of CYPs to activate 
novel anticancer agents selectively in tumours is being explored with agents 
such as phortress [2-(4-amino-3-methylphenyl)-5 fluorobenzothiazole 
lysylamide dihydrochloride], a prodrug, catalyzed by CYP 1A1, resulting in 
electrophilic intermediate metabolites which form DNA adducts, leading to 
highly selective cell death (National Cancer Institute, 2011). At present 
phortress is being tested in clinical phase I trials (Cancer Research UK, 2011).  
The Institute of Cancer Therapeutics (ICT) at the University of Bradford aims 
to research and develop new treatments with a focus on cancer. The team of 
researchers uses a range of skills and equipments within the Institute to take 
the drug through all the necessary preclinical testing. 
I.2. Cytochromes P450 
I.2.1. Introduction 
The cytochrome P450 (CYP) super-family, whose name derives from their 
cellular (cyto) location and characteristics (chrome) when complexed to 
carbon monoxide, absorb light at wavelengths around 450 nm (Figure 1.1) 
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(Omura and Sato, 1962). This is a large and diverse group of enzymes found 
in both prokaryote and eukaryote organisms (Nelson et al., 1996). 
 
Figure 1.1: A typical CO- difference spectrum of Pigment 450 showing the reduced form of 
P450s, when complexed to carbon monoxide, absorbing visible light with a lambda max at 
450 nm.  
Unlike other haem containing proteins, CYPs have four ligands provided by 
nitrogens on the haem ring. Near the haem, there is a region for two ligands. 
One ligand is a thiolate anion that contains the functional group composed of 
negatively charged sulphur. The sulphur comes from a conserved cysteine at 
the haem binding area of the active site. These properties give CYPs an 
unusual spectrum at 450nm (Montellano, 1995; Yano et al., 2004). 
CYP enzymes catalyze many types of reactions. The most common is 
hydroxylation, and the general reaction of hydroxylation catalyzed by CYPs is 
RH + O2 + 2H
+ + 2e–      CYP       ROH + H2O 
The RH represents multitudes of substrates including N- and O-alkyl drugs, 
fatty acids, and xenobiotics such as carcinogens and chemotherapeutics.  
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The ROH product may be more or less therapeutically active than the RH but 
it is more polar and thus more water soluble. In consequence, the CYP 
system can activate or deactivate compounds (Montellano, 1995).  
CYP enzymes are called monooxygenases because of the insertion of one 
atom of oxygen into a substrate while the other oxygen atom is reduced to 
water. The insertion of two electrons (reduction) to the CYP haem can break 
the strong bond of a di-oxygen molecule. To initiate the reaction, CYPs need 
a source of electrons. The electrons are donated one by one from another 
source. This transfer of electrons is called an electron transfer chain 
(Wiseman, 2004).  
CYPs have two different redox systems for the electron transfer chain, 
depending on whether the enzymes conjugate in the smooth endoplasmic 
reticulum (ER) or in the mitochondrial inner membrane (Hazzard et al., 1997). 
The electron transfer chain in the endoplasmic reticulum initiates when the 
flavin adenine dinucleotide (FAD) cofactor, containing enzyme NADPH-P450 
reductase (CPR), accepts electrons from nicotinamide adenine dinucleotide 
phosphate reduced (NADPH), transfers them to the flavin mononucleotide 
(FMN) cofactor located in CPR, then passes them to the haem iron group in 
cytochrome P450 (Scheme 1.1)(Lewis and Hlavica, 2000; Wang et al., 1997; 
Zhao et al., 1999) (Figure 1.2).  
 
NADPH → FAD → FMN → P450 → O2 
Scheme 1.1: The general flow of electron transfer in the CYPs bound to the smooth 
endoplasmic reticulum. 
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On the other hand the system in human adrenal mitochondria, which is 
similar to that of many prokaryotes except for the source of protons (NADH in 
prokaryotes), transfers ferredoxin electrons from NADPH-dependent 
ferredoxin reductase (a flavoprotein containing FAD)  to cytochrome P450 
(Lewis and Hlavica, 2000; Pochapsky et al., 1996; Xia et al., 1995) (Scheme 
1.2). Cytochrome b5 can serve as a second source of electrons, either from 
CPR or cytochrome b5 reductase (Bridges et al., 1998). 
NAD(P)H → FAD → Fe2S2 → P450 → O2 
 
Scheme 1.2: The general flow of electron transfer in CYPs bound to the mitochondrial 
membrane and free cytosolic enzymes in some prokaryotes.  
 
 
Figure 1.2: Structure of a biological microsomal membrane showing the correlation between 
cytochromes P450 (CYPs) and NADPH- P450 reductase (CPR). (A) CPR enzyme associates 
with both flavin adenine dinucleotide (FAD) and flavin mononucleotide (FMN). The CPR 
enzyme accepts a pair of electrons from nicotinamide adenine dinucleotide phosphate 
reduced (NADPH) and transfers them one at a time to a P450 molecule. (B) Three-
dimensional structure of CPR. The cofactors are shown as ball and sticks, FAD in yellow, 
FMN in light blue and NADP
+
 in orange. Modified from (Wang et al., 1997). 
In mammals CYPs are primarily membrane bound, the majority in the ER or 
in the inner mitochondrial membrane of cells. The presence of a lipophilic    
N-terminal helix acts to anchor the protein in the hydrophobic core of the lipid 
A B 
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bilayer membrane. The general shape of CYPs involves 12 helices and loops 
denoted A-L. In addition, a few β-sheets are present in CYP structures.    
Between the B and C helices is the B-C loop region, and between the F and 
G helices is the F-G loop region. These loop regions help mediate the access 
of molecules to the CYP active site. The G helix is also in part embedded in 
the membrane due to its hydrophobic characteristic, bringing the F-G loop 
region partially into the membrane. This leaves the hydrophilic C-terminal 
exposed in the cytosol (Figure 1.3) (Williams et al., 2000b) .  
Mammalian CYPs are highly expressed in the liver and found in all other 
tissues as well as a number of cancers including the kidney, breast, and 
prostate (Hukkanen et al., 2002; Williams et al., 2000a).  
 
Figure 1.3: Topology of CYP. (A) the fold of CYP shows the N terminus in blue dye, the C 
terminus in red, and the general location of the F-G loop. (B) Position of the haem moiety in 
the conserved haem binding site illustrating the interactions of all of the components and the 
common folding of the CYP. Adapted from (Williams et al., 2000b). 
 
A B 
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I .2.2. CYPs in humans 
 The main functions of CYPs in mammals are:  
1) Synthesis of steroid hormones and cholesterol  
2) Synthesis of Vitamin D and Vitamin A  
3) Metabolism of endogenous compounds especially fatty acids and 
steroids. 
4) Metabolism of exogenous compounds such as environmental pollutants, 
drugs and plant alkaloids (Williams et al., 2000b) 
During the past decade, major advances in knowledge about human CYPs 
have come from the evolution of many scientific fields. One is X-ray 
crystallography, and another is the study of genetic differences. The 
completion of the sequence for the human genome has confirmed there are 
57 different active genes encoding human CYPs and 58 pseudogenes 
(Guengerich, 2008). These human CYPs are distributed into 18 families and 
43 subfamilies. According to David Nelson, 11,294 CYPs had been identified 
and reported across all species by August, 2009. 
(http://drnelson.uthsc.edu/P450.statistics.Aug2009.pdf).  
 
I.2.3. CYPs nomenclature 
CYPs are classified based on gene sequence identity. There is a 40% amino 
acid similarity for membership in a family and a 55% rule for a subfamily.  
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Cytochrome P450 families are abbreviated by CYP followed by an Arabic 
number, for example CYP 3, CYP 4 and CYP 27. The subfamily is indicated 
by the addition of a letter, for example CYP 3A and CYP 4F. To prevent 
confusion with the numbers ‘0’ and ‘1’, the letters ‘O’ and ‘I’ have been not 
used as subfamily names. After this, the individual CYP is identified by 
another an Arabic numeral, for example CYP 1A1 is a different CYP from 
CYP 1A2, within the same family CYP 1 and the same subfamily CYP 1A  
(Nebert et al., 1991; Phillips and Shephard, 2006). 
The names of human CYP functional genes are: 
CYP 1A1 CYP 1A2 CYP 1B1 CYP 2A6 CYP 2A7 CYP 2A13 CYP 2B6 CYP 2C8 
CYP 2C9 CYP 2C18 CYP 2C19 CYP 2D6 CYP 2E1 CYP 2F1 CYP 2J2 CYP 2R1 
CYP 2S1 CYP 2U1 CYP 2W1 CYP 3A4 CYP 3A5 CYP 3A7 CYP 3A43 CYP 4A11 
CYP 4A22 CYP 4B1 CYP 4F2 CYP 4F3 CYP 4F8 CYP 4F11 CYP 4F12 CYP 4F22 
CYP 4V2 CYP 4X1 CYP 4Z1 CYP 5A1 CYP 7A1 CYP 7B1 CYP 8A1 CYP 8B1 
CYP 11A1 CYP 11B1 CYP 11B2 CYP 17 CYP 19 CYP 20 CYP 21A2 CYP 24 
CYP 26A1 CYP 26B1 CYP 26C1 CYP 27A1 CYP 27B1 CYP 27C1 CYP 39 CYP 46 
CYP 51 
       
 
I.2.3.1. The CYP 1 family  
The human CYP 1 family includes two subfamilies, CYP 1A and CYP 1B. The 
CYP 1A subfamily contains two members, CYP 1A1 and CYP 1A2, while the 
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CYP 1B subfamily has only one member, CYP 1B1, which is high frequency 
expressed in cancer cells including kidney, breast, brain, lung and colon 
(Chang et al., 2005; Hakkola et al., 1997; Muskhelishvili et al., 2001). In 
contrast, studies by (Patterson and Murray, 2002) have demonstrated that 
the expression of CYP 1A is not determined in specific tumour types of colon 
and ovarian cancers. The up-regulation and over-expression of CYPs in 
cancer is discussed in more detail in section I.3. 
CYP 1A1 and CYP 1A2 enzymes share approximately 70% homology in their 
amino acid sequences (Berndtson and Chen, 1994; Boyd et al., 1995; Wakui 
et al., 2005). CYP 1A2 represents 15% of the human hepatic CYP content 
(Shirley et al., 2003). Both CYP 1A1 and CYP 1A2 have been well studied 
because of their involvement in the activation of carcinogens. All the CYP 1 
family members are under transcriptional control of the aryl hydrocarbon 
receptor (AhR) and participate in the metabolism of endogenous substrates, 
as well as converting procarcinogens to active carcinogens such as polycyclic 
aromatic hydrocarbons (PAHs). CYP 1A is induced by PAHs and 2, 3, 7, 8-
tetra chlorodibenzo-p-dioxin in vivo (Hanioka et al., 2000). PAHs are 
generally found in environment pollutants including coal tars, vehicle exhaust, 
soot, and cigarette smoke (Spink et al., 2008). The CYP 1 family is involved 
in the activation of an inactive prodrug to a anticancer agent such as 
cyclophosphamide (Xie et al., 2002) and tamoxifen (Patterson, 2002a). 
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CYP 1A1 
The human CYP 1A1 enzyme is encoded by the CYP 1A1 gene located on 
chromosome 15. The enzyme contains 512 amino acids and is found on the 
ER membrane. CYP 1A1 is the major enzyme involved in the metabolic 
activation of procarcinogens. The metabolic activation of PAHs in tobacco 
smoke such as benzo[a] pyrene, a known human carcinogen, induces gene 
expression of CYP 1A1. A high frequency expression of CYP 1A1 in lung 
tissue has been found in smokers when compared to non-smokers. This is 
due to differences in the methylation of the CYP 1A1 promoter. Cigarette 
smoke correlates with decreased methylation and hence a higher CYP 1A1 
expression, which increases the possibility of developing lung cancer (Anttila 
et al., 2003; Oyama et al., 2004).  
There is a strong epidemiological relationship between the development of 
bladder cancer and exposure to PAHs, whether the exposure is occupational 
or from tobacco smoke. In addition, a statistically significant association has 
been shown between the genetic polymorphism of CYP 1A1 and the 
development of bladder cancer (Figueroa et al., 2008; Grando et al., 2009). 
It has also been suggested that CYP 1A1 plays a role in the development of 
breast cancer by metabolising environmental pollutants which are able to 
induce significant changes in gene expression in specific target cells (Li et al., 
2005). The activation of PAHs from cigarette smoke can also increase the 
risk of breast cancer among women (Li et al., 2004).  
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On the other hand some flavonoids, for instance 7-hydroxyflavone, are potent 
inhibitors of CYP 1A1 (Zhai et al., 1998). Moreover, a number of studies have 
attempted to discover whether the inhibition of AhR will directly inhibit        
CYP 1A1. Aminoflavone and phortress are not only substrates for CYP 1A1 
but are also simultaneously able to induce CYP 1A1 expression by binding to 
AhR. Both agents are metabolised and activated by CYP 1A1 to a toxic 
metabolite which causes DNA damage (National Cancer Institute, 2011). 
Currently, phortress is being tested in clinical phase I trials (Cancer Research 
UK, 2011). 
All this evidence may have important implications for cancer prevention. 
Although CYP 1A1 plays an important role in the metabolism and activation 
of exogenous toxic and carcinogenic xenobiotics, it appears to have some 
significance in the metabolism of endogenous substances including 
arachidonic acid (AA), bilirubin, and oestrogen (Denison and Nagy, 2003; 
Ricci et al., 1999).  
Moreover, CYP 1A1 is one of the CYP enzymes which can activate           
prodrugs like AQ4N forming the active metabolite AQ4 in the hypoxic 
conditions of the tumour microenvironment. In solid tumours, hypoxic cells 
are resistant to radiotherapy and cytotoxic agents. AQ4N is a weak DNA 
binder, but AQ4 interacts tightly with DNA and increases the effectiveness of 
DNA damage within a tumour tissue (Albertella et al., 2008; Ali et al., 1999; 
Patterson et al., 2000).  
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A more recent example is ICT 2700, a prodrug developed at the ICT, which is 
the subject of this thesis and potentially activated by CYP 1A1. ICT 2700 is 
derived from the natural product duocarmycin. The pharmacophore consists 
of a deactivated chloromethylindoline which may undergoe oxidation by    
CYP 1A1. Hydroxylation (specifically at C-5) would lead to spirocyclisation 
resulting in DNA alkylation (Figure 1.4) (Pors et al., 2011).   
 
Figure 1.4: Activation of chloromethylindoline (ICT 2700). Adapted from (Pors et al., 2011). 
 
I.2.3.2. The CYP 2 family 
In humans, the CYP 2 family includes subfamilies CYP 2A, CYP 2B, CYP 2C, 
CYP 2D, CYP 2E, CYP 2F, CYP 2G, CYP 2J, CYP 2R, CYP 2S, CYP 2T 
CYP 2U and CYP 2W. These subfamilies contain sixteen active enzyme 
members. 
The percentage of CYP 2 enzymes in the human liver are as follows:       
CYP 2C9 more than 15%, CYP 2E1 15%, CYP 2A6 10%, CYP 2C8 5%, and 
CYP 2C19, CYP 2B6, CYP 2D6 less than 5% (Pelkonen et al., 2008).      
CYP 2E1 and CYP 2A6 are the major CYP 2 enzymes that metabolize 
carcinogens, which can lead to tumour initiation (Gonzalez and Gelboin, 
1994). Together with CYP 3A4, the CYP 2 family enzymes CYP 2B6,        
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CYP 2C9, CYP 2C19 and CYP 2D6 are responsible for metabolizing more 
than 75% of marketed drugs, with the two most important enzymes being 
CYP 3A4 and CYP 2D6 (Guengerich, 2008; Lynch and Price, 2007; Wienkers 
and Heath, 2005). 
The CYP 2 family plays an important role in both endogenous and exogenous 
metabolism. For example, CYP 2A6 metabolises all trans-retinoic acid (ATRA) 
and arachidonic acid, CYP 2J2 metabolises arachidonic acid, testosterone 
and linoleic acid, CYP 2B6 metabolises testosterone, and CYP 2R1 is a 
vitamin D hydroxylase (Du et al., 2004). 
Many members of the CYP 2 family have been identified in extra-hepatic 
tissue. In this family, 13 genes (CYP 2A6, CYP 2A7, CYP 2B6, CYP 2C9, 
CYP 2C18, CYP 2C19, CYP 2D6, CYP 2E1, CYP 2J2, CYP 2R1, CYP 2S1, 
CYP 2U1, and CYP 2W1) are expressed in skin (Du et al., 2004). The 
enzyme CYP 2D6 is responsible for the metabolism of the majority of drugs in 
the CYP 2 family. 
Furthermore it has been established that CYP 2W1 is particularly expressed 
in human tumours. CYP 2W1 is therefore one of the potential drug targets for 
cancer therapy (Li et al., 2009b). 
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CYP 2W1  
The human CYP 2W1 enzyme is encoded by the CYP 2W1 gene located on 
chromosome 7. In family 2, it has highest identity to CYP 2D6 (Karlgren et al., 
2005). 
CYP 2W1 has been found in microsomes, mitochondria and interestingly 
about 8% is on the cell surface. It has been suggested that CYP 2W1 was in 
a reverse direction in the ER membrane which prevents interaction with CPR 
(Gomez et al., 2010). 
Unlike the other CYP 2 family enzymes, CYP 2W1 is not expressed in the 
adult human liver or in human hepatocytes (Girault et al., 2005) .  
The expression of the enzyme is seen in 54% of human colon and adrenal 
tumours, but no expression has been detected in normal human colons for 
adult and foetal tissues. This finding can help in developing prodrugs 
activated selectively by CYP 2W1 and in using this enzyme as a drug target 
in cancer.  
Moreover, high expression of CYP 2W1 has been detected in two human cell 
lines, Caco-TC7 and HepG2. The expression level is high in Caco-TC7 but 
not in the HEK293 cell line (Gomez et al., 2007; Karlgren et al., 2006; 
Karlgren and Ingelman-Sundberg, 2007). 
A lack of expression of hepatic CYP 2W1 would reduce the unwanted 
metabolism in the liver for potential prodrugs that are designed to be 
selectively activated by CYP 2W1 only in the tumour site. This approach 
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would depend on a high level of active CYP 2W1 enzyme in tumour cells 
(Karlgren and Ingelman-Sundberg, 2007).  
CYP 2W1 can metabolise arachidonic acid to the main metabolites 8, 9-
DHET, 11, 12-DHET and 14, 15-DHET (Karlgren et al., 2006). 
It can also metabolise benzphetamine and indole, and has significant activity 
with many procarcinogens including PAHs and sterigmatocystin. It can also 
activate aflatoxin B1 to a cytotoxic product. The binding of benzphetamine 
and indole to the active site of CYP 2W1 is confirmed by its 3D structure 
(Figure 1.5). In indoles, C-2, C-3 and C-6 are the common oxidation sites for 
catalysis by CYPs (Gomez et al., 2010; Li et al., 2009b; Wu et al., 2006)  
 
Figure 1.5: The structure of the binding of CYP 2W1 with benzphetamine in (A) N-
demethylation, (B) aromatic hydroxylation and (C) indole. Haem is shown as a red stick. Key 
residues are represented by green sticks and substrates with cyan sticks. (D) 2D structures 
of benzphetamine and indole. Adapted from (Li et al., 2009a) 
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Although there is a similarity between the amino acid sequences of CYP 2W1 
and CYP 2D6, the CYP 2W1 enzyme demonstrates a similarity with CYP 1 
enzymes in the matter of substrate specificity. In comparing with other CYPs, 
the substrate recognition sites for CYP 2W1 are highly similar to CYP 1A1 
(Karlgren and Ingelman-Sundberg, 2007). 
(Karlgren and Ingelman-Sundberg, 2007) have raised many issues regarding 
the CYP 2W1 enzyme, including substrates and anticancer drugs, the role of 
endogenous metabolism, and the reason for high expression in foetal colon 
tissue. One of the most important problems is the design of a prodrug that is 
catalyzed selectively by CYP 2W1 and binds to the active site of the enzyme 
with high affinity to form cytotoxic products sufficient to lead to cell death. 
Such a treatment could help to cure gastrointestinal cancers, especially colon 
cancer, one of the three most common types of cancer in the western world. 
I.2.3.3. The CYP 3 family 
The human CYP 3 family contains four genes, CYP 3A4, CYP 3A5, CYP 3A7 
and CYP 3A43. The CYP 3A proteins are abundantly found in the liver and in 
the small intestine. Therefore the CYP 3A subfamily is involved in the 
metabolism of 50% of currently prescribed drugs (Figure 1.6). Additionally, 
CYP 3A has a broad spectrum of substrates. This subfamily can catalyze 
many endogenous substances, including many environmental chemicals of 
toxicological significance and medicinal relevance (Qiu et al., 2008). 
The induction and inhibition of CYP 3A enzymes are regulated by the 
pregnane X receptor. Many drugs can induce this receptor, which activates 
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transcription of CYP 3A genes and induce synthesis of CYP 3A subfamily 
members (Nebert and Russell, 2002).   
In the CYP 3A subfamily, the CYP 3A7 isoform is the only one expressed in 
human foetal liver (Qiu et al., 2008). The amino acid sequences of CYP 3A4 
and CYP 3A5 enzymes match approximately 90% (Ioannides and Royal 
Society of Chemistry (Great Britain), 2008). In particular, CYP 3A4 
contributes to most CYP 3A-mediated drug metabolites as well as to a 
diversity of endogenous substrates, such as steroids and bile acids 
(Guengerich, 1999; Nebert and Russell, 2002). Recently, numerous CYP 3A4 
substrates have been reported as metabolic probes to evaluate the catalytic 
activity of CYP 3A4, for instance testosterone, erythromycin, midazolam, 
triazolam, cortisol, nifedipine and dapsone (Williams et al., 2002; Zaigler et al., 
2000). 
Although CYP 3A4 represents the majority of human liver CYPs, it is also 
expressed in other organs and tissues of the body such as the human 
intestine, endometrium, prostate and brain (Chu et al., 2007; Granvil et al., 
2003; Robertson et al., 2003). It has also been identified as having high 
expression in many kinds of human cancers. Thus CYP 3A4 can activate 
anticancer agents and prodrugs selectively in tumours, for instance in the 
bioreductive activation of AQ4N, a cytotoxic prodrug targeted to hypoxic 
tumours (Raleigh et al., 1998). 
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Figure 1.6: Involvement of enzymes in the metabolism of marketed drugs. UGT, 
glycosyltransferase. FMO, flavin-containing monooxygenase. NAT, N-acetyltransferase and 
MAO, monoamine oxidase. 3A4 (+3A5) is mainly due to CYP 3A4. Adapted from 
(Guengerich, 2008). 
 
 
I.2.3.4. The CYP 4 family 
In mammals family 4 contains six subfamilies, CYP 4A, CYP 4B, CYP 4F, 
CYP 4V, CYP 4X and CYP 4Z. These subfamilies include 13 genes that 
encode enzymes which are mainly involved in the metabolism of saturated 
and unsaturated fatty acids such as arachidonic acid, as well as participating 
in the synthesis of water-soluble bile acid from cholesterol. In humans, two 
CYP 4A enzymes have been characterized, CYP 4A11 and CYP 4A22, which 
share 94% gene sequence identity. 
These members have been identified in the liver and kidney. The CYP 4A 
subfamily catalyzes the ω-hydroxylation of the medium-chain fatty acids such 
as lauric acid (C12:0), fatty acids which can be a source of energy, especially 
when the body needs more energy or in fasting periods (Costa et al., 1998; 
Ioannides and Royal Society of Chemistry (Great Britain), 2008). 
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The CYP 4B subfamily contains CYP 4B1, which is expressed in the human 
bladder and can metabolises xenobiotics and short chain fatty acids like 
octanoic acid (C8:0) (Hardwick, 2008). 
The CYP 4X1 gene has been expressed in the brain, hippocampus, cortex, 
cerebellum, and vascular endothelial cells. In contrast there is no evidence 
that CYP 4X1 can catalyze long chain fatty acids to the same degree as    
CYP 4Z1, which is high frequency expressed in breast cancer. Moreover, the 
CYP 4V2 gene is expressed in the kidney, lung and liver (Hardwick, 2008). 
The CYP 4F subfamily contains seven genes, CYP 4F2, CYP 4F3A,         
CYP 4F3B, CYP 4F8, CYP 4F11, CYP 4F12 and CYP 4F22. The CYP 4F 
subfamily shares more than 90% gene identity. These CYP 4F proteins 
catalyze the ω-hydroxylation of long-chain fatty acids, such as the essential 
polyunsaturated long-chain fatty acid arachidonic acid ‘20:4(ω-6)’ into the 
potent eicosanoids (20-hydroxy-5, 8, 11, 14-eicosatetraenoic acid), as well as 
vitamin E,  leukotrienes, prostaglandins and hydroeicosatetraenoic acids (Cui 
et al., 2000; Hardwick, 2008). These metabolites participate in many 
biological processes including inflammation.  
CYP 4F12 is expressed in clones and catalyzes the hydroxylation of ebastine, 
the anti-histamine drug (Hashizume et al., 2001; Hashizume et al., 2002). 
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CYP 4F11 
The CYP 4F11 gene is found on human chromosome 19 (Grimwood et al., 
2004). CYP 4F11 mRNA is principally expressed in human liver as well as 
the kidney, heart, skeletal muscle and brain. This gene encodes the         
CYP 4F11 enzyme (Kalsotra et al., 2004). Human CYP 4F11 is known as one 
of 13 ‘orphans’ because of its unknown function (Tang et al., 2010). 
The CYP 4F11 enzyme has a more open substrate access channel 
compared to CYP 4F3A. The hydrophobic character near the enzyme’s active 
site might control substrate affinity (Kalsotra et al., 2004). 
In comparing CYP 4F3 and CYP 4F11 (Figure 1.7) in terms of the catalytic 
activity of eicosanoids and clinically utilized drugs, it has been shown that 
CYP 4F11 can metabolize eicosanoids, but less so than CYP 4F3. However 
CYP 4F11 demonstrates a much higher conversion of many drugs, such as 
benzphetamine, ethylmorphine, chlorpromazine, imipramine, and the most 
efficient substrate for CYP 4F11, erythromycin (Kalsotra et al., 2004). In 
contrast CYP 4F11 exhibits low activity for some drug N-demethylation 
reactions like erythromycin, but shows high selectivity in the metabolism of 
four fatty acids: palmitic, oleic, arachidonic, and docosahaxaenoic (Tang et al., 
2010). 
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Figure 1.7: Structural models of CYP 4F3A and CYP 4F11.The substrate access channels 
bound by the h1-sheet region on top, FG loop in the middle, and BV helix region on the 
bottom forming the channel down the haem. The grey dye stands for hydrophobic residue, 
yellow for hydrophilic, red for acidic and blue for basic. These models show that CYP 4F3A 
has a more restricted substrate access channel compared to CYP 4F11,as there is no haem 
access in the CYP 4F3A model. Modified from (Kalsotra et al., 2004). 
 
 
Compared to normal tissues, the expression of CYP 4F11 is not detected in 
colorectal cancer and in ovarian cancer, but it is expressed in prostate cancer. 
The explanation for the expression of CYP 4F11 in prostate cancer is that the 
enzyme has a role in oxidative stress during the conversion of normal cells to 
cancer cells in the prostate, in particular because of the involvement of 
inflammatory pathways (Esaú, 2012)    
I.2.3.5. Other CYP families 
Although CYP1, CYP2, CYP3, and CYP4 represent more than 90% of the 
enzymes able to catalyze the metabolism of drug and xenobiotics, it has also 
been shown that other families can also be involved in the metabolism of 
CYP4F3
A 
CYP4F11 
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endogenous compounds (Patterson and Murray, 2002; Wright et al., 2009) 
(Table 1.1). For example, CYP 27A1 and CYP 24 are expressed extra- 
hepatically in colorectal cancer (Matusiak and Benya, 2007). Moreover, 
inhibited CYP 17 has significant antitumour activity in prostate cancer (Attard 
G, 2008). Also, abiraterone acetate, a prodrug which inhibits CYP 17, leads 
to high levels of antitumour activity in prostate cancer (Attard G, 2008; Bruno 
and Njar, 2007).  
Table 1.1: Summary of a group of human CYP families including CYP5, CYP7, CYP8, 
CYP11, CYP17, CYP19, CYP20, CYP21, CYP24, CYP26, CYP27, CYP39, CYP46 and 
CYP51, demonstrating the number of subfamilies, genes and pseudogenes, as well as their 
substrates and function in each family. 
 
Family Function 
Number of subfamilies, 
genes, pseudogene 
Enzyme 
 
Reference 
CYP 5 Thromboxane synthase 1 subfamily, 1 gene CYP 5A1 (Chevalier et al., 2001) 
CYP 7 
Bile acid biosynthesis, 
steroids 
2 subfamilies, 2 genes 
CYP7A1 , 
CYP 7B1 
(Tang et al., 2006),(Kovar et 
al., 2010) 
CYP 8 Bile acid biosynthesis 2 subfamilies, 2 genes 
CYP8A1, 
CYP 8B1 
(Jahan and Chiang, 2005) 
CYP 11 steroid biosynthesis 2 subfamilies, 3 genes 
CYP11A1, 
CYP511B1, 
CYP 11B2 
(Tuckey et al., 2008) 
CYP 17 steroid biosynthesis 1 subfamily, 1 gene CYP 17A1 (Dhir et al., 2007) 
CYP 19 steroid biosynthesis 1 subfamily, 1 gene CYP 19A1 (Lu et al., 2010) 
CYP 20 unknown function 1 subfamily, 1 gene CYP 20A1 (Nelson, 2006) 
CYP 21 steroid biosynthesis 
1 subfamilies, 1 gene, 1 
pseudogene 
CYP 21A2 
(Zollner et al., 2010) 
CYP 24 Vitamine D degradation 1 subfamily, 1 gene CYP 24A1 (Matusiak and Benya, 2007) 
CYP 26 
Retinoic acid 
hydroxylase 
3 subfamilies, 3 genes 
CYP26A1, 
CYP26B1, 
CYP 26C1 
(Kinkel et al., 2009) 
CYP 27 
Bile acid biosynthesis 
activates vitamin D3 
3 subfamilies, 3 genes 
CYP27A1, 
CYP 27B1 
(Matusiak and Benya, 2007) 
CYP 39 24-hydroxycholesterol 1 subfamily, 1 gene CYP 39A1 (Ikeda et al., 2003) 
CYP 46 
Cholesterol 24-
hydroxylase 
1 subfamily, 1 gene CYP 46A1 
(Golanska et al., 2005) 
CYP 51 Cholesterol biosynthesis 
1 subfamily, 1 gene, 3 
pseudogenes 
CYP 51A1 
(Lepesheva et al., 2008) 
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I.2.4. CYP monooxygenase catalytic cycle 
In general the CYP catalytic cycle, shown in Figure 1.8, proceeds as follows: 
1- A substrate enters into the active site region near the haem group in 
the centre of the CYP via a thiolate ligand derived from a cysteine 
residue. The interaction causes a change in the structure of the active 
site.  
2- The change in the state of the active site facilitates the transfer of an 
electron from NAD(P)H via CPR. The donation of the electron depends 
on the way the electron transfer chain reduces the ferric haem iron to 
the ferrous situation, as described in section I.2.1.  
3- Molecular oxygen binds by a covalent bond to the haem iron, the 
oxygen therefore being activated. 
4- A second electron is transferred via the electron-transport system, 
either from CPR, ferredoxins, or cytochrome b5, reducing the dioxygen 
to a negatively charged superoxide. 
5- The superoxide, forming a strong base, adds a proton (H+) from water 
or from surrounding amino acid side chains.  
6- One water molecule is released, forming a highly reactive iron.  
7- The active oxygenating iron is protonated by accepting a proton (H+) 
from the substrate.  
8- The activation bond in the substrate via hydrogen abstraction leads to 
substrate oxidation. 
9- The product is released from the enzyme, while the enzyme returns to 
its original state. 
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These stages have been well characterized, and the crystal structures now 
exist for the substrate-free, substrate-bond, reduced form and oxygen-form 
for bacterium CYP, CYP 101 (Fishelovitch et al., 2010; Ioannides and Royal 
Society of Chemistry (Great Britain), 2008; Meunier et al., 2004). 
 
 
 
 
 
  
Figure 1.8: General CYP catalytic cycle. RH and ROH represent the substrate and the 
product, respectively. Modified from (Guengerich, 2008). 
I.2.5. CYPs and single nucleotide polymorphism  
The simple definition of polymorphism is “a common variation in the 
sequence of DNA among individuals, and is an important factor responsible 
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for inter-individual variability of CYP genes” (Kalsotra and Strobel, 2006). The 
sequence difference between members in a single nucleotide, A, T, C or G, is 
called single nucleotide polymorphism (SNP). The SNPs in CYP genes might 
have an effect on transcriptional and translational properties, enzyme 
effectiveness and enzyme activity (Ingelman-Sundberg, 2001; Oyama et al., 
2004). In human CYP families 1-3, a high degree of polymorphism has been 
identified compared to other CYP families. These 3 families participate in 
approximately 75% of all Phase I metabolism of marketed drugs (Bertz and 
Granneman, 1997; Evans and Relling, 1999; Rodriguez-Antona and 
Ingelman-Sundberg, 2006). The highly polymorphic enzymes are CYP 2D6, 
CYP 2C9 and CYP 2C19. CYP 2D6 is one of most polymorphic CYPs with 
100 different allelic variants, while in CYP 2C9 and CYP 2C19 there are 35 
and 28 SNPs respectively. The different gene variants might affect the activity 
of enzymes either by decreasing or increasing the affinity between an 
enzyme and a certain xenobiotic. Lack of enzyme activity can lead to 
elevations in drugs or chemicals causing drug toxicity. In contrast, rapid 
enzyme activity can also lead to toxicity by increasing the amount of the 
metabolite, which may be more active than the substrate alone (Fonseca et 
al., 2011; Johansson and Ingelman-Sundberg, 2011). 
In CYP 1A1, 3 SNPs have been identified of which two are associated with 
lung cancer risk for Chinese smokers (Song et al., 2001).  
In CYP 2W1, a number of SNPs have been reported; however, 3 of them are 
located in exons. The silent SNPs located in exon 1 and the other 2 exons 
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have dissimilar amino acid sequences (Karlgren and Ingelman-Sundberg, 
2007).  
I.3. CYPs and Cancer  
I.3.1. Carcinogenesis  
Carcinogenesis is a process that causes or leads to cancer. Following the 
definition of cancer in section I.1., cancer develops through an inability to 
control cellular balance leading to abnormal and uncontrolled division of cells. 
Some of these changes occur by genetic predisposition. Others appear as 
the result of mutations caused by viruses, endogenous factors, radiation or 
environmental risk factors. These factors primarily affect not only the function 
of the proteins encoded by the altered genes, but also the whole cell-cycle 
that controls cell growth, proliferation, apoptosis, survival and response to 
stress. Identifying the causes and consequences of these changes is 
fundamental to understanding the mechanisms that cause cancer and to 
improving our ability to successfully prevent, diagnose and treat cancer 
(Tannock et al., 2005).  
In the mechanism of carcinogenesis, when the genes that regulate cell 
growth are damaged, the genes will provide the signals for tumour cells to 
start dividing abnormally (Vogelstein and Kinzler, 2004).  
Many environmental chemicals are identified as carcinogens, and the 
majority need to be activated by enzymes. For example CYP 1A1 can oxidise 
BP to BPDE, which is extremely carcinogenic (Ioannides and Royal Society 
of Chemistry (Great Britain), 2008). 
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I.3.2. Cancer drug fate 
I.3.2.1. Enzyme kinetics 
The rate of metabolism by an enzyme (enzyme kinetics) is measured by the 
number of product molecules formed per active site of the enzyme per minute 
(Figure 1.9). 
 
Figure 1.9: Erythromycin binding to CYP 3A4. Erythromycin is shown as orange sticks and 
the haem is shown in magenta. Adapted from (Ekroos and Sjogren, 2006). 
 
Classically the rate of metabolism is described kinetically using the Michaelis-
Menten equation (Scheme 1.3 and Figure 1.10) by estimating kinetic 
parameters Vmax and Km. Vmax is the maximal reaction rate when the 
substrate is saturated and Km, the Michaelis constant, is the concentration at 
which the maximal rate is achieved  (Hutzler and Tracy, 2002).  
V = (V max * S)/ (K m + S) 
Scheme 1.3: Michaelis-Menten equation: V is enzyme velocity, Vmax is the maximum enzyme 
velocity, S is the substrate concentration and Km is the Michaelis-Menten constant. 
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Figure 1.10: Michaelis- Menten saturation curve of an enzyme reaction. 
Because the Michaelis-Menten plot is nonlinear, it is possible to rearrange the 
kinetic parameters, Vmax and Km, to get linear plots, for example Lineweaver-
Burk plots. The equation can be rearranged from the Michaelis-Menten 
equation (Scheme 1.4 and Figure 1.11). 
 
  
Scheme 1.4: Lineweaver- Burk equation, V is enzyme velocity, Vmax is the maximum enzyme 
velocity, S is the substrate concentration and Km is the Michaelis- Menten constant.    
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Figure 1.11: Lineweaver-Burk linear plot of an enzyme reaction 
 
 
I.3.2.2.  Phase I and Phase II reactions 
Most endogenous and xenobiotic compounds are lipophilic. Lipophilic 
compounds easily cross the lipid bilayer on the plasma membrane and are 
then transported by lipoproteins. The metabolic process is a means of 
transforming lipophilic substances into easily excreted polar metabolites in 
living organisms. This transformation can often be catalyzed by enzymes. 
The process occurs in two distinct metabolic phases. 
Phase I metabolism reactions add functional groups on the molecules, and 
these processes include: 
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1- Oxidations, introducing or unmasking polar functional groups to the 
compound by addition of oxygen or removal of hydrogen. More than 
10 oxidation reactions are catalyzed by CYPs. From the CYP catalytic 
cycle, shown in section I.2.4, it is possible to determine the metabolism 
pathway of each compound.  
2- Reductions, which make an existing functional group more polar. 
3- Hydrolysis, unmasking existing functional groups.  
The common functional groups are hydroxyl (-OH), amino (-NH2), and 
carboxyl (-COOH).  
Phase II metabolism reactions are described as conjugation reactions, and 
include: 
1- Glucuronidation, adding glucuronic acid. 
2- Sulphonation and phosphorylation, adding a sulphate or phosphate  
group  respectively. 
3- Amino acid conjugation, adding glycine or glutamine.  
4- Glutathione (GSH) conjugation. 
5- Acetylation, adding acetyl (-COCH3).  
6- Methylation, adding methyl (-CH3). 
If the products of Phase I reactions are polar enough, they may be excreted 
at this point. Nevertheless, many Phase I metabolites are not readily 
eliminated and need Phase II reactions to form a highly polar conjugate. The 
majority of Phase I metabolism activity is located in the microsomal fraction of 
Introduction                                                                                                    Chapter 1  
 
 
33 
the cells while the majority of Phase II metabolism activity is located in the 
cytosolic fraction of the cells. 
Many enzymes participate in Phase I reactions, such as CYPs, flavin-
containing monooxygenases and molybdenum hydroxylase. However, 
oxidation comprises the bulk of Phase I reactions and the CYP superfamily 
catalyzes the majority of oxidation reactions. CYP monooxygenase enzymes 
catalyze many reactions, for example epoxidation, hydroxylation, N, O, S-
dealkylation, S, N, P-oxidation, desulphuration, dehalogenation, and nitro 
reduction (Alonen et al., 2005; Nassar et al., 2009).  
I.3.3. CYPs in cancer  
I.3.3.1. Resistance 
Chemotherapy is one of principal therapies for tumours see section I.1.         
A number of cancers respond to the treatment rapidly after the first dose of 
the chemotherapy drug. However, drug resistance, a critical limitation to the 
effective treatment, might occur at any time. Although the mechanism of drug 
resistance has been well studied in order to increase the effectiveness of 
cancer treatment (Liu, 2009; O'Connor, 2009), resistance remains one of the 
main problems in many tumour types.  
CYPs are involved in the activation and detoxification of foreign compounds 
including therapeutic drugs. Many CYPs are expressed in high frequency in 
tumour tissue and surrounding stroma as compared to normal tissue. These 
CYPs include CYP 1A1 (Androutsopoulos et al., 2009), CYP 1B1 (Gibson et 
al., 2003; Tokizane et al., 2005), CYP 2J2 (Jiang et al., 2005), CYP 2S1 (Wu 
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et al., 2006), CYP 2W1 (Karlgren et al., 2006; Wu et al., 2006) and                     
CYP 4Z1 (Zollner et al., 2009). Patterson, Loadman, Gill, Sutherland and 
Laye at the Institute of Cancer Therapeutics in the University of Bradford 
have also identified high expression of CYP 4F11 in clinical tumours.  
These CYPs are potential targets for anticancer therapy. Induction or 
inhibition of CYPs in tumour tissue may improve the cytotoxicity of 
chemotherapy and reduce drug resistance (Figure 1.12).  
 
 
Figure 1.12: Roles of CYPs in cancer prevention and therapy. Modified from (Bruno and Njar, 
2007). 
I.3.3.2.  Cancer Prodrugs 
A cancer prodrug is a type of drug, initially in the inactive form, which is 
biotransformed to the active drug in the body. The reasons for using          
prodrugs in cancer are to improve the therapeutic index of cytotoxins. Some 
anticancer prodrugs are bioactivated by CYPs, such as: 
Induce
r 
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 Cyclophosphamide, which is effective against many solid and 
malignant tumours, is a DNA-alkylating agent and adds an alkyl group 
to DNA. This prodrug need to be activated by human CYPs. CYP 2B6 
is the major enzyme that catalyzes cyclophosphamide to form 4-
hydroxycyclophosphamide. This is not cytotoxic but an unstable 
metabolite decomposed to form phosphoramide mustard, which is 
cytotoxic. 4-hydroxycyclophosphamide metabolite catalysis by the 
CYP 2C subfamily, including CYP 2C8, CYP 2C9 and CYP 2C19, 
forms aldophosphamide, which is a cytotoxic compound. On the other 
hand, the CYP 3A subfamily can inactivate cyclophosphamide. The   
N-dechloroethylation of the prodrug yields inactive                              
2- dechloroethylcyclophosphamide and a neurotoxic and nephrotoxic 
by- product (Ioannides and Royal Society of Chemistry (Great Britain), 
2008; Patterson and Murray, 2002). 
 Dacarbazine and procarbazine are prodrugs activated by CYPs. The 
hydroxylation of these prodrugs leads to the release of a DNA 
methylating species. CYP 1A and CYP 2B subfamilies catalyze the 
bioactivation of procarbazine. CYP 1A1, CYP 1A2 and CYP 2E1 
enzymes catalyze the N-demethylation of dicarbazine, and the 
metabolite decomposes to amino-imidazol carboxamide and methan 
diazohydroxide, which forms a DNA methylating species (Patterson 
and Murray, 2002). 
 AQ4N is a di- N- oxide anticancer prodrug that generates a cytotoxic 
metabolite, a topisomerase II inhibitor, AQ4, in hypoxic regions of solid 
tumours, (Scheme 1.5).  
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Scheme 1.5: AQ4N activation by CYPs. Chemical structure of AQ4N and its active 
metabolite AQ4.  
AQ4N is relatively nontoxic due to its poor affinity for DNA, but when 
reduced to AQ4 this affinity increases several fold due to the cationic 
charge of the metabolite allowing interaction with the sugar phosphate 
backbone of the DNA (Smith and McLaughlin, 1997). The 4- electron 
reduction metabolite of AQ4N has a high affinity for DNA, a DNA 
processing enzyme vital to cell division (Patterson, 2002a). The drug is 
stable under neutral pH and is a good substrate for the CYP 3A 
subfamily (Patterson et al., 1999; Patterson and Murray, 2002). In 
comparison, AQ4N has greater capacity than tirapazamine to 
penetrate the tissue and reach hypoxic regions. Studies by Tredan et 
al. (2009) and Albertella, Loadman et al. (2008), suggest that AQ4N 
penetrates deeper in tumour tissues and accumulates selectively in 
hypoxic tumour cells. Furthermore, AQ4N is well documented as a 
N-oxide reduction 
reduction 
Introduction                                                                                                    Chapter 1  
 
 
37 
very effective enhancer of radiotherapy (McKeown et al., 1996; 
McKeown et al., 1995; Patterson et al., 2000). 
 
 Aminoflavone and phortress are not only substrates for CYP 1A1 but 
also simultaneously able to induce CYP 1A1 expression by binding to 
AhR. Both agents are metabolised and activated by CYP 1A1 to an 
electrophilic metabolite, which causes DNA damage (National Cancer 
Institute, 2011). 
I. 4. Aims and Objectives 
Despite the significant advances in cancer treatment using molecularly 
targeted drugs, chemotherapy remains an essential part of the effective 
control and treatment of cancer. Hence there is now a re-emergence of 
interest in targeted chemotherapy. One possible approach is to develop 
treatment based on the differential metabolism of cancer prodrugs by CYPs 
expressed in high frequency in tumours compared to normal tissues. This can 
be exploited to elicit a selective chemotherapeutic effect by metabolising inert 
small molecules to potent cytotoxins.  
 
The overall aim of this project was to explore the CYP metabolism of selected 
chloromethylindolines and hence help rationalise their potential as prodrugs 
that could be activated by specific CYPs expressed in tumours. 
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The specific objectives are to optimise HPLC and LC-MS methods to 
separate and identify metabolite profiles of chloromethylindoline prodrugs.  
 
The reactivity of any electrophilic metabolites with glutathione will also be 
determined both as a secondary method of metabolite identification but also 
towards development of a method to demonstrate the reactivity of CYP- 
generated metabolites.  
 
The metabolites identified can then be correlated with in vitro 
chemosensitivity. The main focus of this work is ICT 2700, a 
chloromethylindoline studies will use incubates of recombinant human CYPs, 
transfected cell lines and liver microsomes in an MTT (3-(4,5-dimethyl-2-
thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide) colorimetric cytotoxicity assay 
as well as cell uptake studies.      
 
Finally the robustness of the chloromethylindolines as potential drugs will be 
ascertained from a preliminary pharmacokinetic analysis of an exemplar 
chloromethylindoline (ICT 2706) in CYP 2W1 expressing tumour xenografts 
in mice.  
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II. General materials and methods 
II.1. Materials 
II.1.1. Chemicals and reagents  
β-nicotinamide adenine dinucleotide 2′-phosphate reduced tetrasodium salt 
hydrate (NADPH), glucose-6-phosphate (G6P), glucose-6-phosphate 
dehydrogenase (G6PDE), β-nicotinamide adenine dinucleotide phosphate 
hydrate (NADP+), magnesium chloride (MgCl2), erythromycin,                       
7-ethoxycoumarin, umbelliferone (7-hydroxycoumarin), palmitic acid, 
hydroxypalmitic acid, bovine serum albumin (BSA), Bradford reagent, 
glutathione (GSH), Roswell Park Memorial Institute (RPMI-1640) medium 
(500 ml), minimum essential medium eagle (EMEM) media (500 ml), non-
essential amino acid (100X), trypsin-EDTA solution, L-glutamine, sodium 
pyruvate, fetal bovine serum, trifluoroacetic acid (TFA), dimethyl sulfoxide 
(DMSO), ammonium formate, acetic acid (AA) and formic acid (FA) were 
purchased from Sigma  (Sigma Aldrich, Pool, UK). 3-(4, 5-dimethyl-2-
thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide (MTT) was obtained from 
Sigma Aldrich chemicals (St. Louis, MO, USA). 
Trishydroxymethylaminomethane (Tris) was purchased from Bio-Rad 
(Hercules, CA, USA). High purity High Performance Liquid Chromatography 
(HPLC) grade acetonitrile (MeCN), ethanol, ammonium formate, methanol 
(MeOH) and triple distilled water were purchased from Fisher Scientific UK 
Ltd. (Leicestershire, England). Polypropylene auto sampler vials (Sigma-
Aldrich) were used to load samples for HPLC analysis. All novel compounds 
were provided by the Institute of Cancer Therapeutics (ICT).  All chemicals 
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used were of analytical grade (Sigma) and all solvents were HPLC and mass 
spectrometry grade (Fisher or Sigma) unless otherwise stated.  
II.2. Methods  
II.2.1. Cell seeding 
Cells were grown in cell culture plasticsware (Corning Incorporated, Corning, 
NY) in monolayer cultures and maintained in RPMI-1640 media (A-549,    
SW480_2W1 and SW480_Mock) or EMEM media (EJ-138, HEK293_Mock, 
HEK293_2W1 and HEK293_4F11). RPMI-1640 was supplemented with 10% 
foetal calf serum (FCS), 2mM L-glutamine and 1mM sodium pyruvate whilst 
EMEM was supplemented with 10% FCS, 2mM L-glutamine and 5ml of     
100 X non-essential amino acids.  
Cells were cultured in 75 cm2 flasks in a sterile environment and incubated at 
37°C in a 5% CO2 atmosphere. The cells were maintained by passage when 
they reached 70- 90% confluence.  
II.2.2. Cell passaging 
For passage, consumed medium was aspirated carefully and discarded from 
each 75cm2 flask. Adherent cells were washed twice with 10ml of Hanks 
Balanced Salt Solution (HBSS) before harvesting using 0.25% Trypsin/ EDTA 
(3ml) and incubation for 2- 5 minutes (depending on type of cell line) at 37°C 
until the cells had become detached from the bottom of flask. The appropriate 
medium (7-8ml) was added to block further action of the trypsin/ EDTA before 
the cells were centrifuged (Heraeus Megafuge 1.0; Heraeus, Hanau, 
Germany) for 5 minutes at 1000g. Supernatant was discarded and the cell 
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pellets re-suspended in the required amount of medium (10ml) by vortexing 
(Autovortex mixer SA2; Stuart Scientific, UK). Cells were counted (see 
section II.2.3.) before being re-passaged.  
All cells were harvested in the exponential log phase of their proliferation. The 
required amount of cell suspension was seeded into fresh 75 cm2 flasks 
containing the appropriate amount of complete medium. 
II.2.3. Cell counting 
After trypsinising cells for an appropriate time, cells were detached into 
suspension. Cell number was determined using a haemocytometer. 10µl of 
cell suspension was added in both sides of the chamber. The 
haemocytometer had 2 reading areas; each had a number of grids scored 
onto the glass with five main squares. A total of the cells in each square were 
counted under the microscope (Olympus; CK2) and the mean cell number 
was determined. This mean value was multiplied by 104 to give the number of 
cells per ml.   
II.2.4. Growth curve 
To be sure that the cells used were dividing at a constant rate (Log phase) 
during the incubation period (4 days) they were seeded at four different initial 
concentrations (1x103cells/ml, 3x103cells/ml, 1x104cells/ml and 3x104cells/ml) 
in a 96 well plate. 200μl of cell suspension was added to each well plate and 
incubated at 37°C, 5% CO2 for 4 days. The total number of viable cells was 
determined by the MTT method (see section II.2.5). The time points were 
taken at 0, 1, and 2 days and after 4 days. Samples were measured using a 
micro-plate reader (Multiskan EX; Thermo Fisher Scientific, Waltham, MA, 
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USA) at a wavelength of 540nm. Microsoft® Excel 2007 was used for data 
analysis.   
II.2.5. MTT assay  
The MTT (3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide) 
colorimetric assay was used to determine cell viability (for further information 
see Appendix C) (Mosmann, 1983). For this purpose, 5mg/ml MTT stock 
solution was prepared by dissolving MTT in demineralised water (FistreemTM 
Calypso; FistreemTM International, Loughborough, Leicestershire, UK). After 
vortexing (Autovortex mixer SA2; Stuart Scientific, UK) for 20min, insoluble 
residues were removed by sterile filtration (0.20µm, Corning Incorporated, 
Corning, Germany) and the stock was stored at 4°C. The MTT stock solution 
(0.5mg/ml) was diluted in RPMI-medium prior to use. Samples were 
measured using a micro-plate reader (Multiskan EX; Thermo Fisher Scientific, 
Waltham, MA, USA) at a wavelength of 540nm. Microsoft® Excel 2007 was 
used for data analysis. 
II.2.6. Liquid chromatography (LC)  
II.2.6.1. HPLC system 
Sample analysis was performed using a waters 2695 (Alliance) separations 
system (high performance liquid chromatography, HPLC). A C18 HIRPB, 
Hichrom column, 250mm x 4.6mm i.d. (inner diameter), was used for 
separation. A Waters 2996 photodiode array and a Shimadzu RF-10, a 
fluorescence detector, with Empower pro software (Waters) was used for 
spectral analysis of the peaks of interest. Either isocratic or gradient 
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separation methods were performed using mobile phase A (MPA) and mobile 
phase B (MPB). The peak areas and retention times of the injected samples 
were obtained and optimized for each substrate.  
II.2.6.2. Mass spectrometry (LC-MS) 
Sample analysis was performed using LC-MS system. The system, 
comprising a Waters 996 photodiode array detector (DAD), Waters 474 
scanning fluorescence detectors, and Micromass ZMD single quadrupole 
electrospray with Masslynx software (Waters), was used for spectral and 
mass to charge analysis of the peak of interest. A high purity based 
deactivated silica C18 HIRPB Hichrom, column length 250mm, i.d. 4.6mm, 
silica particle size 5µm, was used for separation. Either isocratic or gradient 
separation methods were performed using MPA and MPB. The peak areas 
and retention times of the injected samples were obtained and optimized for 
each substrate.   
II.2.6.3. Mass spectrometry (LC- MS/MS) 
Sample analysis was performed using an LC-MS/MS system. The system, 
comprising a Waters Acquity binary solvent manager, Acquity PDA detector, 
and Quattro premier XE Micromass triple quadrupole electrospray with 
Masslynx software (Waters), was used for spectral and mass to charge 
analysis of the peak of interest. A high purity based deactivated silica C18 
HIRPB Hichrom, column length 250mm, i.d. 4.6mm, silica particle size 5µm, 
was used for separation. Gradient separation was performed using MPA and 
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MPB. The peak area and retention time of the injected samples were 
obtained and optimized for each substrate.  
II.2.7. Enzyme kinetics 
Different substrate concentrations will have an effect on the rate of an 
enzyme-catalyzed reaction. The rate of reaction was measured from different 
substrate concentrations. The substrate was separated and analysed using 
either HPLC or LC-MS systems. A plot of product versus time and the slope 
of the curve, 'that is, the rate of reaction', was obtained for each concentration. 
Subsequently, the kinetic parameters (Vmax and Km) were obtained using a 
spreadsheet to determine Michaelis-Menten and linear Lineweaver-Burk plot.  
II.2.8. Calibration curves 
Calibration curves were prepared on the same day of each experiment using 
the same stock for both the calibration curve and the experimental samples. 
All standard concentrations were diluted in the mobile phase to give 100µM, 
which were further diluted to prepare the required standard in mobile phase 
as required. The following equation was used to prepare the calibration curve 
standards: 
 
Where: 
c1= Stock concentration 
v1= Volume of the stock concentration 
c2= unknown concentration 
v2= Final volume 
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In all cases, the calibration curves used were linear and the equation used for 
calculating the unknown concentration was the linear regression equation as 
follows: 
 
 
Where 
x is the unknown concentration  
y is the substrate peak area 
yº is the y-intercept and        
a is the slope. 
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III. Studying the catalyzing properties of CYP 1A1 
III.1. Introduction 
CYP 1A1 is one of two members of the CYP 1A subfamily, the second one is 
CYP 1A2. CYP 1A1 is controlled by AhR and can participate in the 
metabolism of endogenous substrates as well as converting procarcinogens 
to active carcinogens such as PAHs. It has been reported that CYP 1A1 
enzyme is mainly expressed in extra- hepatic tissues that exposed to        
procarcinogens such as tobacco, occupational exposure and environmental 
pollutants. The instances of extra-hepatic tissues are lung, small intestine, 
breast and bladder and the expression levels of the enzyme in the liver are 
low for more details see section I .2.3.1. Although CYP 1A1 and CYP 1A2 
have high similarity in their amino acids their substrate specificity is different. 
For example, dibenzo [a] pyrene, which is a potent carcinogen, is activated in 
humans by CYP 1A1 to highly mutagenic diol- epoxides (Shou et al., 1996). 
Moreover, a statistically significant relationship has been found between the 
development of bladder cancer and genetic polymorphism in CYP 1A1 
(Figueroa et al., 2008; Grando et al., 2009). 
In addition, a variety of CYP isoforms are quite often expressed in high 
frequency during the development phase of cancer cells, leading from the 
benign form to a highly metastatic malignant phenotype, and one of these 
enzymes is CYP 1A1 (Sissung et al., 2006; Wenzlaff et al., 2005). Currently 
the use of CYPs, particularly expressed in high frequency in cancer cells, for 
the bioactivation of inactive prodrugs into active cytotoxic molecules in 
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tumour tissues, is being exploited for designing specific chemotherapeutic 
agents. 
Taking advantage of this concept, in this chapter, the catalyzing properties of 
CYP 1A1 have been investigated for novel chloromethylindoline prodrugs       
(ICT 2700, ICT 2705 and ICT 2726). These novel prodrugs are based on the 
natural product duocarmycin. 
 It has been shown that ICT 2700 has to undergo CYP 1A1 mediated 
oxidation, resulting in production of a potent and highly specific DNA minor 
groove alkylation agent (Pors et al., 2011). But is the ICT 2700 activated by 
other CYPs or in mouse tissues (liver- kidney- lung) or in human liver all this 
will be discussed in this work.     
Moreover, the chemosensitivity of ICT 2700 incubated with EJ138_1A1 
transfected cell lines increases 75-fold relative to wild type EJ-138.  
Negligible chemosensitivity was observed with ICT 2700 in EJ138_1A2 
transfected cell lines (Sutherland et al., 2012). In this chapter the 
chemosensitivity of ICT 2700 metabolites catalysed by human CYP 1A1, 
CYP 2D6 or CYP 3A4 bactosomes or in mouse liver microsomes are 
presented. 
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III.2. Materials 
All chemicals and reagents used in this chapter were described in Chapter 2. 
III.2.1. Human bactosomes 
CYP1A1R, CYP1A2R, CYP2D6R and CYP3A4R enzymes were purchased 
from Cypex (Dundee, Scotland, UK). 
III.2.2. Human liver samples 
Five human liver samples were provided from the Ethical Tissue Bank at the 
Institute of Cancer Therapeutics, University of Bradford (for more details see 
Appendix A).  
III.2.3. Mouse tissues 
Mouse liver, kidney and lung tissues were obtained from the Institute of 
Cancer Therapeutics, University of Bradford.  
III.2.4. Cell lines 
Human lung carcinoma cell line (A-549) was purchased from the American 
Type Culture Collection (ATCC). EJ-138 (human bladder carcinoma cell line) 
was obtained from the European Collection of Cell Cultures (ECACC). 
III.3. Methods 
III.3.1. Preparing microsomes  
Mouse kidney and lung microsomes and human liver tissue were prepared as 
described for mouse liver microsomes in the next section, III.3.1.1. 
Catalyzing properties of CYP 1A1                                                                 Chapter 3  
 
51 
III.3.1.1. Preparing mouse liver microsomes  
Liver microsomes were prepared from mouse and human liver tissue using                
a differential centrifugation method. First, the liver sections were 
homogenised in 100 mM Tris-HCL buffer (pH 7.4) at a ratio of 1:3 using  an 
Ultra-Turrax basic homogeniser (IKA Werke GmbH & Co. KG, Staufen, 
Germany). During this process samples were kept cold at 4°C. Homogenates 
were centrifuged (Labofuge 400R; Heraeus, Hanau, Germany) at 9000rcf 
(relative centrifugal force) for 20min at 4°C to sediment cell debris and nuclei, 
producing S9 fractions which were stored at -80°C for future use. The 
supernatant was transferred to ultracentrifuge tubes and centrifuged (Optima; 
LT ultracentrifuge; BECKMAN, USA) at 100,000rcf for an hour at 4°C to 
sediment microsomes. The cytosolic supernatant was transferred to fresh 
tubes and stored at -80°C for future use. The microsomal pellet was gently 
resuspended in 100mM Tris-HCL buffer (pH 7.4) at 4°C and the ratio of pellet 
to buffer was 1:3. The protein concentration of this microsomal fraction was 
determined using the Bradford assay (see section III.3.2) before the sample 
was split into 50-100µl aliquots and stored at - 80°C for future use, if not used 
immediately. 
III.3.2. Measuring protein concentration in mouse liver microsomes 
using the Bradford assay method 
This method was used to measure the protein of all mouse and human 
microsomes. A serial dilution of bovine serum albumin (BSA) (1mg/ml, 
0.5mg/ml, 0.25mg/ml, 0.125mg/ml and 0.0625mg/ml) was used to create a 
standard curve of absorbance.  After the addition of 3ml of Bradford reagent 
to 100µl of the BSA standards, the standards were incubated at room 
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temperature for 15min. The BSA standard concentration was analysed 
colorimetrically using a Cary 50 Bio ultra-violet (UV)-visible spectrometer 
(Varian Inc., CA, USA) at a wavelength of 595nm. Samples with unknown 
concentration were prepared in the same manner and the results compared 
to the standard curve produced. Microsoft® Excel 2007 was used for data 
analysis.     
III.3.3. Microsome incubation 
Microsomal pellets were thawed rapidly in a 37°C incubator with gentle 
agitation. The desired final protein concentration was added to an appropriate 
buffer system (100mM Tris-HCL buffer pH 7.4) for the enzyme assay. The 
final concentration of all substrates was calculated. The final concentration for 
the NADPH was 2mM, or alternatively an NADPH-regenerating system was 
used which included 1.3mM NADP+, 3.5mM G6P, 0.4U/ml G6PDE and 
3.3mM MgCl2. The incubation mixtures were prepared with a final volume of 
300µl. The complete mixture was incubated at 37°C for 2hrs. The incubation 
period for reactions was variable (see Appendix B). Time points were taken 
during the incubation at 0, 30, 60, 90 and 120min to observe the increasing 
appearance of metabolites and to see if there were any unstable intermediate 
metabolites. After incubation of the sample at 37°C, the reaction was 
terminated by adding 20µl of cold MeCN to 10µl of sample. The protein 
precipitation technique (see section III.3.5) was used to extract the substrate, 
then the sample was analysed by injecting 10µl in either the HPLC or mass 
spectrometry systems see section II.2.6. 
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III.3.4. Bactosome incubation  
Substrates were incubated with human bactosomes, including CYP- 
reductase, as follows. The incubation mixtures were prepared with a final 
volume of 300µl containing 30picomole/ml enzyme, 100μM substrate,   
100mM Tris-HCL buffer pH 7.4 and 2mM NADPH. The latter was added after 
pre-incubation at 37°C for 2min. The complete mixture was incubated at    
37°C for 2hrs. Control incubates were prepared without NADPH. Time points 
(samples) were taken during incubation at 0, 15, 30, 60, 90 and 120min to 
observe increases in metabolites and to see if there were any intermediate 
metabolites. The reaction was stopped by adding 20µl of cold MeCN to 10µl 
of sample. Subsequently, the protein precipitation technique was used to 
extract the substrate (see section III.3.5). The substrate was transferred to a 
new tube while the pellet was discarded. This substrate was analysed by 
injecting 10µl of sample in either the HPLC or mass spectrometry systems 
see section II.2.6. 
III.3.5 Substrate extraction from microsomes and bactosomes using 
protein precipitation  
The extraction technique enabled detection of very low concentrations of the 
substrates and a pure sample that could be injected safely into the HPLC and 
mass spectrometry systems without blocking its column and MS detector. In 
this method, cold 20µl MeCN was added to a 10µl sample to give a final 
volume of 30µl. The sample was mixed for few seconds then centrifuged 
(Labofuge 400R; Heraeus, Hanau, Germany) for 5min at 4°C with a speed of 
10,000rcf. Supernatant was then carefully removed to a new tube and 10µl 
was injected into ether the HPLC or mass spectrometry systems. 
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III.3.6. Metabolism of 7- ethoxycoumarin by mouse liver microsomes 
III.3.6.1. HPLC analysis 
HPLC reverse-phase separation was used to measure the production of 
specific metabolites and monitor loss of 7-ethoxycoumarin. The probe was 
selected to test the activity of the CYP 1A subfamily in mouse liver 
microsomes. Mobile phases (MPs) were as follows: MPA was composed of 
95% 10mM ammonium formate buffer and 5% MeCN. MPB was composed of 
40% 10mM ammonium formate buffer and 60% MeCN. An isocratic method 
of 50% MPA and 50% MPB was used for 25 minutes. Ammonium formate 
buffer was prepared by dissolving 0.63g of ammonium formate in 1l of 
distilled water and the pH was adjusted to 3.55 using 0.5-1ml of formic acid. 
MPs were degassed before introduction onto the HPLC system by vacuum 
filtration through a 0.45µm pore nylon filter membrane. The flow rate was set 
at 1ml/min using a Waters 2795 (Alliance HT) separations module system. 
The fluorescence parameters of the detector were λex 324nm and λemm 
458nm. The total running time of each sample was 25 minutes and the 
volume of injection was 10µl. 
III.3.7. Metabolism of chloromethylindoline (ICT 2700) by four different 
human bactosomes (CYP1A1, CYP1A2, CYP2D6, CYP3A4), three 
different mouse microsomes (liver, kidney, lung) and five samples of 
human liver microsomes 
III.3.7.1. HPLC analysis  
HPLC reverse-phase separation was used to measure the production of 
specific metabolites and monitor loss of ICT 2700. MPs were as follows: MPA 
was composed of 90% HPLC grade water, 10% MeOH and 0.1% formic acid 
(FA). MPB was composed of 10% HPLC grade water, 90% MeOH and 0.1% 
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FA. The gradient method was used with an initial ratio of 50% MPA and 50% 
MPB. This ratio was changed by time until 15 min to 30% MPA and 70% 
MPB. Then the ratio was changed again until min 25 to 10% MPA and 90% 
MPB. This ratio was held constant for 4 min until min 29. Subsequently the 
ratio was returned at min 30 to the initial gradients, 50% MPA and 50% MPB. 
MPs were degassed before introduction onto the mass spectrometry system 
by vacuum filtration through a 0.45µm pore nylon filter membrane. The flow 
rate was set at 1ml/min using a Waters 2695 (Alliance) separations system. 
The photodiode array detector was scanned in the range of 200-400nm. The 
total running time of each sample was 40 minutes and the volume of injection 
was 10µl. 
III.3.7.2. LC-MS analysis 
LC-MS system was used in positive mode and the mass spectrometry 
parameters were optimised to desolvation gas flow 650l/hr, cone gas flow 
30l/hr, capillary 3.00kV, sample cone 30V, extraction cone 5V, RF lens 0.20V, 
source block temperature 100°C and desolvation temperature 200°C. Parent 
substrates and their metabolites were detected as singularly positive charged 
ions (ES+) with scanning in the range 250-500m/z, then using selected ion 
recording (SIR) (360.0, 366.2, 380.2, 396.2, 393.2, 398.2 and 412.2m/z). The 
loss of chlorine from metabolites was monitored in a spectral analysis of the 
chlorine isotopes. 
 III.3.8. MTT assay  
The chemosensitivity testing described in this chapter is the same as in 
section II.2.5. 
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III.3.8.1. Cell seeding for MTT assay 
Cells were counted (see section II.2.3) then cell suspensions were prepared 
at a cell density of 1x104 cells/ml in an appropriate medium dependent on cell 
lines (see section II.2.1). 180μl of cell suspension was added into each well 
of a 96 well plate, apart from the first column which remained blank. The 
plates were incubated at 37°C for 24hrs. After cells adhered to the bottom of 
the plates, cells were treated with substrates of interest. The first column of 
the plate was left without any cells and the second column was not treated 
but used as a control of 100% cell survival. Cells used for drug treatment 
were used between passage one and ten. 
III.3.8.2. Enzyme incubation for MTT assay  
The enzyme incubation method was the same as in section III.3.3 and III.3.4 
and samples were taken during the incubation (0 and 120min). The sample 
volume was 450μl including the stop reaction solvent (MeCN). Subsequently, 
the protein precipitation technique was used for substrate extraction from 
microsomes and bactosomes (see section III.3.5). The extracted substrate 
was evaporated (Genevac EZ-2 plus, SP Scientific, UK) for 2 hours to 
increase the concentration of metabolites and to avoid the effects of MeCN 
on the cells. Five concentrations (the concentration range of prodrugs:  
10μM-1nM) were prepared for each enzyme incubation. From each 
concentration 20µl was added to each well (4 wells for each concentration) 
resulting in a final volume of 200µl. The effect of DMSO (drug dissolving 
solvent) in cells was avoided by keeping the final DMSO concentration not 
more than 1%. The cells were incubated with the substrates at 37°C for 72hrs 
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in a 5% CO2 atmosphere before assessment of cytotoxicity. Cytotoxicity was 
expressed as an IC50 value which is the concentration of drug required to 
reduce cell survival by 50%. 
After incubation of the cells with compounds in 96 well plates, the medium 
was removed then the cells were washed twice with 200μl of HBSS. MTT 
solution (200μl) was added to each well and incubated at 37°C for 4hrs 
(Mosmann, 1983). MTT solution was removed and replaced by 150 μl DMSO. 
The blue formazan crystals were carefully dissolved to avoid creating air 
bubbles and the samples were measured using a micro-plate reader 
(Multiskan EX; Thermo Fisher Scientific, Waltham, MA, USA) at a wavelength 
of 540nm. Microsoft® Excel 2007 was used for data analysis. Survival was 
calculated as the true absorbance of treated lanes divided by the true 
absorbance of control lanes and expressed as a percentage. Each 
experiment was conducted in triplicate. 
III.3.9. Fragmentation of ICT 2700 and its metabolites   
III.3.9.1 HPLC analysis  
The method used was the same as in section III.3.7.1. 
III.3.9.2. LC- MS/ MS analysis 
An LC-MS/MS system was used in positive ionization mode (ES+) and the 
mass spectrometry parameters were optimised to desolvation gas flow 
650l/hr, cone gas flow 30l/hr, capillary 2.93kV, sample cone 85V, collision 
voltages 30V, extraction cone 4V, RF lens 1.0V, source block temperature 
149°C, desolvation temperature 294°C and Collision Gas Flow 0.35ml/min. 
Multiple reaction monitoring (MRM) mode was used. The parent substrate 
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and metabolites were fragmented into two parts to monitor metabolic 
additions to each part of the molecule. 
III.3.10. Drug stability of ICT 2700 and ICT 2740 
Drug stability at a concentration of 100µM for ICT 2700 and ICT 2740 was 
monitored at 37°C in both Tris-HCL buffer and MeOH. Six time points at 0, 10, 
30, 60, 90 and 120min were taken over a 2 hours period. Each time point was 
injected and analysed in the mass spectrometry system using same method 
as in section III.3.7. The total running time of each sample was 40 minutes 
and the volume of injection was 10µl. 
III.3.11. Drug uptake of ICT 2700 and ICT 2740 in A-549 cells 
Two concentrations (10 µM and 100 µM) were used to measure the uptake of 
both ICT 2700 and ICT 2740 in A-549 cell line. The effect of DMSO (drug 
dissolving solvent) in cells was avoided by decreasing the concentration to 
not more than 1%. The concentration of the cells was 1x107cells/ml (see 
section II.2.3) and the end volume of suspension was 500µl. After gentle 
mixing the suspension was incubated in 37°C. Time points (1, 10, 30, 60, 120 
and 240min) were taken during the incubation. For each time point, 50µl was 
removed to the new tube then centrifuged (Labofuge 400R; Heraeus, Hanau, 
Germany) at 2000rcf for 2min at 4°C. From the supernatant 20µl was 
removed in a tube (sample A) and the rest of supernatant was discarded. The 
cells were washed in 50µl Hanks (HBSS) then centrifuged (2000rcf for 2min 
at 4°C) to sediment the cells, and after that the HBSS was discarded. Cells 
were resuspended in 50µl MeCN then centrifuged at 10000rcf for 20min at 
4°C. The supernatant was removed to tube (sample B) and the pellet was 
discarded. For sample A, 40µl of MeCN was added (see Appendix D). 
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Samples were analysed in the mass spectrometry system using the same 
method as in section III.3.7. 
III.3.12. Studying the conjugation between glutathione and the 
metabolites of chloromethylindoline 
III.3.12.1.The conjugation of ICT 2700 and ICT 2740 with glutathione  
The conjugation of both ICT 2700 and ICT 2740 with glutathione (GSH) was 
observed. 100µM of substrate was incubated with 10mM GSH at 37°C in 
both Tris-HCL buffer and MeOH. Two time points at 0 and 120min were taken 
over a 2 hour period. Each time point was injected and analysed in the mass 
spectrometry system. The total running time of each sample was 40 minutes 
and the volume of injection was 10µl. 
III.3.12.1.1. HPLC analysis 
The same method was used as in section III.3.7.1. 
III.3.12.1.2. LC-MS analysis 
The same method was used as in section III.3.7.2 except that the MS 
scanning was in the range 250-750m/z and the channels of SIR were 308.3, 
360.1, 380.1, 396.1, 668.18, 688.1 and 704.2m/z. 
III.3.12.2. The conjugation of glutathione with ICT 2700 metabolites 
catalyzed by CYP 1A1 
The same methods as those in section III.3.12.1 were used to monitor the 
conjugations between GSH and metabolites of ICT 2700 catalyzed by      
CYP 1A1. 
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III.3.13. Metabolism of ICT 2705 by three different bactosomes (CYP1A1, 
CYP2D6, CYP3A4) and mouse liver microsomes 
III.3.13.1. HPLC analysis  
The same method was used as in section III.3.7.1. 
III.3.13.2. LC-MS analysis 
The same method was used as in section III.3.7.2, except the channels of 
SIR were 349.9, 355.9, 368.2, 384.9 and 400.9m/z.  
III.3.14. Metabolism of ICT 2726 by three different bactosomes (CYP1A1, 
CYP2D6, CYP3A4) and mouse liver microsomes 
III.3.14.1. HPLC analysis  
The same method was used as in section III.3.7.1. 
III.3.14.2. LC-MS analysis 
The same method was used as in section III.3.7.2, except the channels of 
SIR were 350.9, 369.9, 385.2 and 401.9m/z. 
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III.4. Results 
III.4.1. Measuring protein concentration in mouse liver microsomes 
using the Bradford assay method 
This method was used to measure protein concentration for all microsomes 
(human livers, cell lines and all mouse organ microsomes). After preparing 
mouse liver microsome samples, the Bradford assay was used for measuring 
total protein concentration. The Bradford assay uses Coomassie dye which 
binds proteins causing a spectral shift from 465 to 610nm, with the difference 
between the peaks being greatest at 595nm (Thermo Fisher Scientific Inc., 
2009). The colour produced is proportional to the amount of protein present in 
the sample after reading the absorbance of the standards and each dilution of 
the sample (Table 3.1).   
Table 3.1: An example of absorbance of serial dilutions used to create a standard curve of 
absorbance at a wavelength of 595nm to measure 2 sample dilutions of unknown protein 
concentration in mouse liver microsomes. Results represent dilutions of the two different 
mouse liver microsome preparations. 
 
 
 
 
 
 
 
All unknown samples were diluted to within the range of the calibration curve. 
The absorbance of the unknown sample (A diluted 1/ 10 and B diluted 1/ 50) 
was measured and the results were 2.0891 and 0.5143 respectively. 
Therefore sample B was used because it was in the range of the calibration 
Concentration mg/ ml Absorbance at 595 nm 
0 0.0106 
0.026 0.0265 
0.125 0.1251 
0.25 0.2508 
0.5 0.5003 
1 1.0170 
Sample (A) 1/10 2.0891 
Sample (B) 1/50 0.5143 
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curve. The absorbancies of the standards versus their concentrations were 
plotted. The sample concentration was calculated from the equation of the 
BSA calibration curve in Figure 3.1.  
From the equation y = ax + y°, (y= 0.9954x + 0.0032) we can determine the 
concentration of unknown sample X = y-y°/ax, where X is the unknown 
concentration, y is the substrate peak area, yº is the y-intercept, a is the slope 
and x is the dilution. 
Thus the protein concentration is calculated as follows: 
X = (0.514– 0.0032/0.9954) x 50  
X = 25.65 mg/ml 
 
Figure 3.1: BSA calibration curve and the equation to determine the unknown concentration 
from a mouse liver microsomes sample 
 
The initial protein concentration used for measuring the metabolism of 
substrates in mouse liver microsomes over time was 2mg/ml, so the equation 
C1 * V1 = C2 * V2 was used and the result is:    
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V2 = 2mg x 1000µl/25.65mg 
V2 = 78 µl + 922 µl Tris buffer → 2 mg/ ml. 
III.4.2. 7-ethoxycoumarin O- deethylation (ECOD) catalyzed by CYP 1A 
subfamily in mouse liver microsomes 
ECOD metabolism is an established technique for testing the activity of the 
CYP 1A subfamily in mouse liver microsomes (MLiM). Moreover, it can also 
be used to show activity and ensure the NADPH is at an appropriate 
concentration (Neumann et al., 2003).   
An NADPH-regenerating system was used as an electron donor to the 
reaction. 
The ECOD assay can be performed quantitatively using a known quantity of 
MLiM (end concentration 1mg/ml) to produce the conversion of 1µM              
7-ethoxycoumarin to 7-hydroxycoumarin (Scheme 3.1). The methods are 
described in section III.3.6.   
                       CYPs                         
7- Ethoxycoumarin                         O- Deethylation           Umbelliferone (7- Hydroxycoumarin) 
           FW   192.2                                                                                       FW   162.1     
 
Scheme 3.1: 7- ethoxycoumarin O-deethylation. CYP 1A subfamily catalyzes the metabolism 
of 7- ethoxycoumarin to 7-hydroxycoumarin. 
 
In order to get a good separation of 7-hydroxycoumarin and                          
7- ethoxycoumarin by HPLC, the optimised method in section III.3.6.1 was 
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used to determine the optimum absorbance of 7-ethoxycoumarin and            
7-hydroxycoumarin, which were scanned across the wavelength 200-400nm. 
The optimal wavelength for 7-hydroxycoumarin and 7-ethoxycoumarin was 
324.8nm (Figure 3.2). The 7-hydroxycoumarin retention time (Rt.) was 4.1min 
and the 7-ethoxycoumarin Rt. was 15.0min.  
4.150 Peak 1
200.9
324.8
AU
0.00
0.20
0.40
0.60
0.80
1.00
15.083 Peak 2
200.9
324.8AU
0.00
0.20
0.40
nm
200.00 250.00 300.00 350.00 400.00 450.00 500.00 550.00
 
Figure 3.2: Spectra of 7-hydroxycoumarin and 7-ethoxycoumarin. A, showing                       
7-hydroxycoumarin, and B, 7-ethoxycoumarin, both with a λ max at 324.8nm.   
 
Following findings in the literature, the fluorescence parameters were 
adjusted to λex. 324nm and λemm. 458nm this gave the maximum peak area for 
7-hydroxycoumarin, the product. 
During incubation the 7-hydroxycoumarin peak area increased over time. The 
peak at min 2 represented the NADPH-regenerating system (Figure 3.3). 
The result showed a decrease in 7-ethoxycoumarin, the parent, and an 
increase in 7-hydroxycoumarin, the product, and this gave evidence for the 
A 
B 
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activity of MLiM enzymes; also, the NADPH-regenerating system was 
constantly donating electrons to the reaction.  
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Figure 3.3: Metabolism of 1µM 7-ethoxycoumarin in MLiM (1mg/ml) + NADPH (2mM) for 
30min. 7-hydroxycoumarin demonstrates a Rt 4.7min. The 7-hydroxycoumarin peak area 
increased over time from A in 5min, B in 10min and C in 30min incubation. The massive 
peak in min. 2 represents the NADPH-regenerating system. The fluorescence parameters 
were adjusted to λex. 324nm and λemm. 458nm. This gave the maximum peak area for the 
product but not for the 7-ethoxycoumarin. 
A 
B 
C t= 30 
t= 10 
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III.4.3. Metabolism of chloromethylindoline (ICT 2700) by four different 
bactosomes (CYP 1A1, CYP 2D6, CYP 3A4, CYP 1A2), three different 
mouse microsomes (liver, kidney, lung) and five samples of human liver 
microsomes 
The structure of the novel chloromethylindoline prodrug (ICT 2700) was 
based on the natural product duocarmycin (Scheme 3.2). This ICT 2700 is 
designed to be a potential substrate for CYP 1A1 activation.  
Therefore chloromethylindoline was incubated with a number of human 
bactosomes including CYP 1A1, CYP 2D6 and CYP 3A4 to investigate       
the influence of other CYP isoforms on the metabolism of ICT 2700.           
ICT 2700 was also tested in three different organs of mouse microsomes to 
see if any toxic metabolites were generated from normal mouse tissues. 
Moreover, 5 samples of human liver microsomes (HLM) were also examined 
to make sure no potentially toxic metabolites were produced. This also 
helped in investigating the influence of CYP 1A2 on CYP 1A1, as CYP 1A2 
represents almost 15% of the total CYP content in the human liver (Rendic, 
2002). Furthermore, incubations of the substrate with CYP 1A1 and CYP 1A2 
bactosomes were studied to investigate differences between the two 
enzymes. All these investigations were done in vitro and followed by 
separation of the metabolites in the HPLC then identification of the toxic 
metabolites in the LC-MS.   
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Scheme 3.2.: The structure of duocarmycin and chloromethylindoline (ICT 2700) prodrug 
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III.4.3.1. Identification of ICT 2700  
The optimised method in section III.3.7 was used to determine the optimum 
absorbance and mass to charge of ICT 2700. 
III.4.3.1.1.   Separation of ICT 2700 using HPLC 
ICT 2700 was scanned across the wavelength range 200-400nm. The 
detection of ICT 2700 was confirmed by making a scan of ICT 2700 (100µM) 
and the λ max being shown to be 330nm. The retention time was at 24.32min 
(Figure 3.4). 
ict2700
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Figure 3.4: Detection of  ICT 2700 (10µM) in HPLC. Reverse-phase LC was used for the 
separation of ICT 2700. A, chromatogram of ICT 2700 using diode array detection (DAD) at 
wavelength 330nm and Rt. 24.32min. B, spectrum of ICT 2700 showing the λ max to be 
330nm. 
A 
B 
 
DAD 330 nm 
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III.4.3.1.2. Separation of ICT 2700 using LC-MS 
Identification of the novel anticancer therapeutic ICT 2700 was confirmed by 
MS scanning of 10µM ICT 2700 in the range 220-520 (Figure 3.5). From the 
MS-spectrum (Figure 3.5) we can see two principal stable chlorine isotopes 
at m/z 380.2 and 382.2. This helps in monitoring the existence of chlorine in 
the metabolites. These parameters were used as controls for further studies 
of ICT 2700 metabolism.   
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Figure 3.5: Detection of ICT 2700 (10µM) by LC-MS. Reverse-phase LC was used for the 
separation of ICT 2700. A, B MS trace supporting correct identification of ICT 2700 in MS 
detector. A, total ion chromatogram (TIC) scanning of singularly charged ions [ES+] from 
220-520 with Rt. 24.34min. B, selected ion recording [SIR] in specific [ES+] m/z 380.2 with Rt. 
24.32min. C, spectral characteristics of ICT 2700 at m/z 380.2. This matches ICT 2700 FW 
(379.8) also showing two principal isotopes of chlorine (
35
Cl represented 75% and 
37
Cl 
represented 25%). 
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III.4.3.2. Metabolism of ICT 2700 by CYP 1A1 
The in vitro metabolism of ICT 2700 (100µM) by CYP 1A1 was examined to 
investigate the influence of this enzyme on ICT 2700.  
The method of incubation was as described in section III.3.4 and readings 
were taken at 0, 5, 10, 30, 60, 90 and 120min to identify any intermediate 
metabolites and to monitor increases in the peak area of each metabolite. 
Then the ICT 2700 and its metabolites were extracted using the method 
described in section III.5. Following this, the optimised method described in 
section III.7 was used to separate and identify all metabolites (Figure 3.6). 
Four metabolites were separated in HPLC beside the parent.  
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Figure 3.6: Metabolites of ICT 2700 (100µM) by CYP 1A1 bactosomes (30picomole/ml) + 
NADPH (2mM) for 120min (the incubation volume was 300µl). All HPLC traces of potential 
metabolites separated at Rt (M1) 23.78, (M2) 18.74, (M3) 16.89 and (M4) 13.59min using 
diode array detection at wavelength 330nm. The substrate (S1) eluted at Rt. 24.24min. 
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The parent, ICT 2700, was separated at Rt. 24.24min and the metabolites 
formed (M1, M2, M3 and M4) were eluted at Rt. 23.78, 18.74, 16.89 and 
13.59min respectively.  
During incubation, the intensities of the metabolites gradually increased while 
the amount of substrate gradually decreased with time of incubation (Figure 
3.7). This indicated that the substrate was consumed and metabolites were 
formed. All these peaks were detected using diode array detector (DAD) at 
wavelength 330nm.  
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Figure 3.7: Metabolism of ICT 2700 (100µM) by CYP 1A1 bactosomes (30picomole/ml) + 
NADPH (2mM) for 60min (the incubation volume was 300µl) using DAD at wavelength 
330nm. All HPLC traces showed the ICT 2700 decreased over time from A, time point 0min, 
the peak area was 19574 then in B, time point 30min, the peak area was 15525 while in C, 
time point 60min, the peak area  was 11233. However, the metabolites increased over time: 
initially in A, no metabolites were detected then after 30min B, the total peak area of 
metabolites was 903, while after 60min C, the total amount for metabolites was 1035.   
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m/z 396.24 
(M1, M2 and M3) 
 
 
 
Subsequent identification of the ICT 2700 (S1) and the metabolites formed by 
the substrate was performed by LC/MS analysis, and the mass to charge for 
each was S1 m/z 380.2. M1, M2 and M3 were all m/z 396.24 and M4 was 
m/z 360.0 (see Figure 3.8). The mass to charge for each metabolite 
compared to the structure of substrate helped in obtaining structural 
information for the metabolites. 
ict2700
Time
5.00 10.00 15.00 20.00 25.00 30.00 35.00 40.00
A
U
0.0
1.0e-3
2.0e-3
5.00 10.00 15.00 20.00 25.00 30.00 35.00 40.00
%
-5
95
5.00 10.00 15.00 20.00 25.00 30.00 35.00 40.00
%
-5
95
5.00 10.00 15.00 20.00 25.00 30.00 35.00 40.00
%
-5
95
29.22
28.69
25.85
13.67
3.022.02
12.03
9.865.95
23.85
21.1818.81
29.82 32.49
18.77
16.94
2.55
31.06
23.85
22.41
29.2226.92
24.31
2.78
24.25
18.74
2.87
0.12
13.64
3.35 8.747.89 11.89
16.87
23.80
22.87
30.15
29.14
27.84
30.45
32.00 33.30
35.39
 
Figure 3.8: Metabolites of ICT 2700 (100µM) by CYP 1A1 bactosomes (30picomole/ml) + 
NADPH (2mM) for 120min (the incubation volume was 300µl). Reverse-phase LC was used 
for the separation of A, substrate and their metabolites detected using diode array detection 
at wavelength 330nm.  B, S1 (ICT 2700) eluted at Rt. 24.31min and the mass to charge was 
m/z 380.2. MS traces of C, M1 (Rt. 23.85), M2 (Rt.18.77 min) and M3 (Rt. 16.94 min). All 
these metabolites were detected at m/z 396.24 and D, M4 (Rt. 13.67min) metabolite was 
detected at m/z 360.0. 
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The formation of ICT 2700 metabolites by CYP 1A1 also required the 
presence of NADPH as an electron donor to the reaction. The incubation of 
ICT 2700 in the presence of CYP 1A1 and in the absence of NADPH 
produced no metabolites (Figure 3.9.). This process confirmed that             
ICT 2700 was catalyzed by CYP 1A1 when supplemented with NADPH. 
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Figure 3.9: The activity of CYP 1A1 (30picomole/ml) in ICT 2700 (100µM) without NADPH for 
120min. HPLC reverse phase was used to determine the metabolism of ICT 2700 in the 
absence of NADPH. There is no metabolite detected at wavelength 330nm for 120min. The 
substrate eluted at (S1) Rt. 24.40min. 
 
For the M1, M2 and M3 metabolites (Rt. at 23.84, 18.76 and 16.93min 
respectively) the mass to charge was detected at m/z 396.24. This is clearly a 
hydroxylation of ICT 2700; however it is difficult to predict the exact site of 
hydroxylation (see Figure 3.10 and Scheme 3.3). 
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Figure 3.10: Reverse-phase LC-MS was used for the separation metabolites of ICT 2700 
(100µM) by CYP 1A1 bactosomes (30picomole/ml) + NADPH (2mM) for 120min (the 
incubation volume was 300µl) using selected ion recording (SIR) m/z 396.2 and the Rt. for 
M1, 23.84min, M2, 18.76min and M3, at 16.93min. 
   
 
HN
CH3O
O
N
NH
Cl
HO
C21H18ClN3O3
395.85
395.103669
C 63.72% H 4.58% Cl 8.96% N 10.62% O 12.13% 
    
Scheme 3.3: The anticipated chemical structure of one of the M1, M2 and M3 metabolites 
(FW 395.8). The addition of the hydroxyl group may be in a different place. 
 
In the M4 metabolite (Rt. at 13.65min) the mass to charge was detected at       
m/z 360.0. This is likely to be the result of a potential hydroxylation followed 
by dechlorination resulting in a potential toxic metabolite (see Figure 3.11 and 
Scheme 3.4). Clearly one of the hydroxylated metabolites is an intermediate 
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for this process. The intermediate metabolite is likely to be one of the M1, M2 
and M3 metabolites (Figure 3.10). 
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Figure 3.11: Reverse-phase LC was used for the separation of metabolites of ICT 2700 
(100µM) by CYP 1A1 bactosomes (30picomole/ml) + NADPH (2mM) for 120min (the 
incubation volume was 300µl) using A, SIR m/z 360.0 and the Rt. for M4 at 13.65min. B, 
spectral characteristics of metabolite at m/z 360.0. This shows that no isotopes of chlorine 
were detected and supports the loss of chlorine in the metabolite. 
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Scheme 3.4: The anticipated chemical structure of M4 (potential toxic) metabolite FW 359.38 
 
The peak of interest (m/z 360.0) was detected at time point 8min (t= 8) of 
incubation (Figure 3.12) then continued to increase with time.     
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Figure 3.12: Metabolism of ICT 2700 (100µM) by CYP 1A1 bactosomes (30picomole/ml) + 
NADPH (2mM) for 60min (the incubation volume was 300µl). Traces of the potent toxic 
metabolite separated at Rt. 13.65min in SIR at m/z 360.0 At time points 0, 2 and 4min (A-C) 
there are no metabolite peaks, then in D, E, F and G the metabolite peak area appears in 
8min then increases in 10, 30, 60min incubation. 
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III.4.3.3. Metabolism of ICT 2700 by CYP 2D6 
The in vitro metabolism of ICT 2700 (100µM) in the presence of CYP 2D6 
bactosomes supplemented with NADPH was examined. The methodology 
was similar to that described in section III.4.3.2 unless otherwise stated. 
The method of incubation was the same as in section III.3.4 and the 
extraction method was the same as in section III.3.5. Following incubation all 
metabolites were identified (Figure 3.13). Only two metabolites were detected 
(M5 and M6), at Rt. 16.95 and 13.54min respectively, and the substrate (S1) 
separated at Rt. 24.20min. 
ict2700
Time
5.00 10.00 15.00 20.00 25.00 30.00 35.00 40.00
A
U
-5.0e-4
0.0
5.0e-4
1.0e-3
1.5e-3
2.0e-3
2.5e-3
3.0e-3
3.5e-3
4.0e-3
4.5e-3
5.0e-3
24.20
13.54
2.59
3.10
23.70
16.95
29.84
28.84
 
 
Figure 3.13: Metabolites of ICT 2700 (100µM) by CYP 2D6 bactosomes (30picomole/ml) + 
NADPH (2mM) for 120min (the incubation volume was 300µl). All HPLC traces of potential 
metabolites separated at Rt. (M5) 16.95 and (M6) 13.54min using diode array detection at 
wavelength 330nm, and the substrate (S1) eluted at Rt. 24.20min. 
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Subsequent identification of the ICT 2700 (S1) and the metabolites formed by 
the substrate was performed by LC/MS analysis. The mass to charge for S1 
was m/z 380.20, M5 was m/z 396.23, and M6 was m/z 366.21 (Figure 3.14). 
The mass to charge ratio for each metabolite compared to the structure of the 
substrate helped in obtaining structural information for the metabolites.  
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Figure 3.14: Metabolites of ICT 2700 (100µM) by CYP 2D6 bactosomes (30picomole/ml) + 
NADPH (2mM) for 120min (the incubation volume was 300µl). Reverse-phase LC was used 
for the separation of A, M6 metabolite (Rt. 14.86min) was detected at m/z 366.21. B, M5 
metabolite (Rt. 18.46min) was detected at m/z 396.23. MS traces of C, S1 (ICT 2700) eluted 
at Rt. 25.61min and the mass to charge was m/z 380.20. D, the substrate and its metabolites 
were detected using diode array detection at wavelength 330nm. 
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The M5 metabolite (Rt. at 18.46min) was detected at SIR m/z 396.2. This is 
likely due to hydroxylation of ICT 2700 (see Figure 3.15 and Scheme 3.3). 
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Figure 3.15: Reverse-phase LC was used for the separation of ICT 2700 (100µM) 
metabolites by CYP 2D6 bactosomes (30picomole/ml) + NADPH (2mM) for 120min (the 
incubation volume was 300µl) using A, SIR m/z 396.2 and the Rt. for M5 at 18.41min.  
 
The M6 (Rt. at 14.86min) metabolite was detected at SIR m/z 366.2. This can 
be explained by demethylation of ICT 2700 (see Figure 3.16 and Scheme 
3.5). 
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Figure 3.16: Reverse-phase LC was used for the separation of ICT 2700 (100µM) 
metabolites by CYP 2D6 bactosomes (30picomole/ml) + NADPH (2mM) for 120min (the 
incubation volume was 300µl) using A, SIR m/z 366.2, and the Rt. for M6 was 14.86min. B, 
spectral characteristics of metabolite at m/z 366.2. This shows the principal isotopes of 
chlorine were detected at m/z 366.2 and 368.2 in about 75% and 25% respectively. 
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Scheme 3.5.: The anticipated chemical structure of the M7 metabolite (FW 365.82). 
 
It is significant that no metabolites were detected in SIR at m/z 360.0. The 
incubation of ICT 2700 with CYP 2D6 in the absence of NADPH 
demonstrated no metabolites (figures not shown).  
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III.4.3.4. Metabolism of ICT 2700 by CYP 3A4 
In this reaction, in vitro CYP 3A4 bactosomes supplemented with NADPH 
catalyzed the metabolism of ICT 2700 (100µM).  
The method of incubation was the same as that used in section III.3.4 and the 
extraction method was the same as in section III.3.5. After that, the optimised 
method in section III.3.7 was used to separate and identify all metabolites 
(Figure 3.17). Three metabolites (M8, M9, and M10) were separated in HPLC 
and detected with wavelength 330nm at Rt. 20.39, 18.26 and 14.74min 
respectively, and the substrate (S1) separated at Rt. 25.52min. 
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Figure 3.17: Metabolites of ICT 2700 (100µM) by CYP 3A4 bactosomes (30picomole/ml) + 
NADPH (2mM) for 120min (the incubation volume was 300µl). All HPLC traces of potential 
metabolites separated at Rt. (M8) 20.39, (M9) 18.26 and (M10) 14.74min using DAD at 
wavelength 330nm, and the substrate eluted at (S1) Rt. 25.52min. 
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Identification of the ICT 2700 (S1) and its metabolites was performed by 
LC/MS analysis. The mass to charge for S1 was m/z 380.2, M8 was m/z 
396.23, M9 was m/z 366.24 and M10 was m/z 362.32 (see Figure 3.18). The 
mass to charge for the metabolites compared to the structure of the substrate 
helped in obtaining structural information for the metabolites.  
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Figure 3.18: Metabolites of ICT 2700 (100µM) by CYP 3A4 bactosomes (30picomole/ml) + 
NADPH (2mM) for 120min (the incubation volume was 300µl). Reverse-phase LC was used 
for the separation of A, M10 metabolite (Rt. 11.13min) was detected at m/z 362.32. B, M9 
metabolite (Rt. 13.11min) was detected at m/z 366.24. C, M8 metabolite (Rt. 16.23min) was 
detected at m/z 396.23. D, MS traces of S1 (ICT 2700) eluted at Rt. 23.46 min and the mass 
to charge was m/z 380.2. E, substrate and its metabolites were detected using diode array 
detection at wavelength 330nm.  
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The M8 metabolite (Rt. at 16.25min) was detected at SIR m/z 396.3. This is 
likely due to hydroxylation as seen previously (see Figure 3.19 and Scheme 
3.3).  
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Figure 3.19: Reverse-phase LC was used for the separation of ICT 2700 (100µM) 
metabolites by CYP 3A4 bactosomes (30picomole/ml) + NADPH (2mM) using A, SIR m/z 
396.3 and the Rt. for M8, 16.25min. B, spectral characteristics of metabolite at m/z 396.3. 
These shows the principal isotopes of chlorine were detected at m/z 396.3 and 398.4. 
 
The M9 metabolite (Rt. at 13.09min) was detected at SIR m/z 366.4. This can 
be explained by a demethylation of ICT 2700 (see Figure 3.20 and           
Scheme 3.5).   
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Figure 3.20: Reverse-phase LC was used for the separation of ICT 2700 (100µM) 
metabolites by CYP 3A4 bactosomes (30picomole/ml) + NADPH (2mM) using A, SIR m/z 
366.2 and the Rt. for M9 was 13.09min. B, spectral characteristics of metabolite at m/z 366.2. 
This shows the principal isotopes of chlorine were detected at m/z 366.4 and 368.3 in about 
75% and 25% respectively.  
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The M10 metabolite (Rt. at 11.09min) was detected at m/z 362.2. This is 
likely due to a replacement of chlorine with a hydroxyl group (Scheme 3.6).   
N
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O
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O CH3
C21H19N3O3
361.40
361.142642
C 69.79% H 5.30% N 11.63% O 13.28% 
 
Scheme 3.6: The anticipated chemical structure of M10 metabolite (FW 361.40) 
None of the potentially toxic metabolites (m/z 360.0) were seen when         
ICT 2700 was incubated in the presence of CYP 3A4 and in the absence of 
NADPH. Incubation without NADPH demonstrated no metabolites at all 
(figures not shown). 
III.4.3.5. Metabolism of ICT 2700 by mouse liver microsomes  
In mammals, CYP families are mainly localised in the liver. Thus, the in vitro 
metabolism of ICT 2700 (100µM) in mouse liver microsomes (MLiM) was 
performed to conduct a metabolic study of ICT 2700 in the presence of MLiM 
supplemented with NADPH. The reaction was incubated for 120min.  
The method of preparing MLiM was same as in section III.3.1.1 and the 
protein concentration was measured as in section III.3.2. The microsome 
incubation method was the same as in section III.3.3 and the extraction 
method was the same as in section III.3.5. Then, the optimised method used 
in section III.3.7 was used to separate and identify all metabolites (Figure 
3.21).  
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M12 
 
Four metabolites (M11, M12, M13, and M14) were separated in HPLC and 
detected with wavelength 330nm at Rt. 19.21, 17.44, 15.21 and 14.01min 
respectively. The substrate (S1) separated at Rt. 24.74min. 
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Figure 3.21: Metabolites of ICT 2700 (100µM) in MLiM (1mg/ml) + NADPH (2mM) for 120min 
(the incubation volume was 300µl). All HPLC traces of potential metabolites separated at Rt. 
(M11) 19.21, (M12) 17.44, (M13) 15.21and (M14) 14.01min. using diode array detection at 
wavelength 330nm, and the substrate eluted at (S1) Rt. 24.74min.  
 
Subsequently identification of the ICT 2700 (S1) and its metabolites was 
performed by LC/MS analysis. The mass to charge for S1 was m/z 380.2, 
M11 and M12 were m/z 396.23, M13 was m/z 360.04, and M14 was m/z 
412.21 (see Figure 3.22).  
Comparing the mass to charge of the metabolites to that of the substrate 
helped in obtaining structural information for the metabolites.   
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Figure 3.22: Metabolites of ICT 2700 (100µM) in MLiM (1mg/ml) + NADPH (2mM)for 120min. 
Reverse-phase LC was used for the separation of A, the M14 metabolite (Rt. 11.52min) was 
detected at m/z 412.21. B, M13 metabolite (Rt. 14.86min) was detected at m/z 360.04. C, 
M12 and M11 metabolites (Rt. 18.39 and 20.16min respectively) were detected at m/z 
396.23. D, MS traces of S1 (ICT 2700) were eluted at Rt. 25.67min and the mass to charge 
was m/z 380.2. E, substrate and its metabolites were detected using diode array detection at 
wavelength 330nm. 
The M11 and M12 metabolites (Rt. at 20.18 and 18.44min respectively) were 
detected at SIR m/z 396.2. The hydroxyl group was added to the ICT 2700 
and might be in a different position for each metabolite (see Figure 3.23 and 
Scheme 3.3).  
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Figure 3.23: Reverse-phase LC was used for the separation of ICT 2700 (100µM) 
metabolites by MLiM (1mg/ml) + NADPH (2mM) using A, SIR m/z 396.2 and the Rt. for M11, 
20.18min and M12, at 18.44min. B, spectral characteristics of metabolite at m/z 396.2. These 
shows the principal isotopes of chlorine were detected at m/z 396.2 and 398.2.  
 
In the M13 metabolite (Rt. at 14.86min) the mass to charge was detected at    
m/z 360.2. This is likely to be the result of potential hydroxylation followed by 
dechlorination resulting in a potential toxic metabolite (see Figure 3.24 and 
Scheme 3.4). This result is discussed in more detail later with comparison to 
MLiM and three human bactosomes including CYP 1A1 (see section III.4.3.6).  
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Figure 3.24: Reverse-phase LC was used for the separation of ICT 2700 (100µM) 
metabolites by MLiM (1mg/ml) + NADPH (2mM) using A, SIR m/z 360.2 and the Rt. for M13 
at 14.86min. B, spectral characteristics of metabolite at m/z 360.2. This shows that no 
isotopes of chlorine were detected and supports the loss of chlorine in the metabolite.  
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In the M14 metabolite (Rt. at 11.47min) the mass to charge was detected at 
m/z 412.2. This can be explained by a double hydroxylation of ICT 2700 (see 
Figure 3.25 and Scheme 3.7). 
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Figure 3.25: Reverse-phase LC was used to separate the metabolites of ICT 2700 (100µM) 
in MLiM (1mg/ml) + NADPH (2mM)using A, SIR, m/z 412.2 and the Rt. for M14 at 11.47min. 
B, spectral characteristics of metabolite at m/z 412. This shows that the principal isotopes of 
chlorine were detected at m/z 412 and 414.  
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Scheme 3.7: The anticipated chemical structure of the M14 metabolite (FW 411.84). 
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III.4.3.6. The comparison of the metabolism of ICT 2700 in three different 
bactosomes (CYP 1A1, CYP 2D6, CYP 3A4) and in mouse liver 
microsomes 
ICT 2700 and all metabolites created when incubated with CYP 1A1,         
CYP 2D6, CYP 3A4, and MLiM were compared at DAD 330nm then identified 
by the LC/MS (Figure 3.26). Four main metabolites were detected at m/z 
412.2, 396.2, 366.2 and 360.0, beside the substrate at m/z 380.2. For more 
details about the potential metabolites of ICT 2700 see Appendix E.  
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Figure 3.26: Comparing the metabolites of ICT 2700 (100µM) by CYP 1A1, CYP 2D6,         
CYP 3A4, (30picomole/ml)  + NADPH (2mM)and MLiM (1mg/ml) after 2 hours incubation (the 
incubation volume was 300µl). All HPLC traces of 4 main metabolites were detected at 
wavelength 330nm then identified by LC-MS at m/z 412.2, 396.2, 366.2 and 360.0, while the 
substrate was at m/z 380.2.  
 
m
/z
 3
9
6
.2
  
m
/z
 3
9
6
.2
  
 m
/z
 3
8
0
.2
  
m
/z
 3
6
0
.0
  
 
MLiM 
3A4 
1A1 
2D6 
 
DAD 330nm 
m
/z
 4
1
2
.2
  
 
Catalyzing properties of CYP 1A1                                                                 Chapter 3  
 
89 
Comparisons were then made between incubations of the different CYPs 
using specific SIR channels, firstly an SIR of m/z 396.2 (Figure 3.27).   
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Figure 3.27: Reverse-phase LC was used for the separation of ICT 2700 (100µM) 
metabolites by CYP 1A1, CYP 2D6, CYP 3A4, bactosomes (30picomole/ml) and MLiM 
(1mg/ml) + NADPH (2mM) after 2 hours incubation using SIR m/z 396.2. Three peaks 
separated in MLiM, one peak in CYP 3A4, one peak in CYP 2D6 and three peaks in         
CYP 1A1. The different peaks are likely to represent the addition of -OH at different positions 
in the molecule. 
 
For channel m/z 396.2, three possible hydroxylated metabolites were 
detected in MLiM and CYP 1A1 incubations while one metabolite was 
detected with CYP 2D6 and one small peak was detected with CYP 3A4. 
For channel m/z 366.2, a possible demethylation, one peak was detected in 
MLiM, CYP 2D6 and CYP 3A4, whereas there was no evidence of 
demethylated metabolites with CYP 1A1 (Figure 3.28). 
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Figure 3.28: Reverse-phase LC was used for the separation of ICT 2700 (100µM) 
metabolites by CYP  1A1, CYP 2D6, CYP 3A4, bactosomes (30picomole/ml) and MLiM 
(1mg/ml) + NADPH (2mM) after 2 hours incubation using SIR m/ z 366.2. One peak 
separated in MLiM, no peaks in CYP 1A1, one big peak in CYP 2D6 and one peak in       
CYP 3A4.  
 
In channel m/z 360.0, a big peak separated in CYP 1A1 and a small peak in 
MLiM. The dechlorination comes after hydroxylation, but no peaks were 
detected in either CYP 2D6 or CYP 3A4 (Figure 3.29). 
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Figure 3.29: Reverse-phase LC was used for the separation of ICT 2700 (100µM) 
metabolites by CYP 1A1, CYP 2D6, CYP 3A4, bactosomes (30picomole/ml) and MLiM 
(1mg/ml) + NADPH (2mM) after 2 hours incubation using SIR m/z 360.0. One tiny peak 
separated in MLiM, no peaks in both CYP 3A4 and CYP 2D6 and one big peak in CYP 1A1.   
 
In channel m/z 412.2, a double hydroxylation, only one peak was separated 
in MLiM (Figure 3.30). 
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Figure 3.30: Reverse-phase LC was used for the separation of ICT 2700 (100µM) 
metabolites of CYP 1A1, CYP 2D6, CYP 3A4, bactosomes (30picomole/ml) and MLiM 
(1mg/ml) + NADPH (2mM) after 2 hours incubation using SIR m/z 412.2. One peak 
separated in MLiM and no peaks in CYP 3A4, CYP 2D6 or CYP 1A1. 
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III.4.3.7. The fragmentation of ICT 2700 as a tool to determine where the 
metabolism occurs following CYP 1A1 and CYP 2D6 activation 
Manipulation of the collision energy (CE) was used to fragment ICT 2700. 
Addition or subtraction of metabolic species from each fragment following 
incubation with CYP 1A1 and CYP 2D6 enables an estimate of where on the 
molecule the metabolism occurred (Scheme 3.8). 
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Scheme 3.8: Fragmentation of ICT 2700 
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Figure 3.31: Reverse-phase LC/ MS- MS was used for the separation of ICT 2700 (100µM). 
A daughter scan was used to obtain 2 fragments, m/z 175 and m/z 205, from the parent ion.   
  
ICT2700Frag1
MW = 175.18
CH3O
O
NH
ICT2700Frag2
MW = 205.7HN
Cl
N
Catalyzing properties of CYP 1A1                                                                 Chapter 3  
 
93 
For example it was important to understand that hydroxylation by CYP 1A1 is 
on the left hand side (Scheme 3.8) of the molecule followed by a loss of 
chlorine in order for the potentially toxic spirocyclisaion to occur. Another 
example is demethylation catalyzed by CYP 2D6. The metabolism was where 
the methoxy group exists in the right hand part of ICT 2700.  
In LC/MS-MS mode, ICT 2700 was first monitored at wavelength 330nm and 
Rt. was 23.39min (Figure 3.31). 
Two daughters were obtained from the fragmentation of ICT 2700, and the 
mass to charges were m/z 205 and m/z 175. The existence of these 
fragments in each metabolite was monitored. Fragmentations of ICT 2700 
incubated with CYP 1A1 were observed (Figure 3.32).  
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Figure 3.32: Metabolites of ICT 2700 (100µM) by CYP 1A1 bactosomes (30picomole/ml) + 
NADPH (2mM) for 120min (the incubation volume was 300µl) using DAD at wavelength 
330nm. Fragmentation of the metabolites shows a possible hydroxylation in peak at Rt. 
19.04min (i.e. m/z 174+ 16) and a dechlorination in Rt. 17.43, 10.95 and 8.32min. See text 
for description of masses.  
 
 
m z 205 
m/z 174 
ICT2700Frag1
MW = 160.18
O
O
NH
ICT2700Frag2
MW = 205.7HN
Cl
N
m/z 190 
 
m/z 186 
m/z 174 
m/z 186 
m/z 190 
m/z 186 
 
Catalyzing properties of CYP 1A1                                                                 Chapter 3  
 
94 
An m/ z 190 suggest a possible hydroxylation has occurred in the right hand 
part of molecule (Frag1).    
For m/z 186 the result is explained by a possible hydroxylation followed by a 
dechlorination in the active part (left hand) of the molecule (Frag2). There is 
also the possibility that the process of fragmentation in the collision cell 
causes dechlorination as an artefact of the MS process and is not necessarily 
a metabolic event.  
Fragmentations of ICT 2700 incubated with CYP 2D6 were observed    
(Figure 3.33). An m/z 160 suggests a possible demethylation has occurred in 
the right hand part of the molecule (Frag1) (i.e. m/z 175-15= m/ z 160). This 
is clearly showing that the predominant product formed by metabolism with 
CYP 2D6 is a demethylated product. 
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Figure 3.33: Metabolites of ICT 2700 (100µM) by CYP 2D6 bactosomes (30picomole/ml) + 
NADPH (2mM) for 120min (the incubation volume was 300µl) detected at wavelength 330nm. 
Fragmentation in MRM shows a possible of hydroxylation in peak at Rt. 17.55min and 
demethylation in Rt. 14.75min. 
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III.4.3.8. Metabolism of ICT 2700 by CYP 1A2 
CYP 1A1 and CYP 1A2 enzymes share approximately 70% homology in their 
amino acid sequences (Berndtson and Chen, 1994; Boyd et al., 1995; Wakui 
et al., 2005). In this study, the toxic metabolite of ICT 2700 incubated with 
CYP 1A1 has been confirmed (see sections III.4.3.2. and III.4.4.). Therefore, 
the selectivity of CYP 1A1 to the prodrug was evaluated by examining this 
prodrug with the closest enzyme to CYP 1A1 which is CYP 1A2. CYP 1A2 
represents 15% of human hepatic CYP content (Shirley et al., 2003). Hence 
the activity of CYP 1A2 human bactosomes was observed by incubation of 
ICT 2700 in the presence of CYP 1A2 and NADPH, taking into account that 
this incubation was in an artificial environment with a high concentration of 
one enzyme and there was no competition with other CYPs for metabolising 
ICT 2700.  
The method of incubation is described in section III.3.4 and the extraction 
method is described in section III.3.5. Following incubation, the optimised 
method in section III.3.7 was used to separate and identify all metabolites. 
The substrate (S1) was eluted at Rt. 24.63min while the chromatographic 
peaks of the formed metabolites (M15, M16, M17 and M18) were eluted at Rt. 
24.14, 19.21, 17.34 and 14.04min respectively (Figure 3.34). 
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Figure 3.34: Metabolites of ICT 2700 (100µM) by CYP 1A2 bactosomes (30picomole/ml) + 
NADPH (2mM) for 120min (the incubation volume was 300µl). All HPLC traces of potential 
metabolites separated at Rt. (M15) 24.14, (M16) 19.21, (M17) 17.34 and (M18) 14.04min 
using diode array detection at wavelength 330nm. The substrate (S1) was eluted at Rt. 
24.63min. 
The chromatograms of the reaction solutions revealed 4 peaks corresponding 
to metabolites formed by CYP 1A1. The formation of ICT 2700 metabolites by 
CYP 1A2 also required the presence of NADPH. 
Subsequent identification of the metabolites formed by ICT 2700 was 
performed by LC/MS analysis and the mass to charge for each was S1 (m/z 
380.2). M15, M16 and M17 were all at m/z 396.24 and M18 was at (m/z 
360.0) (Figure 3.35). The mass to charge results in the CYP 1A2 bactosomes 
were identical to the CYP 1A1 metabolites results in section III.4.3.2. 
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Figure 3.35: Metabolites of ICT 2700 (100µM) by CYP 1A2 bactosomes (30picomole/ml) + 
NADPH (2mM) for 120min (the incubation volume was 300µl). Reverse-phase LC was used 
for the separation of A, substrate and its metabolites, detected using diode array detection at 
wavelength 330nm. B, S1 (ICT 2700) were eluted at Rt. 24.34min and the mass to charge 
was m/z 380.2. MS traces of C, M15 (Rt. 23.84min), M16 (Rt.18.80min) and M17 (Rt. 16.93 
min) metabolites were all detected at m/z 396.2, and D, M18 (Rt. 13.70min) metabolites were 
detected at m/z 360.0. 
III.4.3.9. Metabolism of ICT 2700 by mouse kidney microsomes 
The same in vitro procedure for the metabolic study of 100 µM ICT 2700 for 
MLiM as that used in section III.4.3.5 was conducted in presence of mouse 
kidney microsomes (MKM). The activity of MKM in ICT 2700 was studied to 
see if any metabolic products appeared in normal tissue.  
There was no evidence of any metabolite formation using MKM (Figure 3.36).  
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Figure 3.36: Incubation of ICT 2700 (100µM) with MKM (1mg/ml) + NADPH (2mM) for 
120min (the incubation volume was 300µl). The graph shows no metabolite was detected 
using diode array detection at wavelength 330nm. The substrate (S1) was eluted at Rt. 
24.35min. 
III.4.3.10. Metabolism of ICT 2700 by mouse lung microsomes  
The same in vitro procedure for the metabolic study of 100 µM ICT 2700 for 
MLiM as that used in section III.4.3.5 was carried out in the presence of 
mouse lung microsomes (MLuM) for 120min. The reason for studying the 
stability of ICT 2700 in MLuM was the same as in the previous section 
III.4.3.9. 
There was no evidence of any metabolite formation using MLuM           
(Figure 3.37). 
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Figure 3.37: Incubation of ICT 2700 (100µM) with MLuM (1mg/ml) + NADPH (2mM) for 
120min (the incubation volume was 300µl). This shows that no chromatographic peak of 
metabolite was detected using diode array detection at wavelength 330nm.  
III.4.3.11. Metabolism of ICT 2700 by human liver microsomes  
The in vitro metabolism of ICT 2700 (100µM) in five different human liver 
microsomes (HLM) was studied to investigate the metabolism of ICT 2700 in 
the presence of HLM supplemented with NADPH. The human liver is the 
main organ involved in metabolism in the body and most CYP families are 
primarily localised in the liver. This shows the importance of studying the 
metabolism of ICT 2700 in HLM.   
The method of preparing HLM for all samples was same as in section III.3.1 
and the protein concentration was measured as in section III.3.2. The 
microsome incubation method was the same as in section III.3.3 and the 
extraction method was the same as in section III.3.5. Then the optimised 
method in section III.3.7 was used to separate and identify all metabolites. 
For more details about the HLM samples see Appendix A. 
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The results for the potential metabolites for all five HLM samples were more 
or less the same, so the figures for one HLM sample (code number ET-3124) 
are given in the next section.     
III.4.3.11.1. The activity of ICT 2700 in HLM (ID Number, ET- 3124) 
In one HLM sample, code number ET-3124, three metabolites (M20, M21 
and M22) were separated in HPLC and detected in wavelength 330nm at Rt. 
18.51, 16.23 and 12.58min respectively. The substrate (S1) separated at Rt. 
24.84min (Figure 3.38). 
During incubation, the intensities of the metabolites gradually increased with 
time of incubation (Figure 3.38). All these peaks were detected using diode 
array detector (DAD) at wavelength 330nm. 
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Figure 3.38: Metabolites of ICT 2700 (100µM) in HLM (1mg/ml), code ET-3124, for 120min 
(the incubation volume was 300µl). All potential metabolites separated at Rt. (M20) 18.51, 
(M21) 16.23 and (M22) 12.58min using diode array detection at wavelength 330nm. The 
substrate (S1) eluted at Rt. 24.84min.  
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Subsequently, identification of the ICT 2700 (S1) and its metabolites was 
performed by LC/MS analysis. The mass to charge for S1 was m/z 380.2, 
parent molecule, M20 and M21 was at m/z 396.23, hydroxylation, and M22 
was at m/z 366.26, demethylation (see Figure 3.39).   
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Figure 3.39: Metabolites of ICT 2700 (100µM) in HLM (1mg/ml), code ET-3124, + NADPH 
(2mM) for 120min (the incubation volume was 300µl). Reverse-phase LC was used for the 
separation of A, M22 metabolite (Rt. 13.21min) was detected at m/z 366.26. B, M20 and M21 
metabolites (Rt. 18.76 and 16.49min respectively) were detected at m/z 396.23. C, MS 
traces of S1 (ICT 2700) eluted at Rt. 25.21min and the mass to charge was m/z 380.2. D, 
substrate and its metabolites were detected using diode array detection at wavelength 
330nm. 
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M20 and M21 were identified as hydroxylation products (Scheme 3.3) 
whereas M22 was identified as a demethylation of ICT 2700 (Scheme 3.5). 
The incubation of ICT 2700 in the presence of HLM and in the absence of 
NADPH demonstrated no metabolites; also no peaks were detected in SIR at 
m/z 360.0, the potential toxic metabolite (figures not shown). 
III.4.4.The cytotoxicity of ICT 2700 metabolites from three different 
bactosomes (CYP 1A1, CYP 2D6, CYP 3A4) and mouse liver 
microsomes 
Although metabolites were identified via LC/MS following incubation of        
ICT 2700 with three selected human bactosomes CYP 1A1, CYP 2D6 and 
CYP 3A4 and MLiM, it was important to investigate whether these 
metabolites (or others not detected) were potentially toxic using human 
bladder carcinoma cell line (EJ-138). The methods used are described in 
sections II.2.5 and III.3.8. 
III.4.4.1. Cell line growth curve 
Growth curves of the EJ-138 were monitored (section II.2.4) in order to 
choose the correct concentration of cells and to be sure that cells were in 
exponential growth during the 4 day incubation. The EJ-138 cells were 
seeded at concentrations of 1x 103, 3x 103, 1x 104, and   3x 104cells/ml in a 
volume of 200μl in each well, so the number of cells was 200, 600, 2000, and 
6000 cells per well respectively. Cell counts revealed all concentrations were 
in log phase when incubated for 4 days so any one of these concentrations 
could be used to test the viability of EJ-138 cells (Table 3.2 and Figure 3.40). 
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Table 3.2: An absorbance of four concentrations of EJ-138 cells during 4 days of incubation 
at 540nm. Each absorbance number represents the average of 6 well plate readings. 
 
Cell number (cells/ ml) 
Days 1x10
3
 3x10
3
 1x10
4
 3x10
4
 
0 0.0005 0.0045 0.019333 0.053 
1 0.006167 0.021333 0.103833 0.351167 
2 0.009333 0.030167 0.1655 0.523667 
4 0.036333 0.148167 0.521833 1.1755 
 
 
 
Figure 3.40: Growth curves of four cell seeding densities of bladder carcinoma cell line      
(EJ-138) in 4 days. Growth curves were obtained by plotting the optical density of MTT at 
540nm against the time period (days).  
 
III.4.4.2.   In vitro chemosensitivity testing 
First, ICT 2700 was incubated with human bactosomes CYP 1A1, CYP 2D6,       
CYP 3A4 or MLiM using the method described in section III.3.8.2, then       
EJ-138 cells with concentration 1x104cell/ml were exposed to five 
concentrations of ICT 2700 and its metabolites (10µM-1nM of substrate) for 
72hrs. Afterwards the MTT assay was employed to observe cytotoxic potency. 
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All methods were as described in section III.3.8. Two time points (0 and 
120min) of incubations were used to consider the activity of the metabolites 
and to exclude the effects of other compounds in the reaction such as the 
parent (ICT 2700) or DMSO. The reason for using the EJ-138 cells was 
because they show a low expression of CYPs (Sutherland et al., 2012) (see 
Appendices J and M).  
Incubation of the ICT 2700 metabolites with the EJ-138 cells revealed that 
cell viability was very low after incubation of ICT 2700 with CYP 1A1 for 120 
min (T 120) compared to initial incubation 0min (T0)  (Figure 3.41). 
 
Figure 3.41: Cytotoxicity of five serial dilutions of metabolites from incubation of ICT 2700 
(100µM) with (30p.mol) CYP 1A1 bactosomes+ NADPH (2mM) for 120min on bladder 
carcinoma cell lines   (EJ-138). Error bars (SD) were obtained from 3 independent 
experiments. The blue line (T0) represents initial enzyme incubation and the red line (T120) 
represents 2hrs incubation of ICT 2700 with CYP 1A1. 
The incubation of the ICT 2700 metabolites in the EJ-138 cells showed that 
cell viability after incubation with CYP 2D6 for 120min (T120) was 
approximately the same as at initial incubation (T0) (Figure 3.42). 
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Figure 3.42: Cytotoxicity of five serial dilutions of metabolites from incubation of ICT 2700 
(100µM) with (30p.mol) CYP 2D6 bactosomes+ NADPH (2mM) for 120min on bladder 
carcinoma cell lines (EJ-138). Error bars (SD) were obtained from 3 independent 
experiments. The blue line (T0) represents cell viability with initial incubation and the red line 
illustrates (T120) 2hrs incubation of ICT 2700 with CYP 2D6. 
The incubation of the ICT 2700 in the EJ-138 cells demonstrated that cell 
viability after incubation with CYP 3A4 for 120min (T120) was approximately 
the same as at initial incubation (T0) (Figure 3.43). 
 
Figure 3.43: Cytotoxicity of five serial dilutions of metabolites from incubation of ICT 2700 
(100µM) with (30p.mol) CYP 3A4 bactosomes+ NADPH (2mM) for 120min on bladder 
carcinoma cell lines (EJ-138). Error bars (SD) were obtained from 3 independent 
experiments. The blue line (t0) represents cell viability with initial incubation and the red line 
(t120) represents 2hrs incubation of ICT 2700 with CYP 3A4. 
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The incubation of the ICT 2700 in the EJ-138 cells demonstrated that cell 
viability after incubation with MLiM for 120min (T120) was slightly less than at 
initial incubation (T0) in dilutions 10 and 1µM of ICT 2700 (Figure 3.44). 
 
Figure 3.44: Cytotoxicity of serial dilutions of metabolites from incubation of ICT 2700 
(100µM) with (1mg/ml) MLiM+ NADPH (2mM) for 120min on bladder carcinoma cell lines 
(EJ-138). Error bars (SD) were obtained from 3 independent experiments. The blue line (T0) 
represents cell viability with initial incubation and the red line (T120) represents 2hrs 
incubation of ICT 2700 with MLiM.  
 
The values of IC50 reflect the concentration of drug that is required to reduce 
cell survival by 50%. Cells were incubated with compounds for 72hrs and IC50 
values of chloromethylindoline metabolites were derived from cell viability 
curves for each enzyme incubation (Table 3.3). 
 
Table 3.3: IC50 values (μM) of ICT 2700 in the EJ-138 cell line after incubation with CYP 1A1,     
CYP 2D6, CYP 3A4 and mouse liver microsomes (MLiM). Results represent the mean of 3 
independent experiments. 
 
 IC50 [µM] 
 
compound 
 
ICT 2700 
(CYP 1A1) 
metabolites 
+             - 
(CYP 2D6) 
metabolites 
+             - 
(CYP 3A4) 
metabolites 
+             - 
(MLiM) 
metabolites 
+             - 
Mean IC50 
in μM 
3.05 0.0016    1.23 1.42 1.46 1.39 1.44  1.27 1.43 
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The determined values relate to the prodrug concentrations. The IC50 value of 
ICT 2700 was 3.05µM. Incubation of the ICT 2700 metabolites from         
CYP 1A1 with EJ-138 cells caused a marked decrease in the IC50 value 
(0.0016µM). Insignificant changes in the IC50 value of ICT 2700 were 
obtained after incubation with CYP 2D6, CYP 3A4 and MLiM giving values of 
1.42, 1.39 and 1.27µM respectively, suggesting toxic metabolites are only 
produced by CYP 1A1  
III.4.5.The stability of ICT 2700 and ICT 2740 in methanol and Tris 
(pH7.4) buffer  
The C5 hydroxylated metabolite for ICT 2700 is the intermediate between the 
non toxic ICT 2700 and the highly potent spirocyclised compound capable of 
interacting with DNA. This intermediate (ICT 2740, Scheme 3.9) has been 
synthesised at the ICT and therefore analytical studies to monitor its 
formation in metabolic incubations are important. The method used is 
described in section III.3.10. 
 
N
Cl
O
NH
HN
O CH3
OH
C21H18ClN3O3
395.85
395.103669
C 63.72% H 4.58% Cl 8.96% N 10.62% O 12.13% 
 
 
Scheme 3.9: The structure of ICT 2740 FW 395.8 
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III.4.5.1. Identification of ICT 2740 
The same optimised method of ICT 2700 identification as in section III.3.7 
was used to determine the optimum absorbance and mass to charge of      
ICT 2740.  
III.4.5.1.1.   Separation of ICT 2740 using HPLC 
ICT 2740 was scanned across the wavelength range 200-400nm. The 
detection of ICT 2740 was confirmed by making a scan of ICT 2740 (100µM) 
with a spectrum of 335nm. The retention time was 24.29min (Figure 3.45). 
ict2700
Time
5.00 10.00 15.00 20.00 25.00 30.00 35.00 40.00
A
U
0.0
2.0e-2
4.0e-2
6.0e-2
8.0e-2
1.0e-1
1.2e-1
1.4e-1
24.29
3.66 23.42
 
Figure 3.45: Detection of ICT 2740 (100µM) in HPLC. Reverse-phase LC was used for the 
separation of ICT 2740. A, chromatogram of ICT 2740 (S2) using DAD at wavelength 335nm 
and Rt. 24.29min. B, spectrum of S2 in DAD; the scanning wavelength was 335nm.   
 
III.4.5.1.2. Separation of ICT 2740 using LC-MS 
Identification of the ICT 2740 was confirmed by MS scanning of ICT 2740 
(100µM) in the range 220-520. The parent ion was detected at m/z 396.23 
ict2700
nm
250 300 350 400
A
U
0.0
2.5e-2
5.0e-2
7.5e-2
219
291 335
A 
 
              B 
 
DAD 335nm 
S2 
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and the Rt. was at 24.34min. Development of an SIR at m/z 396.2 for        
ICT 2740 confirmed that the peak eluted at Rt. 24.32min. The MS-spectrum 
showed two principal stable chlorine isotopes at m/z 396.2 and 398.2 (Figure 
3.46).  
ict2700
Time
5.00 10.00 15.00 20.00 25.00 30.00 35.00 40.00
%
-1
99
5.00 10.00 15.00 20.00 25.00 30.00 35.00 40.00
%
-1
99
30.08
26.74
24.34
3.51
2.65
31.18
24.32
31.40
 
ict2700
m/z
220 240 260 280 300 320 340 360 380 400 420 440 460 480 500 520
%
0
396.2
360.3
296.4284.4241.3
221.2 280.4 302.4
359.4338.4 382.3
398.2
413.4 418.2 437.3
448.3 506.2477.3 512.3
   
Figure 3.46: Detection of ICT 2740 (100µM) in LC-MS. Reverse-phase LC was used for the 
separation of ICT 2740. A, B MS trace supporting correct identification of ICT 2740 in MS 
detector. A, total ion chromatogram (TIC) scanning of singularly charged ions [ES+] from 
220-520 with Rt. 24.34min. B, SIR in specific [ES+] m/z 396.2 with Rt. 24.32min. C, spectral 
characteristics of ICT 2740 at m/z 396.2. This matches ICT 2740 (FW 395.8), also showing 
that two principal isotopes of chlorine were detected at m/z 396.2 and 398.2. 
 
TIC scan [ES+] (220- 520) 
A 
B 
C  
 
SIR m/z 396.2 
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III.4.5.2. Stability of ICT 2700 in methanol and Tris (pH7.4) buffer 
Stability studies for ICT 2700 and ICT 2740 were undertaken in both 
methanol and Tris-HCL buffer to demonstrate that ICT 2700 needs metabolic 
activation to be converted to ICT 2740. The stability test was evaluated in 
short-term incubation for 2 hrs at 37°C. Two reference solutions were used 
(MeOH and Tris-HCL buffer) to observe the recovery of ICT 2700 (100µM). 
Samples were analysed at time points 0, 15, 30, 60, 90 and 120min (Table 
3.4, Figure 3.47.).  
Table 3.4:  Stability data of six time points taken from incubation ICT 2700 in either MeOH or 
Tris-HCL buffer (pH 7.4) at 37°C. 
 
 In Tris buffer In MeOH 
Time (min) 
Other 
compounds ICT 2700 Recovery % 
Other 
compounds ICT 2700 
 
Recovery % 
Time (min) Peak area Peak area  Peak area Peak area 
 
0 <10 13999 100.00 <10 17663 100.00 
15 <10 11862 84.73 <10 17832 100.96 
30 <10 12057 86.13 <10 15735 89.08 
60 <10 11650 83.22 <10 17696 100.19 
90 <10 12330 88.08 <10 17068 96.63 
120 <10 11064 79.03 <10 17472 98.92 
 
A short-term stability test performed in MeOH solution showed that the 
samples were stable for 2 hrs with 98.92% recovery while in Tris-HCL buffer 
the recovery of ICT 2700 was 79.03%; no other compounds were found in 
either MeOH or Tris-HCL buffer. The difference in ICT 2700 recovery 
between MeOH and Tris-HCL buffers could be due to other reasons such as 
solubility, time, or prodrug degradation. The solubility issues were not 
assessed in this study. 
Catalyzing properties of CYP 1A1                                                                 Chapter 3  
 
111 
   
Figure 3.47: ICT 2700 stability in Methanol (MeOH) or Tris-HCL buffer (pH 7.4) at 37°C for 
120 min. A, ICT 2700 in buffer B, ICT 2700 in MeOH.  
 
III.4.5.3. Stability of ICT 2740 in methanol and Tris (pH7.4) buffer 
A short-term stability test was performed to evaluate the recovery of ICT 2740 
(100µM). The conditions were as described in section III.4.5.2. 
Results for the Tris-HCL buffer showed that ICT 2740 spontaneously 
degraded over time (Table 3.5, Figure 3.48). 
Table 3.5:  Stability data of six time points taken from incubation ICT 2740 in either MeOH or 
Tris-HCL buffer (pH 7.4) at 37°C. 
 
 In Tris buffer In MeOH 
Time (min) 
Other 
compounds ICT 2740 Recovery % 
Other 
compounds ICT 2740 
 
Recovery % 
 Peak area Peak area  Peak area Peak area 
 
0 1000 8682 100.00 <10 9962 100.00 
15 3261 4798 55.26 <10 10586 106.26 
30 4139 1953 22.49 <10 11319 113.62 
60 5969 921 10.61 109 10428 104.68 
90 6742 148 1.70 122 11259 113.02 
120 7477 <10 <1 165 9919 99.57 
 
A B 
Catalyzing properties of CYP 1A1                                                                 Chapter 3  
 
112 
In MeOH, ICT 2740 was relatively stable over 2hrs although low 
concentrations (< 2%) of degradation products appeared over time.  
In the Tris-HCL buffer spontaneous degradation of ICT 2740 was rapid with a 
similarly rapid increase in product (86.12%) from the ICT 2740. 
    
Figure 3.48: ICT 2740 stability in Methanol (MeOH) or Tris-HCL buffer (pH 7.4) at 37°C for 
120 min. A, ICT 2740 in buffer B, ICT 2740 in MeOH.  
 
III.4.6.The comparison of ICT 2740 and metabolites of ICT 2700  
10 µM ICT 2740 (S 2) was eluted at Rt. 25.16 and the mass to charge was 
confirmed at m/ z 396.17. After 120 min incubation of ICT 2740 in Tris-HCL 
buffer ICT 2740 was undetectable and another peak (M 23) appeared at 
15.08 min with m/ z 359.91 (Figure 3.49.). 
A 
B 
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ict2700
Time
5.00 10.00 15.00 20.00 25.00 30.00 35.00 40.00
A
U
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A
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24.31
 
Figure 3.49: Reverse-phase LC was used for the separation of ICT 2740 incubated in      
Tris-HCL buffer for 120 min in DAD 330nm. A, initial incubation shows ICT 2740 (S2) 
separated at 25.16 min. B, in 120 min incubation the main peak, M23, eluted at 15.08 min. 
ICT 2740 and its degradation product (M23) were compared to the 
metabolites of ICT 2700 by CYP 1A1. This was to make sure that the 
metabolite appearing following incubation of ICT 2700 with CYP 1A1 was the 
same as the degradation product of ICT 2740, thought to be the potential 
toxic metabolite (Figure 3.50).  
ict2700
Time
5.00 10.00 15.00 20.00 25.00 30.00 35.00 40.00
%
-15
85 24.29
14.17
3.49
23.45
26.66
 
Figure 3.50: Comparing of ICT 2740 (100µM) and metabolites of 100µM ICT 2700 by        
CYP 1A1 bactosomes (30picomole/ml) + NADPH (2mM) for 120min. Chromatographic 
separation of A, ICT 2740 matches ICT 2700 metabolites at B, SIR 360.0 m/ z and C, SIR 
396.2 m/ z. 
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B 
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The ICT 2740 was identical to the M1 metabolite of ICT 2700 incubated with 
CYP 1A1 (Figure 3.10) and the M23, from incubation of ICT 2740 in Tris-HCL 
buffer, matched the potential toxic metabolite of ICT 2700 by CYP 1A1, M4 
(Figure 3.11). 
III.4.7.The uptake of ICT 2700 and ICT 2740 in A-549 cell line 
The stability results in this study showed that in Tris-HCL buffer, ICT 2700 
was stable, while spontaneous degradation of ICT 2740 was rapid with a 
similarly rapid increase in product (see section III.4.5). 
Moreover, the spontaneous degradation of ICT 2740, activated authentic 
metabolite, matched the potential toxic metabolite of ICT 2700 activated by 
CYP 1A1 (see section III.4.6).   
One concern could be that the increased cytotoxicity shown by ICT 2740 
compared to ICT 2700 was due to the increased uptake of ICT 2740 into cells. 
The ability of ICT 2740 and ICT 2700 to be taken into human lung 
adenocarcinoma cell line (A-549) cells was investigated. The reason for using 
such a cell line was that it shows a low expression of CYP1 family 
(unpublished observations, ICT; see Appendix M). 
A-549 cells at a concentration of 1X107cells/ml were exposed to two 
concentrations (10µM/100µM) of both ICT 2700 and ICT 2740. Six time 
points (0, 10, 30, 60, 120 and 240min) of incubations were recorded to 
observe the uptake of ICT 2700 and ICT 2740. The method used is described 
in section III.3.11 and Appendix D. 
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III.4.7.1.The uptake of ICT 2700 in A-549 cell line 
Samples of ICT 2700 were taken from inside the cells (uptake) and outside 
the cells (supernatant) for each time point. The method was as described in 
section III.3.11 and Appendix D. 
To calculate the weight of ICT 2700 (in nanomole) either inside or outside the 
cells the dilution factors were used (the end volume was 500µl and the pellet 
samples dissolved in 50µl MeCN while 20µl of supernatant was mixed with 
40µl MeCN, 1:2). The results are given in Table 3.6. 
 
Table 3.6: Weight (n. moles) of ICT 2700 in cell pellets and cell medium following incubation 
of ICT 2700 with human lung adenocarcinoma cell line (A-549) at 37°C with time. 
 
 
 
 
 
 
 
The ICT 2700 concentration in A-549 cell pellet (drug uptake) and cell 
medium (drug remaining in cell incubation medium or effluxes from cells) was 
calculated. The results are given in Table 3.7 and Figure 3.51. 
 10 µM ICT 2700 100 µM ICT 2700 
Time (min) Cells pellet Cell medium Cells pellet Cell medium 
0 <0.5 n. moles <0.5 n. moles <0.5   n. moles <0.5  n. moles 
10 1.03 n. moles 1.54 n. moles 9.83   n. moles 23.22 n. moles 
30 1.4  n. moles 1.59 n. moles 6.93   n. moles 22.2   n. moles 
60 0.4   n. moles 1.35 n. moles 7.4   n. moles 17.2  n. moles 
120 0.96 n. moles 1.66 n. moles 9.26   n. moles 13.75 n. moles 
240 1.03 n. moles 3.52 n. moles 6.81  n. moles 21.49 n. moles 
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Table 3.7: ICT 2700 concentration (µM) in cell pellets and cell medium following incubation of 
ICT 2700 with A-549 cells at 37°C with time. 
 
 
 
 
 
 
 
 
  
Figure 3.51: ICT 2700 concentration (µM) in cell pellets and cell medium following incubation 
of ICT 2700 with human lung adenocarcinoma cell line (A-549) at 37°C with time. 
 
III.4.7.2.The uptake of ICT 2740 in A-549 cell line 
The same procedure as that used in section III.4.7.1 was used to measure 
the weight and concentrations of ICT 2740 inside the cells (uptake) and 
outside the cells (supernatant). The weight of ICT 2740 (10µM and 100µM) in 
nanomoles is given in (Table 3.8).The concentrations of ICT 2740 inside and 
outside A-549 cells were calculated and the results are given in Table 3.9 and 
Figure 3.52. 
 10µM ICT 2700 100µM ICT 2700 
Time (min) 
Cells  pellet 
(µM) 
Cell medium 
(µM) 
Cells  pellet 
(µM) 
Cell medium 
(µM) 
0 <10 <10 <10 <10 
10 68.6 3.08 655.3 46.44 
30 93.3 3.18 462 44.4 
60 26.6 2.7 493.3 34.4 
120 64 3.32 617.3 27.5 
240 68.6 7.04 454 42.98 
Concentration of 10µM and 100µM ICT 2700 inside and outside A- 549 cells  
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Table 3.8: Weight (n. moles) of ICT 2740 in cell pellets and cell medium following incubation 
of ICT 2700 with human lung adenocarcinoma cell line (A-549) at 37°C with time. 
 
 
 
Table 3.9:  ICT 2700 concentration (µM) in cell pellets and cell medium following incubation 
of ICT 2700 with A-549 cells at 37°C with time. 
 
 
Figure 3.52: ICT 2740 concentration (µM) in cell pellets and cell medium following incubation 
of ICT 2700 with human lung adenocarcinoma cell line (A-549) at 37°C with time. 
 
In comparison to ICT 2700, the uptake in ICT 2740 was more than 4 folds 
lower in cells. Therefore, the toxicity shown by ICT 2740 cannot be explained 
by preferential uptake over ICT 2700. 
 Cells  uptake Supernatant 
Time (min.) 10uM ICT 2740 100uM ICT 2740 10uM ICT 2740 100uM ICT 2740 
0 <0.5 n. moles 1.93 n moles 3.61 n moles 18.85 n moles 
10 0.17 n moles 0.44 n moles 0.72 n moles 23.85 n moles 
30 0.07 n moles 0.24 n moles 0.70 n moles 16.33 n moles 
60 0.05 n moles 0.56 n moles 1.63 n moles 22.74 n moles 
120 0.03 n moles 0.26 n moles 1.56 n moles 15.24 n moles 
240 0.03 n moles 0.10 n moles 1.65 n moles 23.26 n moles 
 10µM ICT 2740 100µM ICT 2740 
Time (min) 
Cells  uptake 
( µM) 
Supernatant 
( µM) 
Cells  uptake 
( µM) 
Supernatant 
( µM) 
0 <1 <1 <1 <1 
10 37.3  1.44  97.3  47.7  
30 15.3  1.4  53.3  32.66  
60 10.6  3.26  124  45.48  
120 6.6  3.12  57.3  30.48  
240 6.6  3.06  22  46.52  
Concentration of 10µM and 100 µM ICT 2740 inside and outside A-549 cells  
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III.4.8. CYP 1A1-dependent glutathione conjugation with ICT 2740 and 
ICT 2700    
Glutathione (GSH) (Scheme 3.10) conjugation is a common Phase II 
metabolic reaction for electrophilic drugs and metabolites. In this reaction, 
10mM GSH was used to test if there were any conjugations between GSH 
and the potential reactive metabolites from either ICT 2700 when incubated 
with CYP 1A1 or ICT 2740, the authentic active metabolite. The method was 
as described in section III.3.12.  
HOOC
NH
NH COOH
NH2
O
SH
O
C10H17N3O6S
307.32
307.083807
C 39.08% H 5.58% N 13.67% O 31.24% S 10.43%                          
Scheme 3.10: The structure of glutathione (GSH) FW 307.32 
The stability of ICT 2700 and ICT 2740 was examined in section III.4.5. 
Incubations of GSH with ICT 2700 demonstrated that the substrate was 
stable (Figure 3.53) and no product formation could be detected over 120min.  
 
Figure 3.53: Reverse-phase LC was used for monitor the stability of ICT 2700 incubated with 
10mM glutathione (GSH) for 120min detected using diode array detection at wavelength 
(330nm). A, GSH Rt. at 2.98 min. B, ICT 2700 eluted at Rt. 23.88 min. 
DAD 330nm 
GSH 120 min 
ICT 2700 120 min 
A 
B 
S1 GSH 
Gamma- glutamyl- cystemyl- glycine  
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However, incubations of GSH with ICT 2740 for 120min demonstrated that 
the substrate was unstable and spontaneously conjugated with GSH in          
2 peaks detected at m/z 668.1 (Figure 3.54.). 
 
 
 
Figure 3.54: Reverse-phase LC was used to monitor the conjugation of ICT 2740 with 10mM 
GSH in 120min. A, ICT 2740 eluted at Rt. 23.18min (m/z 396.2) no GSH. B, 100µM ICT 2740 
incubated with 10mM GSH for 120min includes 4 peaks eluted at Rt. 13.60, 10.85, 6.91 and 
2.44min; mass to charges were m/z 360.1, 668.1, 668.1, and 308.1 respectively. C, 10µM 
ICT 2740 incubated with 10mM GSH for 120min peaks were same as in B, while in D, 1µM 
ICT 2740 incubated with 10mM GSH for 120min no peaks were detected at DAD 330nm. 
 
At the same time incubation of GSH with metabolites of ICT 2700 by          
CYP 1A1 clearly showed the same conjugation products with GSH in 2 peaks 
with m/z 668.1 (Figures 3.54 and 3.55). 
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Figure 3.55: Reverse-phase LC was used for monitor the conjugation of ICT 2700 
metabolites by CYP 1A1 with 10mM GSH in 120 min. At t=0, ICT 2700 (S1) eluted at Rt. 
23.94min (m/z 380.1). At t=120, metabolites of 100µM  ICT 2700 from CYP 1A1 incubated 
with 10mM GSH for 120min includes 7 peaks eluted at Rt. (23.94, 18.52,16.71, 13.38, 10.21, 
6.59 and 2.44min and the mass to charges were m/z 380.1, 396.2, 396.2, 360.0, 668.1, 
668.1, and 308.2 respectively.  
 
From these results, it is clear that the GSH adduct following incubation with 
ICT 2740 is the same as that from the metabolites of ICT 2700 obtained from 
CYP 1A1 metabolism.  
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III.4.9. Metabolism of chloromethylindoline (ICT 2705) by (CYP 1A1,   
CYP 2D6 and CYP 3A4 bactosomes) and mouse liver microsomes  
 
ICT 2705 (Scheme 3.11) is a close analogue of ICT 2700, where the methoxy 
group is substituted with fluorine.  
ICT 2705 and all metabolites created when incubated with three CYP 1A1, 
CYP 2D6 and CYP 3A4 bactosomes were observed at DAD 320 nm then 
identified by LC/ MS. Moreover, mouse liver microsomes (MLiM) were 
examined to investigate whether the global content of CYPs in mouse liver 
could convert the prodrug to the active drug. For more details about the 
potential metabolites of ICT 2705 see Appendix F. 
HN
N
Cl
O
NH
F
C20H15ClFN3O
367.81
367.088768
C 65.31% H 4.11% Cl 9.64% F 5.17% N 11.42% O 4.35% 
 
Scheme 3.11: The structure of ICT 2705 FW 367.81 
 
III.4.9.1. Identification of ICT 2705  
The optimised method in section III.3.13 was used to determine the uv/vis 
absorbance spectrum and mass to charge of ICT 2705. 
 
 
 
Catalyzing properties of CYP 1A1                                                                 Chapter 3  
 
122 
III.4.9.1.1. Separation of ICT 2705 using HPLC 
ICT 2705 was scanned across the wavelength range 200-400nm. The 
detection of ICT 2705 was confirmed by making a scan of ICT 2705 (100µM) 
and the λ max being shown to be 320nm. The retention time was 27.22min 
(Figure 3.56). 
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Figure 3.56: Detection of ICT 2705 (100µM) in HPLC. Reverse-phase LC was used for the 
separation of ICT 2705. A, chromatogram of ICT 2705 using diode array detection (DAD) at    
wavelength 320nm and Rt. 27.22min. B, spectrum of ICT 2705 showing the λ max to be 
320nm. 
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III.4.9.1.2. Separation of ICT 2705 using LC-MS 
Identification of ICT 2705 was confirmed by MS scanning of ICT 2705 
(100µM) in the range 220-520 (Figure 3.57). The spectrum was m/z 368.2. 
Then the SIR channel was set up at m/z 368.2. From the MS-spectrum 
(Figure 3.57) we can see two principal stable chlorine isotopes in m/z 368.2 
and 370.2. This helps in monitoring the existence of chlorine in the 
metabolites. These parameters were used as controls for further studies of 
ICT 2705 metabolism.  
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Figure 3.57: Detection of ICT 2705 (100µM) by LC-MS. Reverse-phase LC was used for the 
separation of ICT 2705. A, B MS trace supporting correct identification of ICT 2705 in MS 
detector. A, scanning of singularly charged ions [ES+] from 220-520 with Rt. 27.27min and 
m/z 368.2. B, SIR in specific [ES+] m/z 368.2 with Rt. 27.24min. C, spectral characteristics of 
ICT 2705 at m/z 368.2. This matches ICT 2705 FW (367.81), also showing two principal 
isotopes of chlorine (
35
Cl represented 75% and 
37
Cl represented 25%). 
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III.4.9.2. Metabolism of ICT 2705 by CYP 1A1 
The in vitro metabolism of ICT 2705 (100µM) by CYP 1A1 was examined to 
investigate the influence of this enzyme on ICT 2705.  
The method of incubation was as described in section III.3.4. The ICT 2705 
and its metabolites were extracted using the method described in section 
III.3.5. Following this, the optimised method in section III.3.13 was used to 
separate and identify all metabolites (Figure 3.58). Four metabolites (M24, 
M25, M26 and M27) were separated in HPLC and detected at wavelength 
320nm at Rt. 26.68, 22.39, 21.74 and 17.99min respectively. The parent (S3) 
eluted at Rt. 28.11min. 
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Figure 3.58: Metabolites of ICT 2705 (100µM) by CYP 1A1 bactosomes (30picomole/ml) + 
NADPH (2mM) for 120min (the incubation volume was 300µl). All HPLC traces of potential 
metabolites separated at Rt (M24) 26.68, (M25) 22.39, (M26) 21.74 and (M27) 17.99min 
using diode array detection at wavelength 320nm and the substrate (S3) eluted at Rt. 
28.11min. The peak eluted at Rt 23.36 was also existed when incubated without NADPH. 
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During the incubation, the intensities of metabolites were shown to gradually 
increase with the time of incubation.  
Subsequent identification of the ICT 2705 (S3) and the metabolites formed by 
the substrate was performed by LC/MS analysis. The mass to charge for 
each was S3 m/z 368.2. M24, M25 and M26 were all at m/z 384.2 and M27 
was at m/z 348.21 (Figure 3.59).  
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Figure 3.59: Metabolites of ICT 2705 (100µM) by CYP 1A1 bactosomes (30picomole/ml) + 
NADPH (2mM) for 120min. Reverse-phase LC was used for the separation of A, substrate 
and their metabolites detected using diode array detection at wavelength 320nm. B, ICT 
2705 (S3) eluted at Rt. 28.24min and the mass to charge was in SIR m/z 368.2. MS traces of 
C, M24 (Rt. 26.72min), M25 (Rt.22.43min) and M26 (Rt. 21.76min). All these metabolites 
were detected in SIR at m/z 384.2. D, M27 eluted (Rt. 18.04) at m/z 348.21.  
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The mass to charge for the metabolites compared to structure of the 
substrate helped in obtaining the structural information for the metabolites. 
In the M24, M25 and M26 metabolites (Rt. at 26.72, 22.43 and 21.76min 
respectively) the mass to charge was detected at m/ z 384.2. This is clearly a 
hydroxylation of ICT 2705, although there is insufficient data to predict the 
exact site of hydroxylation (Figure 3.59 and Scheme 3.12). 
HN
N
Cl
O
NH
F
OH
C20H15ClFN3O2
383.81
383.083683
C 62.59% H 3.94% Cl 9.24% F 4.95% N 10.95% O 8.34%  
Scheme 3.12: The anticipated chemical structure of one of the M24, M25 and M26 
metabolites (FW 383.81). The addition of the hydroxyl group may be in a different place. 
 
In M27 (Rt. at 18.04 min) the mass to charge was detected at m/z 348.21. 
This is likely to be the result of a potential hydroxylation followed by 
dechlorination resulting in a potential toxic metabolite (see Figure 3.59 and 
Scheme 3.13.). Clearly one of the hydroxylated metabolites is an 
intermediate for this process. The intermediate metabolite is likely to be one 
of the M24, M25 and M26 metabolites (Figure 3.59). 
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C 69.16% H 4.06% F 5.47% N 12.10% O 9.21%   
 
Scheme 3.13: The anticipated chemical structure of the M27 (potential toxic) metabolite    
FW 347.35 
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III.4.9.3. Metabolism of ICT 2705 by CYP 2D6 
The in vitro metabolism of ICT 2705 (100µM) in the presence of human    
CYP 2D6 bactosomes supplemented with NADPH was examined. 
All methods were the same as in section III.4.9.2. The optimised method in 
section III.3.13 was used to separate and identify all metabolites (Figure 3.60). 
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Figure 3.60: Metabolites of ICT 2705 (100µM) by CYP 2D6 bactosomes (30picomole/ml) + 
NADPH (2mM) for 120min (the incubation volume was 300µl). All HPLC traces of potential 
metabolites separated at Rt. (M28) 22.31min and (M29) 21.63min using diode array 
detection at wavelength (320nm). The substrate (S3) eluted at Rt. 28.01min. The peak eluted 
at Rt 23.26 was also existed when incubated without NADPH. 
  
Only two metabolites (M28 and M29) were separated in HPLC and were 
detected at wavelength 320nm at Rt. 22.31 and 21.63min respectively. The 
parent (S3) separated at Rt. 28.01min. 
Subsequent identification of the ICT 2705 (S3) and the metabolites formed by 
the substrate was performed by LC/MS analysis. The mass to charge for 
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each was S3 (m/z 368.2). M28 and M29 all were at (m/z 384.2) (Figure 3.61.). 
The mass to charge for the metabolites compared to the structure of the 
substrate helped in obtaining the structural information for the metabolites.  
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Figure 3.61: Metabolites of ICT 2705 by CYP 2D6 bactosomes (30picomole/ml) + NADPH 
(2mM) for 120min. Reverse-phase LC was used for the separation of A, substrate and their 
metabolites, detected using diode array detection at wavelength 320nm.  B, S3 (ICT 2705) 
eluted at Rt. 28.21min and the mass to charge was in SIR m/z 368.2. MS traces of C, M 28 
(Rt. 22.43min), and M29 (Rt. 21.76min) all these metabolites were detected in SIR at m/z 
384.2.  
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In the M28 and M29 metabolites (Rt. at 22.43 and 21.76min respectively) the 
mass to charge was detected in SIR at m/z 384.2. This is likely due to a 
hydroxylation of ICT 2705 (Scheme 3.12). 
The incubation of ICT 2705 with CYP 2D6 in the absence of NADPH 
demonstrated no metabolites. It is significant that no metabolites were 
detected in SIR at m/z 348.21, the potential toxic metabolite, (figures not 
shown).  
III.4.9.4. Metabolism of ICT 2705 by CYP 3A4 
In this reaction, in vitro CYP 3A4 human bactosomes supplemented with 
NADPH catalyzed the metabolism of ICT 2705 (100µM).  
All methods were the same as in section III.4.9.2. The optimised method in 
section III.3.13 was used to separate and identify all metabolites (Figure 3.62). 
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Figure 3.62: Metabolites of ICT 2705 (100µM) by CYP 3A4 bactosomes (30picomole/ml) + 
NADPH (2mM) for 120min (the incubation volume was 300µl). All HPLC traces of potential 
metabolites separated at Rt. (M30) 22.29min and (M31) 21.56 min using diode array 
detection at wavelength (320nm) and the substrate (S3) eluted at Rt. 27.96min. The peak 
eluted at Rt 23.20 was also existed when incubated without NADPH. 
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Two metabolites (M30 and M31) were separated in HPLC and detected at 
wavelength 320nm at Rt. 22.29 and 21.56min respectively. The parent (S3) 
separated at Rt. 27.96min. 
Subsequent identification of the ICT 2705 (S3) and the metabolites formed by 
the substrate was performed by LC/MS analysis and the mass to charge for 
each was S3 (m/z 368.2). M30 and M31 all were at (m/z 384.2) (Figure 3.63). 
The mass to charge for the metabolites compared to the structure of 
substrate helped in obtaining structural information for the metabolites. 
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Figure 3.63: Metabolites of ICT 2705 (100µM) by CYP 3A4 bactosomes (30picomole/ml) + 
NADPH (2mM) for 120min. Reverse- phase LC was used for the separation of A, substrate 
and their metabolites detected using diode array detection at wavelength (320nm).  B, S3 
(ICT 2705) eluted at Rt. 27.94min and the mass to charge was in SIR m/ z 368.2. MS traces 
of C, M30 (Rt. 22.19), and M31 (Rt. 21.56min) all these metabolites were detected in SIR at 
m/ z 384.2.   
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In the M30 and M31 metabolites (Rt. at 22.19 and 21.56min respectively) the 
mass to charge was detected at m/z 384.2. This is likely due to a 
hydroxylation of ICT 2705 (Scheme 3.12).  
As with the incubation of ICT 2705 with CYP 2D6 in section III.4.9.3, there 
were no metabolites in the absence of NADPH. It is significant that no 
metabolites were detected in SIR at m/z 348.21, the potential toxic metabolite 
(figures not shown).   
III.4.9.5. Metabolism of ICT 2705 by mouse liver microsomes  
The in vitro metabolism of 100 µM ICT 2705 in the presence of MLiM 
microsomes supplemented with NADPH was examined. 
The method of preparing MLiM was described in section III.3.1 and the 
protein concentration was measured as in section III.3.2. The microsome 
incubation method was the same as in section III.3.3 and the extraction 
method was the same as in section III.3.5. The optimised method in section 
III.3.13 was used to separate and identify all metabolites (Figure 3.64). 
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Figure 3.64: Metabolites of ICT 2705 (100µM) in MLiM (1mg/ml) + NADPH (2mM) for 120min 
(the incubation volume was 300µl). All HPLC traces of potential metabolites separated at Rt. 
(M32) 26.70, (M33) 22.37, (M34) 21.70, (M35) 19.52 and (M36) 18.94min using diode array 
detection at wavelength 320nm. The substrate (S3) eluted at Rt. 28.14min. Other peaks (like 
at Rt. 12.99 were also existed when incubated without NADPH.   
 
Five metabolites (M32, M33, M34, M35 and M36) were separated in HPLC 
and detected at wavelength 320nm at Rt. 26.70, 22.37, 21.70, 19.52 and 
18.94min respectively. The parent (S3) separated at Rt. 28.14min. 
Subsequently, identification of the ICT 2705 (S3) and its metabolites was 
performed by LC/MS analysis and the mass to charge for S3 was                
m/z 368.2. M32, M33 and M34 were at m/z 384.2, M35 was at m/z 400.8 and 
M36 was m/z 348.21 (see Figure 3.65). 
The mass to charge for the metabolites compared to the structure of the 
substrate helped in obtaining structural information for the metabolites.   
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Figure 3.65: Metabolites of ICT 2705 (100µM) in MLiM (1mg/ml) + NADPH (2mM) for 120min. 
Reverse-phase LC was used for the separation of A, substrate and their metabolites 
detected using diode array detection at wavelength 320nm.  B, S3 (ICT 2705) eluted at Rt. 
28.17min and the mass to charge was in SIR m/z 368.2. MS traces of C, M32 (Rt. 26.77), 
M33 (Rt. 22.49min) and M34 (Rt. 21.85min); all these metabolites were detected in SIR at 
m/z 384.2. D, M35 eluted (Rt. 19.65) in SIR m/z 400.8. E, M36 eluted (Rt. 18.13) at m/z 
348.21. 
 
In the M32, M33 and M34 metabolites (Rt. at 26.77, 22.49 and 21.85min 
respectively) the mass to charge was detected at m/z 384.2. This is likely due 
to hydroxylation as seen previously (Scheme 3.12). 
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In M35 (Rt. at 19.65 min) the mass to charge was detected at m/z 400.8. This 
can be explained by a double hydroxylation ICT 2705 (Scheme 3.14). 
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C20H15ClFN3O3
399.81
399.078597
C 60.08% H 3.78% Cl 8.87% F 4.75% N 10.51% O 12.01%                         
 
Scheme 3.14: The anticipated chemical structure of the M47 metabolite (FW 399.81) 
 
In M36 (Rt. at 18.13min) the mass to charge was detected at m/z 348.21. 
This is likely the result of a potential hydroxylation followed by dechlorination 
resulting in a potential toxic metabolite (see Figure 3.65 and Scheme 3.13). 
There is likely to be an intermediate metabolite prior to the production of the 
potentially toxic M36 where there is an addition of a hydroxyl group. The 
intermediate metabolite is likely to be one of the M32, M33 and M34 
metabolites (Figure 3.65). 
III.4.10. Metabolism of ICT 2726 by CYP 1A1, CYP 2D6 and CYP 3A4 
bactosomes and mouse liver microsomes 
Although the chloromethylindoline analogue ICT 2726 (Scheme 3.15) is 
designed to be a potential substrate for CYP 2W1 activation (see next 
chapter) and is non-toxic in mice Loadman, Patterson et al, unpublished 
observation), the activity of ICT 2726 was monitored with CYP 1A1, CYP 2D6 
and CYP 3A4 bactosomes. Moreover, ICT 2726 was tested in MLiM to see if 
there were any toxic metabolites generating mainly in localised places in the 
majority of the CYP families. All these investigations were done in vitro 
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followed by separating the metabolites in HPLC then identifying the 
metabolites in LC-MS. The incubation of ICT 2726 in the presence of CYPs 
and in the absence of NADPH demonstrated no metabolites (figures not 
shown). Also the potential toxin in SIR was searched for at m/z 349.1 
although there was no toxic metabolite with ICT 2726. For more details about 
the potential metabolites of ICT 2726 see Appendix G. 
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368.072784
C 65.14% H 3.83% Cl 9.61% F 5.15% N 7.60% O 8.68%  
Scheme 3.15: The structure of ICT 2726 FW 368.79 
 
III.4.10.1. Identification of ICT 2726  
The optimised method in section III.3.14 was used to determine the optimum 
absorbance and mass to charge of ICT 2726. 
III.4.10.1.1. Separation of ICT 2726 using HPLC 
ICT 2726 was scanned across the wavelength range 210-400nm. The 
detection of ICT 2726 was confirmed by making a scan of ICT 2726 (100µM) 
and the λ max being shown to be 314nm. The retention time was 28.63min 
(Figure 3.66). 
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Figure 3.66: Detection of ICT 2726 (100µM) in HPLC. Reverse-phase LC was used for the 
separation of ICT 2726. A, chromatogram of ICT 2726 using DAD at wavelength 314nm and 
Rt. 28.63min. B, spectrum of ICT 2726 showing the λ max to be 314nm. 
 
III.4.10.1.2. Separation of ICT 2726 using LC-MS 
Identification of ICT 2726 was confirmed by MS scanning of ICT 2726 
(100µM) in the range 220-520 (Figure 3.67). The spectrum was m/z 369.1 
and so the SIR channel was set up at m/z 369.1. From the MS-spectrum 
(Figure 3.67) we can see two principal stable chlorine isotopes in m/z 369.1 
and 371.2. This helps in monitoring the existence of chlorine in the 
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metabolites. These parameters were used as controls for further studies of 
ICT 2726 metabolism.  
ict2700
Time
5.00 10.00 15.00 20.00 25.00 30.00 35.00 40.00
%
-5
95
5.00 10.00 15.00 20.00 25.00 30.00 35.00 40.00
%
-5
95
28.91
18.091.91
34.17 35.32
28.89
30.04
 
ict2700
m/z
220 240 260 280 300 320 340 360 380 400 420 440 460 480 500 520
%
0
369.1
255.3
236.1
233.8 239.1 302.0267.1
281.0 351.1
342.9329.0
505.0461.9371.2
417.0
391.1372.9
374.7
395.2
414.9
417.6
418.5
439.0
453.6
483.0475.6
485.3
505.7
506.7
516.8
 
 
Figure 3.67: Detection of ICT 2726 (100µM) by LC-MS. Reverse-phase LC was used for the 
separation of ICT 2726. A, B MS trace supporting correct identification of ICT 2726 in MS 
detector A, total ion chromatogram (TIC) scanning of singularly charged ion [ES+] from 220-
520 with Rt. 28.91min and B, SIR in specific [ES+] m/z 369.1 with Rt. 28.89min. C, spectral 
characteristics of ICT 2726 at m/z 369.1. This matches ICT 2726 FW (368.79), also showing 
two principal isotopes of chlorine (
35
Cl represented 75% and 
37
Cl represented 25%). 
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III.4.10.1.3. Purification of ICT 2726  
In ICT 2726 more than one peak was separated in HPLC and LC/MS 
(Figures 3.66 and 3.67). The DAD spectrum was 314nm and mass to charge 
was m/z 369.06. 
Each peak was collected after separation by HPLC dependent on the Rt. then 
injected again after 24hrs of incubation at 37°C to see if there was any 
stability issue coming from each peak. The peaks were not split and 
remained without generating any degradation (Figure 3.68).  
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Figure 3.68: Purification of ICT 2726 (100µM) using HPLC. Reverse-phase LC was used for 
the separation of ICT 2726 using a wavelength of 314nm. A shows 3 main peaks at Rt. 25.10, 
26.0 and 26.60min. B is the isolated fraction from potential impurities and C is the parent 
ICT2726. These peaks remained constant after incubation for 24hrs at 37°C. 
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These results will help in the future, not in this study, to purify ICT 2726. 
III.4.10.2. Metabolism of ICT 2726 by CYP 1A1 
The in vitro metabolism of ICT 2726 (100µM) by CYP 1A1 was examined to 
investigate the influence of this enzyme on ICT 2726.  
The method of incubation described in section III.3.4 was used, then the    
ICT 2726 and its metabolites were extracted using the method described in 
section III.3.5. Following this the optimised method in section III.3.14 was 
used to separate and identify all metabolites (Figure 3.69). Only one 
metabolite (M37) was separated in HPLC and detected in wavelength 314nm 
at Rt. 23.70min. The parent (S4) separated at Rt. 28.54min. 
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Figure 3.69: Metabolites of ICT 2726 (100µM) by CYP 1A1 bactosomes (30picomole/ml) + 
NADPH (2mM) for 120min (the incubation volume was 300µl). HPLC traces of potential 
metabolite separated at Rt. 23.70min (M37) using diode array detection at wavelength 
314nm and the substrate (S4) eluted at Rt. 28.54min.  
 
During the incubation the intensities of the metabolites were shown to 
gradually increase with the time of incubation.  
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Subsequent identification of the ICT 2726 (S4) and the metabolite formed by 
the substrate was performed by LC/MS analysis. The mass to charge was S4 
m/z 369.1 and M37 was at m/z 385.2 (Figure 3.70.). The mass to charge for 
the metabolite compared to the structure of the substrate helped in obtaining 
structural information for the metabolite. 
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Figure 3.70: Metabolites of ICT 2726 (100µM) by CYP 1A1 bactosomes (30picomole/ml) + 
NADPH (2mM) for 120min (the incubation volume was 300µl). Reverse-phase LC was used 
for the separation of A, substrate and their metabolites detected using diode array detection 
at wavelength 314nm. B, S4 (ICT 2726) eluted at Rt. 28.53min and the mass to charge was 
in SIR m/z 369.1. MS traces of C, M37 at Rt. 23.69 was detected in SIR at m/z 385.2.  
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In the M 37 metabolite (Rt. at 23.69 min) the mass to charge was detected at    
m/z 385.2. This is clearly a hydroxylation of ICT 2726 (see Figure 3.70 and 
Scheme 3.16). 
N
O
NH
O
F
Cl
OH
C20H14ClFN2O3
384.79
384.067698
C 62.43% H 3.67% Cl 9.21% F 4.94% N 7.28% O 12.47%  
 
Scheme 3.16: The anticipated chemical structure of the M49 metabolite (FW 384.79) 
 
III.4.10.3. Metabolism of ICT 2726 by CYP 2D6 
The in vitro metabolism of ICT 2726 (100µM) in the presence of CYP 2D6 
human bactosomes supplemented with NADPH was examined. 
All the methods were the same as in section III.4.10.2. Following this, the 
optimised method in section III.3.14 was used to separate and identify all 
metabolites (Figure 3.71). One metabolite (M38) was separated in HPLC and 
detected in wavelength 314nm at Rt. 23.61min. The parent (S4) separated at 
Rt. 28.46min.  
During the incubation, the intensities of metabolites were shown to gradually 
increase with the time of incubation.  
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Figure 3.71: Metabolites of ICT 2726 (100µM) by CYP 2D6 bactosomes (30picomole/ml) + 
NADPH (2mM) for 120min (the incubation volume was 300µl). HPLC traces of potential 
metabolite separated at Rt. 23.61min (M38) using diode array detection at wavelength 
314nm and the substrate (S4) eluted at Rt. 28.46min. 
 
Subsequent identification of the ICT 2726 (S4) and the metabolite formed by 
the substrate was performed by LC/MS analysis and the mass to charge was 
S4 m/z 369.1. M38 was at m/z 385.2 (Figure 3.72). The mass to charge for 
the metabolite compared to the structure of the substrate helped in obtaining 
structural information for the metabolite. 
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Figure 3.72: Metabolites of ICT 2726 (100µM) by CYP 2D6 bactosomes (30picomole/ml) + 
NADPH (2mM) for 120min (the incubation volume was 300µl). Reverse-phase LC was used 
for the separation of A, substrate and their metabolites detected using diode array detection 
at wavelength 314nm.  B, S4 (ICT 2726) eluted at Rt. 28.59min and the mass to charge was 
in SIR m/z 369.1. MS traces of C, M38 (Rt. 23.78) was detected in SIR at m/z 385.2.  
 
In the M38 metabolite (Rt. at 23.78 min) the mass to charge was detected at    
m/z 385.2. This is likely due to a hydroxylation of ICT 2726 (Scheme 3.16.). 
III.4.10.4. Metabolism of ICT 2726 by CYP 3A4 
In this reaction, in vitro CYP 3A4 human bactosomes supplemented with 
NADPH catalyzed the metabolism of ICT 2726 (100µM).  
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All the methods used were the same as in section III.4.10.2. (see Figure 3.73). 
One metabolite (M39) was separated in HPLC and detected with wavelength 
314nm at Rt. 23.55min. The parent (S4) separated at Rt. 28.39min. 
ict2700
Time
5.00 10.00 15.00 20.00 25.00 30.00 35.00 40.00
A
U
0.0
1.0e-3
2.0e-3
3.0e-3
4.0e-3
5.0e-3
28.39
3.45
29.35
30.25
 
Figure 3.73: Metabolites of ICT 2726 (100µM) by CYP 3A4 bactosomes (30picomole/ml) + 
NADPH (2mM) for 120min (the incubation volume was 300µl). HPLC traces of potential 
metabolite separated at Rt. 23.55min (M39) using diode array detection at wavelength 
314nm. The substrate (S4) eluted at Rt. 28.39min. 
 
During the incubation, the intensities of metabolites were shown to gradually 
increase with the time of incubation.  
Subsequent identification of the ICT 2726 (S4) and the metabolite formed by 
the substrate was performed by LC/MS analysis and the mass to charge for 
parent was S4 m/z 369.1. M39 was at m/z 385.2 (Figure 3.74). 
The mass to charge for the metabolite compared to the structure of the 
substrate helped in obtaining structural information for the metabolite. 
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Figure 3.74: Metabolites of ICT 2726 (100µM) by CYP 3A4 bactosomes (30picomole/ml) + 
NADPH (2mM) for 120min. Reverse-phase LC was used for the separation of A, substrate 
and their metabolites detected using diode array detection at a wavelength 314nm.  B, S4 
(ICT 2726) eluted at Rt. 28.61min and the mass to charge was in SIR m/z 369.1. MS traces 
of C, M39 (Rt. 23.75min) was detected in SIR at m/z 385.2.  
 
In the M39 metabolite (Rt. at 23.75 min) the mass to charge was detected at    
m/z 385.2. This is likely due to a hydroxylation of ICT 2726 (Scheme 3.16). 
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III.4.10.5. Metabolism of ICT 2726 by mouse liver microsomes  
The in vitro metabolism of ICT 2726 (100µM) in the presence of MLiM 
supplemented with NADPH was examined. 
The method of preparing MLiM was as described in section III.3.1 and the 
protein concentration was measured in the same way as in section III.3.2. 
The microsome incubation method was the same as in section III.3.3 and the 
extraction method was the same as in section III.3.5. The optimised method 
described in section III.3.14 was used to separate and identify all metabolites 
(Figure 3.75). 
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Figure 3.75: Metabolites of ICT 2726 (100µM) in MLiM 1mg/ml + NADPH (2mM) for 120min 
(the incubation volume was 300µl). All HPLC traces of potential metabolites separated at Rt. 
(M40) 22.98 and (M41) 16.85min using diode array detection at wavelength 314nm. The 
substrate (S4) eluted at Rt. 27.80min. 
Two metabolites (M40 and M41) were separated in HPLC and detected in 
wavelength 314nm at Rt. 22.98 and 16.85 min respectively. The parent (S4) 
separated at Rt. 27.80min (Figure 3.75). 
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Some peaks, like the peak at Rt. 12.13, were not potential metabolites 
because they were also detected when incubated without NADPH (Figure 
3.76). 
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Figure 3.76: Incubation of ICT 2726 (100µM) in MLiM (1mg/ml) without NADPH for 120min 
(the incubation volume was 300µl). HPLC reverse-phase was used to determine if there was 
any peak from incubation ICT 2700 in MLiM in the absence of NADPH for 120min. Two 
peaks were detected in wavelength 314nm at Rt. 20.98 and 12.18min. The substrate eluted 
at (S4) Rt. 27.74min. 
Subsequent identification of the ICT 2726 (S4) and the metabolite formed by 
the substrate was performed by LC/MS analysis and the mass to charge for 
the parent was S4 (m/z 369.1). M40 was at m/z 385.2 and M41 was at m/z 
401.2 (see Figure 3.77). The mass to charge for the metabolite compared to 
the structure of the substrate helped in obtaining structural information for the 
metabolite. 
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Figure 3.77: Metabolites of ICT 2726 (100µM) in MLiM (1mg/ml) + NADPH (2mM) for 120min. 
Reverse-phase LC was used for the separation of A, substrate and their metabolites 
detected using diode array detection at wavelength 314nm. B, S4 (ICT 2726) eluted at Rt. 
28.58min and the mass to charge was at m/z 369.1. MS traces of C, M40 (Rt. 23.76min) was 
detected at m/z 385.2 and D, M41 (Rt. 17.65min) was detected at m/z 401.2.   
In the M40 metabolite (Rt. at 23.76 min) the mass to charge was detected at    
m/z 385.2. This is likely due to a hydroxylation of ICT 2726 (Scheme 3.16.). 
In the M41 metabolite (Rt. at 17.65 min) the mass to charge was detected at    
m/z 401.2. This is likely due to a two sequential hydroxylations of ICT 2726 
(Scheme 3.17.). 
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Scheme 3.17: The expectated chemical structure of M 41 metabolite (FW 400.79) 
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III.5. Discussion 
In the development of anticancer therapeutics, a prodrug is an attractive 
approach for targeting the cytotoxic agents to tumours because of its ability to 
1) maximise the cancer-directed cell kill, and 2) minimise the effect on the 
normal cells. Ideally, a cancer chemotherapeutic prodrug is completely inert 
until it is activated by a tumour-specific enzyme, or by an enzyme that is only 
metabolically competent towards the prodrug under physiological conditions 
that are unique to the tumour. An example of the latter case is the bio 
reduction of cancer prodrugs only in the hypoxic environment of a tumour.  
An example of this is the bio reduction of tirapazamine by cytochrome P450 
reductase (Reddy and Williamson, 2009) or AQ4N by various CYPS 
(Albertella et al., 2008; Ali et al., 1999; Patterson et al., 2000). 
 
Several prodrug antitumor agents have retrospectively been identified as 
CYP substrates for which tumour CYP activation may previously have been 
underestimated. Those in clinical use include prodrug alkylating agents; 
ifosphamide, cyclophosphamide, dacarbazine, procarbazine, Tegafur (a 
fluoropyrimidine), methoxymorphylinoadriamycin, tamoxifen and flutamide 
(Patterson and Murray, 2002) 
 
This work has shown that chloromethylindoline prodrugs ICT 2700, ICT 2705, 
ICT 2706 are substrates for CYP 1A1 and CYP 2W1. As such the 
chloromethylindolines represent a new class of prodrug which can be 
converted to cytotoxic agents. The fact that these chloromethylindolines are 
based on the duocarmycin anticancer drugs indicates they represent              
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a potential way to administer ultrapotent cytotoxins in a form that will be inert 
until metabolised by CYP, preferentially in the tumour. This is discussed in 
more detail in Chapter 4. 
 
CYP 1A1 is one of the CYP enzymes which is expressed in tumour tissue 
and surrounding stroma often with high frequency compared to normal tissue 
(Androutsopoulos et al., 2009). The concept of exploiting enzymes selectively 
in the tumour or in the surrounding stroma to convert an inactive prodrug to 
an active chemotherapeutic metabolite has shown significant promise, as 
with capecitabine (Rautio et al., 2008), EO9 (Apaziquone, currently in Phase 
III clinical trials) (Jain et al., 2009), AQ4N (Albertella et al., 2008; Ali et al., 
1999; Patterson et al., 2000), Aminoflavone and phortress (National Cancer 
Institute, 2011). 
  
Bactosomes are bacterial membranes artificially expressing a recombinant 
human CYP co-expressed with NADPH-P450 reductase. In this case a 
system is being created that enables investigation of the compound's specific 
metabolism by a selected CYP. The prodrug is exposed to high 
concentrations of a specific CYP in the incubation mix. However, in cells, 
various CYPs are co-expressed in close proximity within the endoplasmic 
reticulum and, in principle, can compete with each other for metabolising 
substrates. In the bactosomal incubations mix, no competition between 
different enzymes takes place and the question arises as to what extent 
bactosomes are able to reflect cellular condition. 
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In vitro experiments with bactosomes were performed in this work in order to 
examine the activation of chloromethylindoline prodrugs by specific CYP 
isoforms. ICT 2700 and ICT 2705 showed selectivity for CYP 1A1 compared 
to CYP 2D6 and CYP 3A4 bactosomes. The two most important enzymes 
that metabolise marketed drugs are CYP 3A4 and CYP 2D6 (Guengerich, 
2008; Lynch and Price, 2007; Wienkers and Heath, 2005).  
 
In a recent study, the significant increase (21- fold) in in vitro cytotoxicity of 
ICT 2700 in RT-112 cells (CYP 1A1 positive) but not in EJ-138 cells 
(undetectable CYP 1A1) was shown (Sutherland et al., 2012).  
 
HPLC has been a major tool in the analytical laboratory for separating, 
analyzing and purifying compounds since the 1970s. An LC/MS system can 
ionize the peak of interest and provide a molecular weight for each peak. An 
LC/MS/MS system can fragment the parent then separate the daughter ions. 
In this study, the advantages of these systems were used for separating, 
analyzing, fragmenting and identifying prodrugs and their metabolites. Also, 
using MS to monitor the loss of chlorine in each metabolite was very helpful 
in recognizing the formation of the spirocyclised product which is the reactive 
species undergoing attack of the N3 position of adenine when bound to the 
minor groove of DNA (Boger and Johnson, 1995; Boger et al., 1996; Pors et 
al., 2011) which occurs. The spectral characteristics of 2 chlorine isotopes 
were observed (35Cl represented 75% and 37Cl represented 25%). 
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The LC results in this chapter confirm that the chloromethylindoline           
prodrugs (ICT 2700 and ICT 2705) are primarily activated by CYP 1A1 
(Figures 3.11 and 3.59). In contrast to ICT 2700 and ICT 2705, there was no 
activation of ICT 2726 by CYP 1A1 (Figure 3.70). 
 
The CYP 1A subfamily includes CYP 1A1 and CYP 1A2. These two members 
share approximately 70% homology in their amino acid sequences 
(Berndtson and Chen, 1994; Boyd et al., 1995; Wakui et al., 2005). Therefore 
it is important to observe the catalytic activity of CYP 1A2 towards ICT 2700. 
The metabolites of ICT 2700 incubated with CYP 1A2 bactosomes appeared 
identical to CYP 1A1 metabolites. This could be a result of the high 
concentration of the enzyme and lack of competition with other CYPs. In 
contrast, the significant increase in in vitro cytotoxicity of ICT 2700 in EJ-138 
cells transfected with CYP 1A1 was shown within the ICT but not in            
EJ138_1A2 transfected cells (Sutherland et al., 2012). Moreover, CYP 1A2 
represents 15% of the human hepatic CYP content (Shirley et al., 2003). 
However, the results presented in section III.4.3.11 show that there were no 
significant active metabolites (potential toxic metabolites). 
 
To further study the stability of ICT 2700 in mouse liver, kidney and lungs 
(major sites of CYP 1A family members) an in vitro metabolic study was 
conducted. The outcomes of this study were that in MKM and MLuM the drug 
was not seen to be metabolised while in MLiM there were metabolites, one of 
which matched the potential toxic metabolite. However, it has been shown 
that when ICT 2700 is injected in vivo in mice there is no loss of weight and 
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no other signs of toxicity. Hence there appears to be no contribution from 
normal tissue to the antitumour effects observed in vivo against CYP 1A1 
expressing xenografts (Sutherland et al., 2012). Moreover, activation to the 
hydroxylated activate  metabolite (ICT 2740), which has been shown in this 
work to spontaneously convert to the spirocyclised toxic intermediate. 
 
Importantly, in human liver microsomes ex vivo, of the several metabolites 
detected none corresponded to the hydroxylated activate metabolite 
(ICT2740). This suggests that in human subjects the liver will not contribute 
to activation of ICT 2700 supporting the tumour-selectivity and therapeutic 
potential of this CYP-selective prodrug approach. However the data was from 
a sample of only five human livers and from Caucasian origin. Hence the 
heterogeneity of CYP expression across individuals and ethnic backgrounds 
must remain an issue to be explored. In addition the possibility of SNP 
variants changing (normally ameliorating) the contribution of a specific CYP 
isoform to metabolism of these chloromethylindolines must also be 
investigated. 
  
The MTT assay was used to determine EJ-138 cell viability. The reason for 
using EJ-138 cells was that PCR mRNA analysis revealed very low fold 
expression of CYPs including CYP 1A1 (Sutherland et al., 2012). The 
metabolites of CYP 1A1 human bactosome incubations were very toxic to the 
cells (IC50 1.6nM). However, in presence of CYP 2D6, CYP 3A4 and MLiM no 
cytotoxicity was observed. 
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Stability studies for both ICT 2700 and its hydroxylated precursor, ICT 2740, 
were undertaken in both methanol and Tris-HCL buffer to demonstrate that        
ICT 2700 requires metabolic hydroxylation to be converted to ICT 2740.        
A short- term stability test was performed to evaluate the recovery of          
ICT 2700 and ICT 2740. In MeOH both substrates were stable, and 
importantly, in Tris-HCL buffer spontaneous conversion of ICT 2740 was 
rapid with a similarly rapid increase in chlorinated spirocyclised toxic 
metabolite. Nonetheless, ICT 2700 was stable (Table 3.4 and 3.5). The 
separated peak and mass of ICT 2740, the hydroxylated precursor, matched 
that of ICT 2700 metabolites activated by CYP 1A1, and the spontaneous 
degradation of ICT 2740 was identical to the potential toxic metabolite 
activated by CYP 1A1(Figure 3.50).   
 
In drug development, there is always concerns about how readily a drug (or a 
metabolite thereof) molecule will cross membranes or enter cells. In this 
study, one concern could be that the increased cytotoxicity shown by          
ICT 2740 over ICT 2700 was due to the increased uptake of ICT 2740 into 
cells. Therefore, a comparison of ICT 2740 and ICT 2700 uptake into the 
human lung adenocarcinoma cell line (A-549) was investigated. The reason 
for using this cell line was that it shows a low expression of CYP1 family 
(unpublished observations, ICT; see Appendix M). Both ICT 2700 and        
ICT 2740 were taken up into A-549 cells. In comparing ICT 2700 and the 
activated authentic metabolite ICT 2740, uptake into cells by ICT 2700 was 
more than 4 times higher than ICT 2740. (Tables 3.7 and 3.9). Hence, the 
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cytotoxicity shown by ICT 2740 cannot be explained by preferential uptake 
over ICT 2700. 
 
Glutathione (GSH) is a tri-peptide (Gamma- glutamyl- cystemyl- glycine). The 
nucleophilic thiol group (SH) in cysteine donates reducing equivalents to 
electrophilic species, and has an important role to play in neutralising reactive 
oxygen species and other electrophiles (Manda et al., 2009). This process is 
responsible for the biological activity of GSH. This study explored whether 
GSH could react with the reactive intermediates generated from hydroxylation 
and subsequent spirocyclisation of ICT 2700 when incubated with CYP 1A1, 
or the activated authentic metabolite, ICT 2740. A GSH adduct was observed 
following incubation with ICT 2740 and this adduct was shown to be identical 
to arsing from CYP 1A1 hydroxylation of ICT 2700 (see Figures 3.54 and 
3.55 and Scheme 3.18). 
 
 
 
Scheme 3.18: The anticipated chemical structure of conjugation between GSH and either 
ICT 2740 or the toxic metabolite M4  
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The formation of GSH conjugates of chloromethylindolines following their 
metabolic activation suggest that this approach could be used as a facile 
method to show which of the chloromethylindoline analogues yet to be 
investigated are likely to produce toxic metabolites. This would provide an 
alternative and more definitive method to show metabolic activation 
compared to the use of the MTT assay. In complex cellular and in vivo 
settings, where CYP (and other Phase I/II enzyme) compete for substrate 
metabolism, then formation of toxic metabolites can be difficult to predict or 
detect. Therefore simple incubations with GSH and the production of 
conjugates, as shown, could provide an indicator for the production of 
potentially toxic metabolites in more complex systems (see Figure 3.41 and 
Table 3.3.). 
 
III.6. Conclusions  
CYP 1A1 is a mixed function oxidase enzyme which has been shown 
previously to contribute to the activation of a number of cytotoxic drug 
(Patterson and Murray, 2002). As such CYP 1A1 may have value in the 
development of chloromethylindolines as a new class of tumour selective 
anticancer therapy based on the duocarmycins. The current study has shown 
that ICT 2700 and some analogues are substrates for CYP 1A1 and that toxic 
metabolites are generated which have high potency in cell based cytotoxicity 
studies in EJ-138 cells. There is some evidence of activation in mouse liver  
in vitro but this did not contribute to the antitumour activity of ICT 2700 in vivo. 
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These results are encouraging and provide a basis to explore the anticancer 
activity of ICT 2700 and analogues in tumours known to express               
CYP 1A1and possible other CYP isoforms.   
 
 
ICT 2726 was found not to be activated by CYP 1A1, CYP 2D6, CYP 3A4 
bactosomes or mouse liver microsomes. However it was metabolised by   
CYP 2W1 this will investigated and discussed in more detail in Chapter 4. 
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IV. Studying the catalyzing properties of CYP 2W1       
IV.1. Introduction 
CYP 2W1 was considered as one of the 13 ‘‘orphan’’ CYPs because of its 
unknown enzymatic function. However, recent studies have shown that 
recombinant CYP 2W1 exhibits broad catalytic activity towards several 
chemicals (Li et al., 2009b). 
What is more, CYP 2W1 has been found to be highly expressed in 
approximately 54% of human colorectal specimens, whereas a very low 
expression is found in human normal tissues (Karlgren et al., 2006; Karlgren 
and Ingelman-Sundberg, 2007). 
The expression of CYP 2W1 might be used as a prognostic marker for 
survival and malignancy in colorectal cancers (Edler et al., 2009) or as an 
alternative mechanism to activate anticancer prodrugs (Gomez et al., 2007). 
It has been claimed that the enzyme CYP 2W1 was first cloned in the 
Karolinska Institutet laboratory (Karlgren et al., 2006; Karlgren et al., 2005). 
A collaboration between the Karolinska Institutet and the Institute of Cancer 
Therapeutics (ICT) has been developed to use CYP 2W1 as a target in the 
therapy of colorectal cancers using chloromethylindolines as prodrugs.  
All incubations of the prodrugs with CYP 2W1 were undertaken in the 
Karolinska Institutet, Sweden, while the extraction, separation and 
identification of metabolites were conducted in the ICT. 
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In Chapter 3 the chloromethylindoline prodrug, ICT 2700, was shown to be 
activated by CYP 1A1, but not by CYP 2D6 and CYP 3A4 bactosomes, and 
also not activated by HLM, MLiM, MKM or MLuM. The substrate recognition 
site of CYP 2W1 shares the highest identity with CYP 1A1 (Karlgren and 
Ingelman-Sundberg, 2007). 
ICT 2726 (Scheme 3.15) is designed to be a potential substrate for CYP 2W1 
activation. However, in vitro results showed that ICT 2726 was not cytotoxic 
for two types of human transfected cell lines (SW480_2W1 and 
HEK293_2W1) while both ICT 2705 and ICT 2706 killed the cells. These 
observations correspond to mock-transfected cells (unpublished observations, 
Karolinska Institutet, Sweden; see Appendix N). 
This chapter gives the results of catalyzing CYP 2W1 metabolism of 
chloromethylindolines (ICT 2723- ICT 2728) derivatives from ICT 2726 and 
ICT 2706 derived from ICT 2700. Moreover, the pharmacokinetics of           
ICT 2706 in mice is demonstrated in this work. 
 
IV.2. Materials 
Stock solutions of all prodrugs were prepared in DMSO and stored at -20°C. 
Heparinised polypropylene tubes were used for collection of blood samples, 
and polypropylene microcentrifuge tubes (Sigma-Aldrich) were used 
throughout for sample handling and storage. All other chemicals and 
reagents used in this chapter were as stated in Chapter 2. 
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IV.2.1. Cell lines 
HEK293_2W1and SW480_2W1 cell lines transfected with CYP 2W1 and 
SW480_Mock (human colon cell line) were obtained from Karolinska Institutet, 
Stockholm, Sweden. 
IV.2.2. Mouse samples 
Mouse plasma and tissues (tumour, brain, and liver) were obtained from 
Karolinska Institutet, Stockholm, Sweden. Following sacrifice, the tissues are 
then removed and snap frozen in liquid nitrogen before analyzed by            
LC- MS/MS. 
IV.3. Methods 
IV.3.1. Cell seeding 
SW480_2W1, HEK293_2W1, HEK293_Mock and SW480_Mock were 
seeded as described in section II.2.1. 
IV.3.2. Cell passaging 
The same method was used as in section II.2.2. 
IV.3.3. Cell counting 
The same method was used as in section II.2.3. 
IV.3.4. Cell incubation  
SW480_2W1, HEK293_2W1 and corresponding mock transfected cells        
(7x106) were incubated with prodrugs. The period of incubation was variable 
for each prodrug (see Appendix B). The cells were harvested, washed with 
PBS and centrifuged at 3000 rpm for 5min.  
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IV.3.5. Substrate extraction from cells using protein precipitation  
Cell walls were broken with the addition of 100µl ice-cold water. Suspension 
was mixed with 100% ice-cold MeCN, then vortexed and centrifuged at 
13300rpm for 20min. Supernatant was collected and analyzed by HPLC and 
LC- MS. 
IV.3.6. Metabolism of ICT 2723 by CYP 2W1 
IV.3.6.1. HPLC analysis  
The same method was used as in section III.4.3.1.1.    
IV.3.6.2. LC- MS analysis 
The same method was used as in section III.4.3.1.2, except the channels of 
SIR were 420, 426, 439, 455 and 471m/z. 
IV.3.7. Metabolism of ICT 2724 by CYP 2W1 
IV.3.7.1 HPLC analysis 
The same method was used as in section III.4.3.1.1.    
IV.3.7.2. LC-MS analysis 
The same method was used as in section III.4.3.1.2, except the channels of 
SIR were 360.03, 362.03, 368.03, 381.03, 397.03 and 413.03m/z. 
IV.3.7.3. Kinetic analysis of ICT 2724 metabolism by CYP 2W1  
To determine the enzyme kinetics for the CYP 2W1-catalyzed metabolism 
of ICT 2724, six substrate concentrations were used ranging from 0.25 to 
8μM. The rate of reaction was determined then the kinetic parameters were 
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obtained using the Michaelis-Menten equation and Lineweaver-Burk plots. 
Substrate concentrations and their metabolites were separated using the 
same method as in section IV.3.7. 
IV.3.8. Metabolism of ICT 2725 by CYP 2W1 
IV.3.8.1. HPLC analysis  
The same method was used as in section III.4.3.1.1.    
IV.3.8.2. LC-MS analysis 
The same method was used as in section III.4.3.1.2, except the channels of 
SIR were 422, 424, 441, 457 and 473m/z. 
IV.3.9. Metabolism of ICT 2726 by CYP 2W1 
IV.3.9.1. HPLC analysis  
The same method was used as in section III.4.10.1.1    
IV.3.9.2. LC-MS analysis 
The method used was like in section III.4.10.1.2 
IV.3.9.3. Kinetic analysis of ICT 2726 metabolism with CYP 2W1  
The same kinetic method was used as in section IV.3.7.3. Substrate 
concentrations and their metabolites were separated using same method as 
in section IV.3.7. 
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IV.3.10. Metabolism of ICT 2727 by CYP 2W1 
IV.3.10.1. HPLC analysis 
The same method was used as in section III.4.3.1.1.    
IV.3.10.2. LC-MS analysis 
The same method was used as in section III.4.3.1.2, except the channels of 
SIR were 367.95, 369.01, 384.94, 386.95, 402.95 and 418.95m/z. 
IV.3.11. Metabolism of ICT 2728 by CYP 2W1 
IV.3.11.1. HPLC analysis 
The same method was used as in section III.4.3.1.1.    
IV.3.11.2. LC- MS analysis 
The same method was used as in section III.4.3.1.2, except the channels of 
SIR were 426.2, 427.2, 445.2, 461.2 and 477.2m/z. 
IV.3.12. Metabolism of ICT 2706 by CYP 2W1 
IV.3.12.1. HPLC analysis  
The same method was used as in section III.4.3.1.1.    
IV.3.12.2. LC-MS analysis 
The same method was used as in section III.4.3.1.2, except the channels of 
SIR were 420, 426, 439, 455 and 471m/z. 
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IV.3.13. Studying the pharmacokinetics of ICT 2706 in plasma and 
tissues 
IV.3.13.1. Animals   
All in vivo studies were approved by the local animal ethical committee in 
Stockholm, Sweden, and animal care was carried out in accordance with 
institutional guidelines.12 SCID mice were inoculated subcutaneously (s.c.) 
with SW480_2W1 cells (7×106) in both flanks, and the xenografts were 
allowed to grow up to an average size of ~70mm3 before the animals 
received a single i.p. dose of ICT 2706 (100mg/kg). The prodrug was 
dissolved in DMSO and further diluted in corn oil. Vehicle formulation 
consisted of corn oil and 10% DMSO. Following the treatment, animals were 
sacrificed at consecutive time points (t= 0min, 5min, 30min, 1 hour, 4 hours, 
and 24 hours), two animals per time point, and plasma, tumour, liver and 
brain tissue were extracted and snap- frozen in liquid nitrogen.   
IV.3.13.2. Sample preparation (plasma) 
Mouse plasma samples used in the extraction and calibration procedures 
were taken by cardiac puncture from drug-free anaesthetised mice. A volume 
of 100l of blank plasma was spiked with ICT 2706 to give the appropriate 
final concentrations ranging from 0- 10 µg/ml for extraction efficiencies and 
calibration purposes. Three volumes of cold methanol were added to 
precipitate the protein. After vortex-mixing the samples were centrifuged at 
7000xg for 3 minutes, the supernatant was carefully removed, and 10l 
volumes were injected onto the HPLC system. All samples were handled in 
polypropylene microcentrifuge tubes to avoid potential binding to glass. 
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 Calibration Plasma calibration standards were prepared by spiking 
drug- free mouse plasma to give the final concentration range of 0.05-
10.0µgml-1. The calibration curves were determined using linear regression 
analysis of the ratios of the peak areas of the analyte plotted against 
concentrations. The calibration and extraction process was repeated using 
drug-free tumour tissue homogenate to represent non-plasma samples. The 
values of the calibration standards were chosen based on the anticipated 
concentrations of unknown samples. 
IV.3.13.3. Sample preparation (tissue) 
Brain, tumour and liver samples were accurately weighed and homogenised 
in 4 volumes of Tris-HCL buffer (pH 7.4, 100mM). Samples were then        
de-proteinised by adding three volumes of methanol. After vortex-mixing the 
samples were centrifuged at 7000xg for 3 minutes, the supernatant was 
carefully removed and 10l volumes were injected onto the HPLC system. 
The calibration and extraction process described in section IV.3.13.2 was 
repeated using drug-free tumour tissue homogenate to represent non- 
plasma samples. 
IV.3.13.4.   LC- MS/MS 
LC-MS/MS parameters were the same as in section III.3.9.2. MRM mode was 
used to enhance the sensitivity of detection. 
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IV.3.13.5. The pharmacokinetics parameters 
With extravascular administration and in development of any new drug, it is 
important to establish Cmax (drug concentration at the peak) and Tmax (the 
time when the peak occurs). 
The method used to express rate of ICT 2706 elimination is via the half- life, 
t1/2, the time required for substrate blood concentration to fall by 50%.  
The method used to measure the area under the curve is the ‘Trapezoidal 
rule’. Each data point has been joined by straight lines and verticals have 
been constructed from each data point down to the horizontal axis. The area 
for each individual trapezoid was calculated by determines its width and 
average height.  
Trapezoid width= end time - start time. 
Trapezoid average height= start concentration+ end concentration/ 2. 
The area of each trapezoid= width x average height. 
 Then the sum of trapezoids area was used to estimate total AUC0-24hrs. 
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IV.4. Results 
IV.4.1. Metabolism of chloromethylindoline (ICT 2723) by CYP 2W1 
8.4µM ICT 2723 (Scheme 4.1) was incubated in either HEK293_2W1 
transfected cells or HEK293_Mock cells for 7hrs. The extraction of ICT 2723 
and its metabolites was as described in section IV.3.5. 
O
CH3O
Cl
O
N
NHO
O
H3C
C23H19ClN2O5
438.87
438.098250
C 62.95% H 4.36% Cl 8.08% N 6.38% O 18.23%  
Scheme 4.1: The structure of ICT 2723 (FW 438.87) 
IV.4.1.1. Identification of ICT 2723  
The optimised method in section IV.3.6 was used to determine the optimum 
absorbance and mass to charge of ICT 2723. 
IV.4.1.1.1. Separation of ICT 2723 using HPLC 
ICT 2723 was scanned across the wavelength range 190-500nm. The 
method was as described in section IV.3.6.1. The detection of ICT 2723 was 
confirmed by making a scan of ICT 2723 (100µM) and the λ max being 
shown to be 317nm. The retention time was 23.85min (Figure 4.1). 
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Figure 4.1: Detection of ICT 2723 (100µM) in HPLC. Reverse-phase LC was used for the 
separation of ICT 2723.  A, chromatogram of ICT 2723 using diode array detection (DAD) at    
wavelength 317nm and Rt. 23.85min. B, spectrum of ICT 2723, showing the λ max to be 
317nm. 
 
IV.4.1.1.2. Separation of ICT 2723 using LC-MS 
Identification of ICT 2723 was confirmed by MS scanning of ICT 2723 
(100µM) in the range m/z 220-520 (Figure 4.2). The method was as 
described in section IV.3.6.2. A dominant parent ion was detected at m/z 
439.2 then an SIR channel was set up at m/z 439.2. From the MS-spectrum 
(Figure 4.2) we can see two principal stable chlorine isotopes in m/z 439.2 
and 441.4. This helps in monitoring the existence of chlorine in the 
metabolites. These parameters were used as controls for further studies of 
ICT 2723 metabolism. 
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Figure 4.2: Detection of ICT 2723 (100µM) by LC-MS. Reverse-phase LC was used for the 
separation of ICT 2723. A, B MS trace supporting correct identification of ICT 2723 in MS 
detector. A, total ion chromatogram (TIC) scanning of singularly charged ions [ES+] from 
220-520 with Rt. 23.87min and B, SIR in specific [ES+] m/z 439.2 with Rt. 23.89min. C, 
spectral characteristics of ICT 2723 at m/z 439.2. This matches ICT 2723 FW (438.87) also 
showing two principal isotopes of chlorine (
35
Cl represented 75% and 
37
Cl represented 25%). 
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IV.4.1.2. Metabolism of ICT 2723 by CYP 2W1 
The in vitro metabolism of 8.4µM ICT 2723 by CYP 2W1 was examined to 
investigate the influence of this enzyme on ICT 2723. 
The incubation was in duplicate with two separate samples of HEK293_2W1 
transfected cells and one of HEK293_Mock transfected cells. The optimised 
method in section IV.3.6 was used to separate and identify all metabolites 
(Figure 4.3). 
Using the mock transfected cells as a comparison, no metabolites were 
detected in the transfected cells. However degradation products were 
detected in both cell lines. This appeared in the standard (see Figure 4.1). 
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Figure 4.3: Metabolites of 8.4µM ICT 2723 in HEK293_2W1 transfected cells (7x10
6
) for 7hrs. 
No HPLC traces for any potential metabolite were separated using diode array detection at 
wavelength 317nm. The substrate (S5) eluted at Rt. 23.80min. This figure shows one of 2 
replicates of HEK293_2W1 incubation (with the same result) beside HEK293_Mock 
incubation. 
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IV.4.2. Metabolism of chloromethylindoline (ICT 2724) by CYP 2W1 
8.4µM ICT 2724 (Scheme 4.2) was incubated with either HEK293_2W1 
transfected cells or HEK293_Mock cells for 7 hrs. The extraction of ICT 2724 
and its metabolites was described in section IV.3.5. 
O
CH3O
Cl
O
N
NH
C21H17ClN2O3
380.83
380.092770
C 66.23% H 4.50% Cl 9.31% N 7.36% O 12.60% 
 
Scheme 4.2: The structure of ICT 2724 (FW 380.83) 
 
IV.4.2.1. Identification of ICT 2724  
The optimised method in section IV.3.7 was used to determine the λ max and 
establish an SIR channel for ICT 2724. 
IV.4.2.1.1. Separation of ICT 2724 using HPLC 
ICT 2724 was scanned across the wavelength range 200-400nm. The 
method was as described in section IV.3.7.1. The detection of ICT 2724 was 
confirmed by making a scan of ICT 2724 (100µM) and the λ max being 
shown to be 316nm. The retention time was 23.27min (Figure 4.4). 
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Figure 4.4: Detection of ICT 2724 (100µM) in HPLC. Reverse-phase LC was used for the 
separation of ICT 2724. A, chromatogram of ICT 2724 using diode array detection (DAD) at    
wavelength 316nm and Rt. 23.27min. B, spectrum of ICT 2724 in DAD with scanning 
wavelength 316nm. 
 
 
IV.4.2 1.2. Separation of ICT 2724 using LC-MS 
Identification of ICT 2724 was confirmed by MS scanning of ICT 2724 
(100µM) in the mass range 220-520 (Figure 4.5). The method was as 
described in section IV.3.7.2. The SIR channel was established at m/z 381.2. 
From the MS-spectrum (Figure 4.5) we can see two principal stable chlorine 
isotopes at m/z 381.2 and 383.4. This helps in monitoring the existence of 
chlorine in the metabolites. These parameters were used as controls for 
further studies of ICT 2724 metabolism.  
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Figure 4.5: Detection of ICT 2724 (100µM) by LC-MS. Reverse-phase LC was used for the 
separation of ICT 2724. A, B MS trace supporting correct identification of ICT 2724 in MS 
detector. A, total ion chromatogram (TIC) scanning of singularly charged ions [ES+] from 
220-520 with Rt. 23.32min and B, SIR in specific [ES+] m/z 381.2 with Rt. 23.34min. C, 
spectral characteristics of ICT 2724 at m/z 381.2. This matches ICT 2724 FW (380.83) also 
showing two principal isotopes of chlorine (
35
Cl represented 75% and 
37
Cl represented 25%). 
TIC scans [ES+]  
(220 to 520) 
 
 
SIR m/z 381.2 
 
+ 
37
Cl 
+ 
35
Cl 
A 
B 
C 
Catalyzing properties of CYP 2W1                                                                Chapter 4 
 
175 
IV.4.2.2. Metabolism of ICT 2724 by CYP 2W1 
The in vitro metabolism of 8.4µM ICT 2724 by CYP 2W1 was examined to 
investigate the influence of this enzyme on ICT 2724.  
The incubation was in two separate samples of HEK293_2W1 transfected 
and in one of HEK293_Mock transfected cells. The optimised method in 
section IV.3.7 was used to separate and identify all metabolites (Figure 4.6). 
Only one metabolite (M42) was separated by HPLC and detected at a 
wavelength of 316nm at Rt. 16.91min. The parent (S6) separated at Rt. 
23.25min. 
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Figure 4.6: Metabolites of 8.4µM ICT 2724 in HEK293_2W1 transfected cells(7x10
6
) for 7hrs. 
All HPLC traces of potential metabolite separated at Rt. (M42) 16.91min using diode array 
detection at wavelength 316nm and the mass to charge was m/z 363.03. The substrate (S6) 
eluted at Rt. 23.25min. This figure shows one of 2 replicates of HEK293_2W1 incubation 
(with the same result) beside HEK293_Mock incubation. 
Subsequent identification of the ICT 2724 (S6) and the metabolite formed 
was performed by LC/MS analysis. The mass to charge for S6 was m/z 
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381.10 and M42 had a predicted mass of 363.0. The mass to charge ratio for 
the metabolite compared to the structure of substrate helped in obtaining 
structural information for the metabolite. This is likely due to hydroxylation    
(a replacement of chlorine with a hydroxyl group) of ICT 2724 (Scheme 4.3). 
O
CH3O
OH
O
N
NH
              C21H18N2O4
               362.38
               362.126657
                  C 69.60% H 5.01% N 7.73% O 17.66% 
 
Scheme 4.3: The anticipated chemical structure of the M42 metabolite (FW 362.38) 
  
The replacement of chlorine with a hydroxyl group inactivates the metabolite. 
This is unlikely to be the result of a potential hydroxylation followed by 
dechlorination leading to a potential toxic metabolite (Scheme 4.4). 
Inactivation of chloromethylindoline will be discussed in more detail in this 
chapter in the metabolism of ICT 2726 by CYP 2W1 (section IV.4.4.). 
O
CH3O
O
N
NH
O
C21H16N2O4
360.37
360.111007
C 69.99% H 4.48% N 7.77% O 17.76% 
 
Scheme 4.4: The anticipated chemical structure of the potential toxic metabolite (FW 360.37) 
of ICT 2724 
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IV.4.2.3. Enzyme kinetics of ICT 2724 in CYP 2W1 
Enzyme kinetics means determining the affinity between the enzyme and the 
substrate by measuring the change in concentration of either substrates or 
products to determine the rate of an enzyme-catalyzed reaction (rate of 
reaction), as we know enzymes are not consumed by reactions. 
Different ICT 2724 concentrations (0.25, 0.5, 1, 2, 4 and 8µM) were used to 
measure the rate of an enzyme-catalyzed reaction of HEK293_2W1 
transfected cells. 
The peak areas for metabolites of different ICT 2724 concentrations were 
separated by the HPLC system and detected at a wavelength of 316nm. The 
method was described in section IV.3.7. Plots of product versus time (7hrs) 
were obtained for ICT 2724 concentrations (see Table 4.1). 
Table 4.1:  Metabolite peak area for each concentration of ICT 2724 (0.25-8µM) incubated in 
HEK293_2W1 transfected cells (average of 3 independent experiments) and mock cells for 
7hrs. 
 
The slope of the curves, the rate of the reaction, was obtained for each 
concentration (see Figure 4.7 and Table 4.2). 
ICT 2724 concentration (µM)  
0.25 µM  0.5 µM  1 µM  2 µM  4 µM  8 µM  
Peak Area (AU)  (Mock cells)  <5  <5 <5  <5  <5  <5  
Peak Area (AU) (2W1 cells) (n=3)  44  83  129  164  238  327  
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Figure 4.7: The peak area for ICT 2724 concentrations from 0.25-8µM incubated in 
HEK293_2W1 for 7hrs. 
 
Table 4.2:  The rate of reaction for each concentration of ICT 2724 (0.25-8µM) incubated in 
HEK293_2W1 transfected cells (3 independent experiments) for 7hrs. 
 
 
 
 
 
 
 
 
The kinetic parameters (Vmax and Km) were obtained from the plot graph (see 
Figure 4.7 and Table 4.2) by using a spreadsheet to determine the Michaelis-
Menten Equation (Figure 4.8). 
ICT 2724 concentration  µM Rate of reaction  (n moles/ hrs/ 1X10
6
 cells) 
0.25 6.2857 
0.5 11.857 
1 18.429 
2 23.429 
4 34 
8 46.714 
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Figure 4.8: Michaelis-Menten Equation of ICT 2724 (0.25-8µM) incubated with HEK293_2W1 
cells. Vmax = 47µmoles/ hrs/ 1X10
6
 cells and Km = 2µM. Results represent 3 independent 
experiments. 
 
The linear Lineweaver-Burk parameters (Table 4.3) were determined from the 
graph plot (see Figure 4.7 and Table 4.2).  
Table 4.3: Lineweaver-Burk parameters (1/S and 1/V) for each concentration of ICT 2724 
(0.25-8µM) incubated in HEK_2W1 transfected cells (3 independent experiments) for 7hrs. 
 
 
 
 
 
 
 
Concentration µM (S) 1/ S 
Rate of reaction µmoles/hrs/ 1X10
6
 cells 
(V) 1/V 
0.25 4 6.2857 0.159 
0.5 2 11.857 0.084 
1 1 18.429 0.054 
2 0.5 23.429 0.0426 
4 0.25 34 0.0294 
8 0.125 46.714 0.0214 
Michaelis- Menten Plot ICT2724 (0.25-8µM) + CYP2W1  
 
V max 
1/ V max 
K m 
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The linear Lineweaver-Burk equation was determined from the plot graph 
(Figure 4.9).  
 
Figure 4.9: Lineweaver-Burk plot of ICT 2724 (0.25-8µM) incubated with HEK293_2W1 
transfected cells. Results represent an average of 3 independent experiments. From the 
equation y = mx + c (y = 0.0343 X + 0.0201) we can determine the maximum enzyme 
velocity Vmax = 49.7µmoles/hrs/1X10
6
 cells and the Michaelis-Menten constant Km = 
1.704µM..   
 
From the Lineweaver- Burk plot equation:  y = m x + c, y = 0.0343 X + 0.0201 
1/ V= (Km / Vmax) (1/ S) + (1/ V max)  
V max = 1/ 0.0201= 49.7 µmoles/ hrs/ 1X10
6 cells.       
K m= (K m / V max) (V max) 
K m= 0.0343 X 49.751 = 1.704 µM 
All the kinetic parameters (Vmax and Km) in this study are approximated values 
as it was only one data point for each concentration to measure the rates. 
 
 
Lineweaver- Burk plot ICT2724 (0.25 -8µM) + CYP 2W1  
 
1/ S 
1
/ 
V
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IV.4.3. Metabolism of chloromethylindoline (ICT 2725) by CYP 2W1 
8.4µM ICT 2725 (Scheme 4.5) was incubated in either HEK293_2W1 
transfected cells or HEK293_Mock cells for 7 hours. The extraction of ICT 
2725 and its metabolites was described in section IV.3.5. 
O
CH3O
Cl
O
N
NH
O CH3
O CH3
C23H21ClN2O5
440.88
440.113900
C 62.66% H 4.80% Cl 8.04% N 6.35% O 18.14% 
 
Scheme 4.5: The structure of ICT 2725 FW 440.88 
 
IV.4.3.1. Identification of ICT 2725  
The optimised method in section IV.3.8 was used to determine the optimum 
absorbance and mass to charge of ICT 2725.  
IV.4.3.1.1. Separation of ICT 2725 using HPLC 
ICT 2725 was scanned across the wavelength range 190-500nm. The 
detection of ICT 2725 was confirmed by making a scan of ICT 2725 (100µM) 
and the λ max being shown to be 321nm. The retention time was 23.90min 
(Figure 4.10). 
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23.90
24.90
   
Figure 4.10: Detection of ICT 2725 (100µM) in HPLC, Reverse-phase LC was used for the 
separation of ICT 2725.  A, chromatogram of ICT 2725 using diode array detection (DAD) at    
a wavelength 321nm and Rt. 23.90min. B, spectrum of ICT 2725 in DAD, wavelength 321nm. 
 
IV.4.3.1.2. Separation of ICT 2725 using LC-MS 
Identification of ICT 2725 was confirmed by MS scanning of ICT 2725 
(100µM) in the range 220-520 (Figure 4.11). The spectrum indicated a parent 
ion at m/z 441.2 so the SIR channel was set up at m/z 441.2. From the MS-
spectrum (Figure 4.11) we can see two principal stable chlorine isotopes in 
m/z 441.2 and 443.4. This helps in monitoring the existence of chlorine in the 
metabolites. These parameters were used as controls for further studies of 
ICT 2725 metabolism.  
A 
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A
U
0.0
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Figure 4.11: Detection of ICT 2725 (100µM) by LC-MS. Reverse-phase LC was used for the 
separation of ICT 2725. A, B MS trace supporting correct identification of ICT 2725 in MS 
detector. A, total ion chromatogram (TIC) scanning of singularly charged ions [ES+] from 
220-520 with Rt. 23.95min and B, SIR in specific [ES+] m/z 441.2 with Rt. 23.97min. C, 
spectral characteristics of ICT 2725 at m/z 441.2. This matches ICT 2725 (FW 440.88) also 
showing two principal isotopes of chlorine (
35
Cl represented 75% and 
37
Cl represented 25%). 
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IV.4.3.2. Metabolism of ICT 2725 by CYP 2W1 
The in vitro metabolism of 8.4µM ICT 2725 by CYP 2W1 was examined to 
investigate the influence of this enzyme on ICT 2725.  
The incubation was in duplicate with two separate samples of HEK293_2W1 
transfected and one of HEK293_Mock transfected cells. The optimised 
method in section IV.3.8 was used to separate and identify all metabolites 
(Figure 4.12). 
Comparisons between the mock and transfected cell lines suggested no 
metabolites were evident in HPLC from the incubation of ICT 2725 in 
HEK293_2W1 transfected cells. However degradation products were 
detected in both cell lines. This appeared in the standard (see Figure 4.10). 
CPI
Time
0.00 5.00 10.00 15.00 20.00 25.00 30.00
A
U
0.0
2.0e-3
4.0e-3
23.89
23.27
1.04 3.81 5.42 9.71
24.89
 
Figure 4.12: Metabolites of 8.4µM ICT 2725 in HEK293_2W1 transfected cells (7x10
6
) for 
7hrs. There was no evidence for any potential metabolite separated using diode array 
detection at a wavelength of 321nm. The substrate (S7) eluted at Rt. 23.89min. This figure 
shows one of 2 replicates of HEK293_2W1 incubations (with the same result) beside 
HEK293_Mock incubation. 
 
HEK-mock 
HEK-2W1 
S7 
DAD 321nm 
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IV.4.4. Metabolism of chloromethylindoline (ICT 2726) by CYP 2W1 
8.4µM ICT 2726 (Scheme 4.6) was incubated in vitro with either 
HEK293_2W1 transfected cells or HEK293_Mock cells for 7hrs. The 
extraction of ICT 2726 and its metabolites was described in section IV.3.5. 
O
Cl
O
N
NH
F
C20H14ClFN2O2
368.79
368.072784
C 65.14% H 3.83% Cl 9.61% F 5.15% N 7.60% O 8.68% 
 
Scheme 4.6: The structure of ICT 2726 FW 368.79 
 
The identification of ICT 2726 using both HPLC and LC-MS was described in 
section IV.3.9. 
The incubation was in duplicate with two separate samples of HEK293_2W1 
transfected and one HEK293_Mock transfected cell preparation. The 
optimised method in section IV.3.9 was used to separate and identify all 
metabolites (Figure 4.13). 
The substrate (S8) eluted at Rt. 24.88 min while the chromatographic peaks 
of the formed metabolites (M43, M44 and M45) were eluted at Rt. 21.06, 
18.52 and 14.67min respectively (Figure 4.13).  
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Figure 4.13: Metabolites of 8.4µM ICT 2726 in HEK293_2W1 transfected cells (7x10
6
) for 
7hrs incubation. All HPLC traces of potential metabolites separated at Rt. (M43) 21.06, (M44) 
18.52, (M45) 14.67min using diode array detection at a wavelength 314nm. The mass to 
charges were m/z 367.07, 351.03 and 404.88 respectively and the substrate (S8) eluted at 
Rt. 24.88min. This figure shows one of 2 replicates of the HEK293_2W1 incubation (with the 
same result) beside HEK293_Mock incubation. 
 
Subsequent identification of the ICT 2726 (S8) and the metabolites formed 
following incubation with the enzyme was performed by LC/MS analysis. The 
mass to charge for S8 was m/z 369.02, M43 was at m/z 367.07, M44 was at 
m/z 351.03, and M45 was at m/z 404.88. The mass to charge ratio for the 
metabolite compared to the structure of substrate helped in obtaining 
structural information for the metabolites. 
M43 (m/z 367.07) is likely due to a double hydroxylation of ICT 2726, one of 
which was a replacement of chlorine with a hydroxyl group (Scheme 4.7). 
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N
O
NH
O
F
OH
OH C20H15FN2O4
366.35
366.101585
C 65.57% H 4.13% F 5.19% N 7.65% O 17.47%  
Scheme 4.7: The anticipated chemical structure of M43 metabolite (FW 366.35) 
 
M44 (m/z 351.03) is likely due to hydroxylation (a replacement of chlorine 
with a hydroxyl group) of ICT 2726 (Scheme 4.8). 
O
O
N
NH
F
OH
C20H15FN2O3
350.35
350.106671
C 68.57% H 4.32% F 5.42% N 8.00% O 13.70% 
 
Scheme 4.8: The anticipated chemical structure of M44 metabolite (FW 350.35) 
 
The replacement of chlorine with a hydroxyl group inactivates the metabolite. 
This is unlikely to be the result of a potential hydroxylation followed by 
dechlorination leading to a potential toxic metabolite (Scheme 4.9).  
O
O
N
NH
F
O
C20H13FN2O3
348.33
348.091021
C 68.96% H 3.76% F 5.45% N 8.04% O 13.78% 
 
Scheme 4.9: The anticipated chemical structure of potential toxic metabolite (FW 348.33) of 
ICT 2726 
 
This result was interpreted according to the previous observation of a lack of 
cytotoxicity when HEK293_2W1 was treated with ICT 2726 (unpublished 
observations, ICT; see Appendix N). 
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M45 (m/z 404.88) is likely due to a double hydroxylation of ICT 2726 
(Scheme 4.10), and from the spectrum two principal isotopes of chlorine still 
exist. 
N
O
NH
O
F
Cl
OH
OH
C20H14ClFN2O4
400.79
400.062613
C 59.94% H 3.52% Cl 8.85% F 4.74% N 6.99% O 15.97%  
Scheme 4.10: The anticipated chemical structure of M45 metabolite (FW 402.81) 
 
IV.4.4.1. Enzyme kinetic of ICT 2726 in CYP 2W1 
Different ICT 2726 concentrations (0.25, 0.5, 1, 2, 4 and 8µM) were used to 
measure the rate of an enzyme-catalyzed reaction of HEK293_2W1 
transfected cells. 
The peak areas for metabolites of different ICT 2726 concentrations were 
obtained by using the HPLC system and detected in wavelength 321nm and 
the method was demonstrated in section IV.3.9. Plots of product versus time 
(7hrs) were obtained for ICT 2726 concentrations (see Table 4.4).   
 
Table 4.4:  The sum of metabolites peak area for each concentration of ICT 2726 (0.25-8µM) 
incubated in HEK293_2W1 transfected cells (average of 3 independent experiments) and 
mock cells for 7 hrs. 
ICT 2726 concentration (µM)  0.25 µM 0.5 µM 1 µM 2 µM 4 µM 8 µM 
Peak Area (AU) (Mock cells)  <5 <5 <5 <5 <5 <5 
Peak Area (AU) (2W1 cells) (n=3)  72  146  263  471  1474  2055  
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The slope of the curve, the rate of reaction, was obtained for each 
concentration (see Figure 4.14 and Table 4.5). 
 
Figure 4.14: The peak area for ICT 2726 concentrations from 0.25-8µM incubated in 
HEK293_2W1 and mock transfected cells for 7hrs. 
 
 
Table 4.5:  The rate of reaction for each concentration of ICT 2726 (0.25-8µM) incubated in 
HEK293_2W1 transfected cells (3 independent experiments) for 7hrs. 
 
 
  
 
 
 
 
 
ICT 2726 concentration  µM Rate of reaction    µmoles/hrs/ 1X10
6
 cells 
0.25 10.286 
0.5 20.857 
1 37.571 
2 67.286 
4 210.57 
8 293.57 
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The kinetic parameters (Vmax and Km) were obtained from the plot graph (see 
Figure 4.14 and Table 4.5) by using a spreadsheet to determine the 
Michaelis-Menten Equation (Figure 4.15).   
  
Figure 4.15: Michaelis-Menten Equation of ICT 2726 (0.25-8µM) incubated with 
HEK293_2W1 cells. Vmax= 400 µmoles/hrs/ 1X10
6
 cells and Km= 4µM. Results represent an 
average of 3 independent experiments. 
 
The linear Lineweaver- Burk parameters (Table 4.6) were determined from 
the plot graph (see Figure 4.14 and Table 4.5).  
Table 4.6:  Lineweaver- Burk parameters (1/S and 1/V) for each concentration of ICT 2726 
(0.25-8µM) incubated in HEK_2W1 transfected cells (3 independent experiments) for 7hrs. 
 
Concentration µM (S) 1/S 
Rate of reaction µmoles/hrs/ 1X10
6
 cells 
(V) 1/V 
0.25 4 10.286 0.0972 
0.5 2 20.857 0.0479 
1 1 37.571 0.0266 
2 0.5 67.286 0.0148 
4 0.25 210.57 0.0047 
8 0.125 293.57 0.0034 
Michaelis- Menten Plot ICT2726 (0.25- 8µM) + CYP2W1  
 
K m 
V max 
1/V max 
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The linear Lineweaver-Burk equation was determined from the plot graph 
(Figure 4.16). 
 
Figure 4.16: Lineweaver-Burk plot of ICT 2726 (0.25-8µM) incubated with HEK293_2W1 
cells. Results represent 3 independent experiments. From the equation y = m x + c, (y= 
0.0241 X + 0.0008) we can determine the maximum enzyme velocity Vmax = 1250 
µmoles/hrs/ 1X10
6
 cells and the Michaels-Menten constant Km = 51.86µM.   
 
From the Lineweaver- Burk plot equation:  y = m x + c, y = 0.0241 X + 0.0008 
1/ V= (Km / Vmax) (1/ S) + (1/ V max)  
V max = 1/ 0.0008= 1250 µmoles/hrs/ 1X10
6 cells 
Km= (Km/ V max) (V max) 
Km=0.0241 X 1250 = 51.867µM 
IV.4.5. Metabolism of chloromethylindoline (ICT 2727) by CYP 2W1 
ICT 2727 (Scheme 4.11) was incubated in either HEK293_2W1 transfected 
cells or HEK293_Mock cells for 7hrs. The extraction of ICT 2727 and its 
metabolites was described in section IV.3.5. 
 
Lineweaver- Burk plot ICT2726 (0.25- 8µM) + CYP 2W1  
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O
Cl
O
N
NH
F
F C20H13ClF2N2O2
386.79
386.063362
C 62.11% H 3.39% Cl 9.17% F 9.82% N 7.24% O 8.27%  
Scheme 4.11: The structure of ICT 2727 FW 386.79 
IV.4.5.1. Identification of ICT 2727  
The optimised method described in section IV.3.10 was used to determine 
the optimum absorbance and mass to charge of ICT 2727.  
IV.4.5.1.1. Separation of ICT 2727 using HPLC 
ICT 2727 was scanned across the wavelength range 190-500nm. The 
detection of ICT 2727 was confirmed by making a scan of ICT 2727 (100µM) 
and the λ max being shown to be 309nm. The retention time was 28.26min 
(Figure 4.17). 
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Figure 4.17: Detection of ICT 2727 (100µM) in HPLC. Reverse-phase LC was used for the 
separation of ICT 2727. A, chromatogram of ICT 2727 using diode array detection (DAD) at    
wavelength 309nm and Rt. 28.26min. B, spectrum of ICT 2727 in DAD at wavelength 309nm. 
 
IV.4.5.1.2. Separation of ICT 2727 using LC-MS 
Identification of ICT 2727 was confirmed by MS scanning of ICT 2727 
(100µM) in the range 220-520 (Figure 4.18). The spectrum was m/z 387.1 
and the SIR channel was set up at m/z 387.1. From the MS-spectrum (Figure 
4.18) we can see two principal stable chlorine isotopes at m/z 387.1 and 
489.4. This helps in monitoring the existence of chlorine in the metabolites. 
These parameters were used as controls for further studies of ICT 2727 
metabolism.  
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Figure 4.18: Detection of ICT 2727 (100µM) by LC-MS. Reverse-phase LC was used for the 
separation of ICT 2727. A, B MS trace supporting correct identification of ICT 2727 in MS 
detector. A, total ion chromatogram (TIC) scanning of singularly charged ions [ES+] from 
220-520 with Rt. 26.22min and B, SIR in specific [ES+] m/z 387.1 with Rt. 26.16min. C, 
spectral characteristics of ICT 2727 at m/z 387.1 This matches ICT 2727 (FW 386.79), also 
showing two principal isotopes of chlorine (
35
Cl represented 75% and 
37
Cl represented 25%). 
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IV.4.5.2. Metabolism of ICT 2727 by CYP 2W1 
The in vitro metabolism of 8.4µM ICT 2727 by CYP 2W1 was examined to 
investigate the influence of this enzyme on ICT 2727.  
The incubation was in duplicate with two separate samples of HEK293_2W1 
transfected and one of HEK293_Mock transfected cells. The optimised 
method in section IV.3.10 was used to separate and identify all metabolites 
(Figure 4.19). Two metabolites (M46 and M47) were separated by HPLC and 
detected at a wavelength of 309nm and at Rt. 20.18 and 16.66min 
respectively. The parent (S9) separated at Rt. 26.07min (Figure 4.19). 
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Figure 4.19: Metabolites of 8.4µM ICT 2727 in HEK293_2W1 transfected cells (7x10
6
) for 
7hrs. All HPLC traces of potential metabolite separated at Rt. (M46) 20.18min and (M47) 
16.66min using diode array detection at wavelength 309nm. The mass to charges were m/z 
369.01 and 384.94 respectively, and the substrate (S9) eluted at Rt. 26.07min. This figure 
shows one of 2 replicates of HEK293_2W1 incubation (with the same result) beside 
HEK293_Mock incubation. 
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Subsequent identification of the ICT 2727 (S9) and the metabolite formed 
from the parent substrate was performed by LC/MS analysis. The mass to 
charge for S9 was established at m/z 387.10, M46 was at m/z 369.01 and 
M47 was at m/z 384.94. The mass to charge ratio for the metabolite 
compared to the structure of the parent helped in obtaining structural 
information for the metabolites.  
M46 (m/z 369.01) is likely due to a hydroxylation (a replacement of chlorine 
with a hydroxyl group) of ICT 2727 (Scheme 4.12). 
N
O
NH
O
F
OH
F
C20H14F2N2O3
368.34
368.097249
C 65.22% H 3.83% F 10.32% N 7.61% O 13.03% 
 
 
Scheme 4.12: The anticipated chemical structure of the M46 metabolite (FW 368.34) 
 
The replacement of chlorine with a hydroxyl group inactivates the metabolite. 
This is unlikely to be the result of a potential hydroxylation followed by 
dechlorination leading to a potential toxic metabolite (Scheme 4.13). 
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C 65.58% H 3.30% F 10.37% N 7.65% O 13.10%  
Scheme 4.13: The anticipated chemical structure of the potential toxic metabolite (FW 
366.32) of ICT 2727 
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M47 (m/z 384.94) is likely due to a double hydroxylation of ICT 2727 
(Scheme 4.14). 
N
O
NH
O
F
OH
F
OH
C20H14F2N2O4
384.34
384.092164
C 62.50% H 3.67% F 9.89% N 7.29% O 16.65%  
Scheme 4.14: The anticipated chemical structure of the M47 metabolite (FW 384.34) 
 
IV.4.6. Metabolism of chloromethylindoline (ICT 2728) by CYP 2W1 
8.4µM ICT 2728 (Scheme 4.15) was incubated in either HEK293_2W1 
transfected cells or HEK293_Mock cells for 7hrs. The extraction of ICT 2728 
and its metabolites was described in section IV.3.5. 
O
Cl
O
N
NH
F
O
O
CH3
F C22H15ClF2N2O4
444.82
444.068841
C 59.40% H 3.40% Cl 7.97% F 8.54% N 6.30% O 14.39%  
 
Scheme 4.15: The structure of ICT 2728 FW 444.82 
 
IV.4.6.1. Identification of ICT 2728  
The optimised method in section IV.3.11 was used to determine the optimum 
absorbance and mass to charge of ICT 2728. 
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IV.4.6.1.1. Separation of ICT 2728 using HPLC 
ICT 2728 was scanned across the wavelength range 190-500nm. The 
detection of ICT 2728 was confirmed by making a scan of ICT 2728 (100µM) 
and the λ max being shown to be 289nm. The retention time was 26.57min 
(Figure 4.20).  
 
CPI
Time
5.00 10.00 15.00 20.00 25.00 30.00
A
U
0.0
2.0e-1
4.0e-1
6.0e-1
26.57
27.08
 
Figure 4.20: Detection of  ICT 2728 (100µM) in HPLC. Reverse phase LC was used for the 
separation of ICT 2728. A, chromatogram of ICT 2728 using diode array detection (DAD) at    
wavelength 289nm and Rt. 26.57min. B, spectrum of ICT 2728 in DAD at wavelength 289nm.   
 
IV.4.6.1.2. Separation of ICT 2728 using LC-MS 
Identification of ICT 2728 was confirmed by MS scanning of ICT 2728 
(100µM) in the range 220-520 (Figure 4.21). The parent was seen at m/z 
445.1. From the MS-spectrum (Figure 4.21) we can see two principal stable 
chlorine isotopes in m/z 445.1 and 447.3. This helps in monitoring the 
A 
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250 300 350 400 450
A
U
0.0
1.0e-1
2.0e-1
3.0e-1
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existence of chlorine in the metabolites. These parameters were used as 
controls for further studies of ICT 2728 metabolism.  
CPI
Time
5.00 10.00 15.00 20.00 25.00 30.00
%
-2
98
5.00 10.00 15.00 20.00 25.00 30.00
%
-2
98
26.74
24.96
22.84
7.04
21.10
8.63
11.97 16.53
27.07
27.40
29.89
26.63
26.51
26.74
26.81
27.22
28.07
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%
0
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336.5 380.1363.9352.8 439.1390.4398.9 431.0417.0
447.3
475.0
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467.4
506.9
484.9
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Figure 4.21: Detection of ICT 2728 (100µM) by LC-MS. Reverse-phase LC was used for the 
separation of ICT 2728. A, B MS trace supporting correct identification of ICT 2728 in MS 
detector. A, total ion chromatogram (TIC) scanning of singularly charged ions [ES+] from 
220-520 with Rt. 26.74min and B, [ES+] m/z 445.1 with Rt. 26.63min. C, spectral 
characteristics of ICT 2728 at m/z 445.1 This matches ICT 2728 FW (444.87), also showing 
two principal isotopes of chlorine (
35
Cl represented 75% and 
37
Cl represented 25%). 
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IV.4.6.2. Metabolism of ICT 2728 by CYP 2W1 
The in vitro metabolism of 8.4µM ICT 2728 by CYP 2W1 was examined to 
investigate the influence of this enzyme on ICT 2728.   
The incubation was in duplicate with two separate samples of HEK293_2W1 
transfected cells and one of HEK293_Mock transfected cells. The optimised 
method in section IV.3.11 was used to separate and identify all metabolites 
(Figure 4.22). 
Like in the mock transfected cells no potential metabolite was separated in 
HPLC from the incubation of ICT 2728 in HEK293_2W1 transfected cells. 
However degradation products were detected in both cell lines. This 
appeared in the standard (see Figure 4.20).  
CPI
Time
5.00 10.00 15.00 20.00 25.00 30.00
A
U
0.0
1.0e-3
2.0e-3
3.0e-3
4.0e-3
5.0e-3
26.49
22.75
19.2116.05
11.89
11.48
9.057.61
6.614.48
15.53 18.06
19.80
25.33
23.95
28.85
27.05
29.16
 
Figure 4.22: Metabolites of 8.4µM ICT 2728 in HEK293_2W1 transfected cells (7x10
6
)  for 
7hrs. No HPLC traces for any potential metabolite were separated using diode array 
detection at wavelength 289nm. The substrate (S10) eluted at Rt. 26.49min. This figure 
shows one of 2 replicates of HEK293_2W1 incubation (with the same result) beside 
HEK293_Mock incubation. 
 
HEK-mock 
HEK-2W1 
S10 
DAD 289 nm 
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IV.4.7. Metabolism of chloromethylindoline (ICT 2706) by CYP 2W1 
ICT 2706 (Scheme 4.16) was incubated in either SW480_2W1 transfected 
cells or SW480_Mock transfected cells for 7hrs. The extraction of ICT 2706 
and its metabolites was described in section IV.3.5. 
HN
Cl
Cl
O
N
NH
C20H15Cl2N3O
384.26
383.059218
C 62.51% H 3.93% Cl 18.45% N 10.94% O 4.16% 
 
Scheme 4.16: The structure of ICT 2706 FW 484.26 
 
IV.4.7.1. Identification of ICT 2706 
The optimised method in section IV.3.12 was used to determine the optimum 
absorbance and mass to charge of ICT 2706. 
IV.4.7.1.1. Separation of ICT 2706 using HPLC 
ICT 2706 was scanned across the wavelength range 190-500nm. The 
detection of ICT 2706 was confirmed by making a scan of 8µg/ml ICT 2706 
and the λ max being shown to be 322nm. The retention time was 28.56 min 
(Figure 4.23).  
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Figure 4.23: Detection of ICT 2706 (8µg/ml) in HPLC. Reverse-phase LC was used for the 
separation of ICT 2706.  A, chromatogram of ICT 2706 using diode array detection (DAD) at 
wavelength 322nm and Rt. 28.56min. B, spectrum of ICT 2706 in DAD at wavelength 322nm. 
 
IV.4.7.1.2. Separation of ICT 2706 using LC-MS 
Identification of ICT 2706 was confirmed by MS scanning of ICT 2706 
(8µg/ml) in the range 220-520 (Figure 4.24). The parent was m/z 384.3.  
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Figure 4.24: Detection of 8µg/ml µM ICT 2706 by LC- MS. Reverse-phase LC was used for 
the separate of ICT 2706. A, B MS trace supporting correct identification of ICT 2706 in MS 
detector A, scanning of singularly charged ion [ES+] from 220-520 with Rt. 28.54 minutes 
and B, [SIR] m/z 384.3 with Rt. 28.53 minutes C, Spectral characteristics of ICT 2706 at     
m/z 384.3 this match to ICT 2706 FW (384.26). 
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IV.4.7.2. Metabolism of ICT 2706 by CYP 2W1 
The in vitro metabolism of 8.4µM ICT 2706 by CYP 2W1 was examined to 
investigate the influence of this enzyme on ICT 2706.   
The incubation was in six separate samples of SW480_2W1 transfected cells 
and two mock transfected cells. The optimised method in section IV.3.12 was 
used to separate and identify all metabolites (Figure 4.25). Only one 
metabolite (M48) was separated by HPLC and detected in wavelength      
322nm at Rt. 20.56min. The parent (S11) separated at Rt. 29.09min. 
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Figure 4.25: Metabolites of 8.4µM ICT 2706 in SW480_2W1 transfected cells (7x10
6
) for 7hrs. 
All HPLC traces of potential metabolite separated at Rt. (M48) 20.56min using diode array 
detection at wavelength 322nm. The mass to charge was m/z 364.20, and the substrate (S11) 
eluted at Rt. 29.09min. This figure shows one of 6 replicates of SW480_2W1 incubation (with 
the same metabolite result) and 2 replicates of SW480_Mock incubation. 
 
Only one metabolite (M48) was separated by HPLC and detected at a 
wavelength of 322nm and Rt. 20.56min. The parent (S11) separated at 
Rt.29.09min.  
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Subsequent identification of the ICT 2706 (S11) and the metabolite formed by 
substrate was performed by LC/MS analysis. The mass to charge for S11 
was m/z 384.3 and for M48 it was m/z 364.20. The mass to charge ratio for 
the metabolite compared to the structure of substrate helped in obtaining the 
structural information for metabolites. This is likely due to a hydroxylation 
followed by dechlorination leading to a potential toxic metabolite of ICT 2706 
(Scheme 4.17). 
N
O
NH
NH
Cl
O
C20H14ClN3O2
363.80
363.077455
C 66.03% H 3.88% Cl 9.75% N 11.55% O 8.80% 
 
Scheme 4.17: The anticipated chemical structure of M48 metabolite (potential toxic 
metabolite) (FW 363.80) of ICT 2706 
 
The replacement of chlorine with a hydroxyl group inactivates the metabolite 
(Scheme 4.18) as in previous incubations of other chloromethylindolines, 
such as ICT 2724 and ICT 2726. This is unlikely to be the result of the M48 
metabolite.   
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Cl
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O
N
NH
C20H16ClN3O2
365.82
365.093105
C 65.67% H 4.41% Cl 9.69% N 11.49% O 8.75%  
Scheme 4.18: The anticipated chemical structure of inactivated metabolite (FW 365.82) 
 
Catalyzing properties of CYP 2W1                                                                Chapter 4 
 
206 
IV.4.7.3.The pharmacokinetics of ICT 2706 in mouse plasma and tissue 
samples 
In vivo pharmacokinetics of ICT 2706 were monitored in the plasma, tumours, 
liver and brains of mice. 
Six time points were taken at 0, 5, and 30min and 1, 4 and 24hrs from mice 
after ICT 2706 had been injected i.p. The method used is described in section 
IV.3.13. The weight ranges of mouse tumour samples investigated are given 
in Appendix H.  
The calibration curves were established in vitro in blank plasma and random 
tumour mouse tissue using a standard range of ICT 2706 (0-10µg/ml). The 
method used is described in section IV.3.13. The calibration curve for MeCN 
was compared to the calibration curves of other biological samples to see if 
there was any loss of the prodrug when incubated with the biological samples. 
However there was no significant loss of ICT 2706 for the calibration curve in 
both blank plasma and random mouse tumour tissue (see Appendix I). 
Calibration standards were chosen based on the expected concentrations of 
unknown samples. The method was described in section IV.3.13. Then the 
optimised method in section IV.3.12 was used to separate ICT 2706 by HPLC 
system at a wavelength of 322nm. 
100mg/kg ICT 2706 was administrated in mice in vivo. The method used is 
described in section IV.3.13. The incubation took place in the Karolinska 
Institutet. The extraction, separation, and identification of the existence of  
ICT 2706 at each time point took place in the ICT. 
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The peak area of ICT 2706 was detected at a wavelength of 322nm for tested 
samples (see Table 4.7). 
Table 4.7:  Peak area of ICT 2706 at time points 0, 5, 30min and 1, 4, 24 hours of mouse 
plasma and tissue samples after adding the dilution factor to tumour samples 1:4 and for liver 
and brain 1:5. Readings represent an average of 2 replicates of incubated mice tissues and 
plasma samples. 
 
  
ICT 2706 peak area (AU) 
  
Time of incubation (min) 
Mean in 
liver (n=2) 
Mean in 
brain (n=2) 
Mean in 
plasma (n=2) 
Mean in 
tumour (n=2) 
0 < 100 < 100 < 100 < 100 
5 181570 < 100 < 100 < 100 
30 381118 20113 < 100 < 100 
60 320893 53548 16312 1500 
240 464052 363694 108364 38569 
1440 1178 1287 < 100 1259 
 
For time point 5min, a peak area of ICT 2706 was detected only in the liver, 
then at time point 30min ICT 2706 appeared in both liver and brain samples. 
At time point 1 hour all tested samples contained ICT 2706. After this         
ICT 2706 increased over time until time point 4hrs when all tested samples 
reached the maximum peak area. ICT 2706 had decreased by time point 
24hrs for all the samples. By this time no ICT 2706 was detected in the 
plasma. 
The concentration of ICT 2706 was determined using a calibration curve 
equation x = y/27625.8. Liver and brain values were multiplied by 5 and 
tumour values by 4 to take into account dilution factors (see Table 4.8 and 
Figure 4.26). 
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Table 4.8:  Concentration of ICT 2706 at time points 0, 5, 30min and 1, 4, 24 hours of mouse 
plasma and tissues samples after adding the dilution factor to tumour samples 1:4 and liver 
and brain 1:5. Readings represent an average of 2 replicates of incubated mice tissues and 
plasma samples. 
 
 
 
Figure 4.26: Pharmacokinetics of ICT 2706 in mouse liver, plasma, brain and tumour 
samples following administration of 100mg/kg (ip). Six time points (0, 5, 30min and 1, 4, 
24hrs) were taken from plasma and tissues. The dilution factor was added to samples, 1:4 in 
tumours and 1:5 in liver and brain. Readings represented an average of 2 replicates of 
incubated mice tissues and plasma samples. 
 
  
      ICT 2706 concentration (µg/ml) 
  
Time of incubation (min) 
Mean in 
liver (n=2) 
Mean in 
brain (n=2) 
Mean in 
plasma (n=2) 
Mean in 
tumour (n=2) 
0 < 0.01 < 0.01 < 0.01 < 0.01 
5 32.87 < 0.01 < 0.01 < 0.01 
30 68.97 3.64 0.01 < 0.01 
60 58.07 9.67 1.18 0.4 
240 84 65.83 7.8 11.2 
1440 0.2 0.23 < 0.01 0.32 
Total AUC h 0-24 (µg.hr/ml) 1110.11 778.69 91.77 129.50 
Cmax ( µg/ml) 84 65.83 7.8 11.2 
Tmax (min) 240 240 
240 240 
t1/2 (min) 138.6 147.44 125 231 
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The pharmacokinetics parameters were estimated (see Table 4.8). The area 
under the curve (AUC) showed that the exposure of ICT 2706 in the tumours 
was approximately 1.5 times that in the plasma. The maximum drug 
concentration peak (Cmax) and the time when the peak occurred (Tmax) for 
the duration of 24hrs were obtained (Table 4.8). The time it took to lose half 
the ICT 2706 concentration (half-life, t½) in the mice plasma was 125min and 
t½ in the liver, brain and tumour tissues was 138.6, 147.44 and 231min 
respectively. 
IV.5. Discussion 
 
ICT 2700 analogues have been developed with variations in the 
pharmacophore as well as functional groups to ensure enhanced activity and 
selectivity profiles of CYPs. 
 
In order to study CYP metabolism and activation in detail, other in vitro 
methods have been established. Experiments can be carried out with cancer 
cells with low levels of CYPs which are then transfected with the CYP isoform 
of interest.  
 
For this purpose, two cell lines of HEK293_2W1 and human colon cancer 
SW480_2W1 with a stable expression of CYP 2W1 were used in this study to 
investigate the activation of several derivatives of ICT 2700 by CYP 2W1. 
The endogenous expression of CYP 2W1 was not detected in the parent cell 
lines. 
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In a study of 162 patients by (Edler et al., 2009) high CYP 2W1 protein 
expression was associated with worse cases of colorectal cancer. Therefore 
the existence of CYP 2W1can be used as a prognostic value of CYP 2W1 for 
survival and malignancy in colorectal cancers.  
 
CYP 2W1 is not expressed in adult human liver (Girault et al., 2005). In 
addition there is no significant expression in adult human liver, kidney, 
intestine, trachea, lung, stomach, small intestine and spleen tissues, or in 
foetal brain, heart, kidney, liver, spleen, thymus and lung tissues (Karlgren et 
al., 2005).  
 
Moreover CYP 2W1 is highly expressed in colorectal cancer tissues and 
relatively low levels of both mRNA and protein are found in normal human 
adult tissues (Gomez et al., 2007; Karlgren et al., 2006). 
  
In a recent study CYP 2W1 was suggested as a drug target in the treatment 
of colon cancer, by using specific CYP 2W1-activated prodrugs (Gomez et al., 
2010). 
 
From previous findings, CYP 2W1 can be considered as one of the most 
specific CYPs expressed in gastrointestinal tumours. 
  
Though ICT 2726 was designed to be metabolised by CYP 2W1, in vitro 
results have shown that ICT 2726 is not cytotoxic for two types of human 
tumour cell lines transfected with CYP 2W1 (SW480_2W1 and                
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HEK293_2W1) (unpublished observations, Karolinska Institutet, Sweden; see 
Appendix N). ICT 2726 can be used as a non toxic marker of CYP 2W1 
presence.  
 
The primary aim of the work presented here was to reveal if there was any 
metabolism of chloromethylindolines prodrugs by CYP 2W1, and if there were 
metabolites, to identify them. 
 
Therefore, in this chapter, the activity of CYP 2W1 in 7 novel prodrugs      
(ICT 2723, ICT 2724, ICT 2725, ICT 2726, ICT 2727, ICT 2728 and ICT 2706) 
was monitored using HPLC and LC-MS.  
 
Clearly, incubation of ICT 2726 in HEK293_2W1 transfected cell line for 7hrs 
demonstrated 3 potential metabolites M43 (hydroxylation), M44 (double 
hydroxylation) and M45 (double hydroxylation) nevertheless there was no 
metabolism when incubated in HEK293_Mock transfected cells (Figure 4.13). 
 
None of the mass to charge results of the ICT 2726 metabolites matched the 
anticipated chemical structure of the potential toxic metabolites (FW 348.33) 
(see Scheme 4.9). This finding was explained by the lack of cytotoxicity of 
ICT 2726 incubated in HEK293_2W1 transfected cells. 
 
Similarly to the inactivation results of ICT 2726, the metabolism of ICT 2724 
and ICT 2727 in HEK293_2W1 transfected cells showed one and two 
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detected metabolites respectively, but all were potentially inactive metabolites 
(Figures 4.6 and 4.19). 
 
This study has demonstrated that CYP 2W1 catalyzes ICT 2724, ICT 2726 
and ICT 2727. These agents could potentially be used as enzyme probes for 
CYP 2W1. Thus it was necessary to determine the affinity between the 
enzyme and substrates. 
 
To estimate the affinity between the enzyme and the substrates, a kinetic 
study was performed for ICT 2724 and ICT 2726. The purpose was to 
estimate kinetic parameters Vmax and Km values based on the Michaelis-
Menten Equation and Lineweaver-Burk plot. In ICT 2726 the sum of all 3 
metabolites was calculated for kinetic parameters while in ICT 2724 only one 
metabolite was detected. The kinetic parameters signify that the affinity for 
ICT 2724 was higher than for ICT 2726. Km, the Michaelis constant, is the 
concentration at which half of the maximal rate is achieved, so the lower the 
Km, the greater the affinity between the enzyme and its substrate (Hutzler and 
Tracy, 2002).  
 
Thus the catalytic efficiency of ICT 2724 oxidation was greater than that of 
ICT 2726. Moreover it is possible that the enzyme converted the 
hydroxylation product of ICT 2726 to the double hydroxylation. This could 
affect the affinity of the enzyme with the parent.  
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Interestingly, the results in this chapter indicate that the ICT 2706 prodrug 
was activated in HEK293_2W1 transfected cells (Figure 4.25). This 
corresponds to what has been demonstrated in in vitro results, ICT 2706 was 
cytotoxic for two types of human cell lines transfected with CYP 2W1 
(SW480_2W1 and HEK293_2W1) (unpublished observations, Karolinska 
Institutet, Sweden; see Appendix N). 
 
In this chapter, the pharmacokinetics of ICT 2706 throughout the fluids and 
tissues of the mouse body and bio-distribution were examined (Figure 4.26). 
The purpose of this work was to obtain the pharmacokinetics and tissue 
distribution of the prodrug flowing injection of 100mg/kg in mice bearing 
SW480_2W1 colon cancer xenografts. Six time points were taken from mice, 
at 0, 5, 30min and 1, 4 and 24hrs, after ICT 2706 had been injected. The   
LC-MS/MS system was used in MRM mode to determine the concentration of 
ICT 2706 in plasma and tissues. 
 
The prodrug was clearly distributed to the plasma and body tissues (tumour, 
liver and brain). It continued to accumulate over the first 4hrs after 
administration of ICT 2706. At 24hrs ICT 2706 concentrations in tissues 
(brain, liver and tumour) still existed but in plasma no prodrug was found. 
Sufficient concentrations of 2706 were achieved in tumour and the prodrug 
was affected to elicit a cytotoxic effect and the affinity of a drug to its target 
into tumour.  
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IV.6. Conclusion  
ICT 2724, ICT 2726 and ICT 2727 were shown to create potential non- toxic 
metabolites when incubated in HEK293_2W1 cells transfected with CYP 2W1. 
The findings in this chapter explain the lack of cytotoxicity of the prodrugs 
incubated in HEK293_2W1 transfected cells. These agents could potentially 
be used as metabolic probes to evaluate the catalytic activity of CYP 2W1.  
 
In this work, ICT 2706 showed the mass to charge of a potential toxic 
metabolite when incubated in HEK293_2W1 cells transfected with CYP 2W1 
but not in the wild type of HEK293 cells.  
 
The pharmacokinetics results in this study show that ICT 2706 was well 
distributed in the plasma and tissues of mice and was delivered significantly 
more to the tumour than to the plasma.  
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V. Studying the catalyzing properties of CYP 4F11       
V.1.   Introduction 
CYP 4F11 expression in bladder, colon and lung tumours is high compared to 
matched pair normal bladder, colon and lung tissues has been shown in 
clinical tumours as compared to normal tissues (J. Gill, ICT; see Appendix L).   
CYP 4F11 has demonstrated a much higher conversion of many drugs, such 
as benzphetamine, ethylmorphine, chlorpromazine, imipramine, and the most 
efficient substrate for CYP 4F11, erythromycin (Kalsotra et al., 2004). In 
contrast, this enzyme has exhibited low activity for some drug N-
demethylation reactions like erythromycin, but high selectivity in the 
metabolism of four fatty acids: palmitic, oleic, arachidonic, and 
docosahaxaenoic (Tang et al., 2010). 
In this chapter the demethylation of erythromycin catalyzed by CYP 4F11 was 
slow (data not shown). Compared to the HEK293_ Mock transfected, the 
HEK293_4F11 transfected cells catalyzed the hydroxylation of palmitic acid 
to hydroxypalmitic acid.  
MLiM (obtained from the ICT) also catalyzed the hydroxylation of palmitic 
acid to hydroxypalmitic acid. 
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V.2. Materials  
V.2.1. Chemicals 
All chemicals and reagents used in this chapter were as stated in Chapter 2. 
V.2.2. Cell lines 
HEK293_4F11 (human embryonic kidney cell line transfected with CYP 4F11) 
and HEK293_Mock (human embryonic kidney cell line) were obtained from 
Sutherland .M, ICT.  
V.3. Methods 
V.3.1. Cell seeding 
HEK293_2W1 and HEK293_Mock were seeded as described in section II.2.1. 
V.3.2. Cell passaging 
The same method was used as in section II.2.2. 
V.3.3. Cell counting 
The same method was used as in section II.2.3. 
V.3.4. Microsome preparation  
The same method was used as in section III.3.1. 
V.3.5. Measuring protein concentration  
The same method was used as in section III.3.2. 
V.3.6. Microsome incubation  
The same method was used as in section III.3.3. 
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V.3.7. Substrate extraction from microsomes and bactosomes using 
protein precipitation  
The same method was used as in section III.3.5. 
V.3.8. Metabolism of erythromycin by mouse liver microsomes and 
CYP4F11 
V.3.8.1. HPLC analysis  
The HPLC reverse-phase system was used to measure the production of 
metabolites and monitor loss of erythromycin. MPs were as follows: MPA was 
composed of 90% HPLC grade water, 10% MeCN and 0.1% TFA. MPB was 
composed of 40% HPLC grade water, 60% MeCN and 0.1% TFA. An 
isocratic method was used with 50% MPA and 50% MPB. MPs were 
degassed before introduction onto the mass spectrometry system by vacuum 
filtration through a 0.45µM pore nylon filter membrane. The flow rate was set 
at 1.2ml/min using a Waters 2695 (Alliance) separation system. The total 
running time of each sample was 15 minutes and the volume of injection was 
10µl. 
V.3.8.2. LC-MS analysis 
The LC-MS system was used in positive mode, Masslynx software, and the 
mass spectrometry parameters were optimised to: desolvation gas flow 
506l/hr, cone gas flow 35l/hr, capillary 3.5kV, sample cone 45V, extraction 
cone 5V, RF lens 0.20V, source block temperature 100°C and desolvation 
temperature 150°C. The parent substrate and their metabolites were detected 
as singularly positive charged ions (ES+) using a scanning range of  220-520 
m/z then using selected ion recording (SIR) 734.4 and 720.4m/z. 
Catalyzing properties of CYP 4F11                                                          Chapter 5  
 
219 
V.3.9. Metabolism of palmitic acid by mouse liver microsomes and 
CYP4F11 
V.3.9.1. HPLC analysis 
The HPLC reverse-phase gradient system was used to measure the 
production of specific metabolites and monitor loss of palmitic acid. MPs were 
as follows: MPA was composed of 95% HPLC grade water, 5% MeCN and 
0.1% acetic acid. MPB was composed of 5% HPLC grade water, 95% MeCN 
and 0.1% acetic acid. The gradient method started with 20% MPA and 80% 
MPB, then at minute 30, 0% MPA and 100% MPB, then it returned at minute 
31 to initial concentration 20% MPA and 80% MPB. The mobile phase was 
degassed before introduction into the HPLC system. The flow rate was set at 
1.4ml/min using a Waters 2695 (Alliance) separation system. The total 
running time of each sample was 40 minutes and the volume of injection was 
10µl. 
V.3.9.2. LC-MS analysis 
The mass spectrometry parameters were optimised to: desolvation gas flow 
568l/hr, cone gas flow 45l/hr, capillary 3.0kV, sample cone 30V, extraction 
cone 6V, RF lens 0.23V, source block temperature 100°C and desolvation 
temperature 250°C. The parent substrate and metabolites were detected as 
singularly negative charged ions (ES-) using scanning in the range 220-520 
m/z, then using selected ion recording (SIR) 255.4 and 271.5m/z. 
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V.4. Results 
V.4.1. Metabolism of palmitic acid by CYP 4F11 
Palmitic acid (Scheme 5.1) was incubated in microsomes of either 
HEK293_4F11 transfected cells or HEK_Mock transfected cells for 1 hour. 
The method of preparing microsomes was the same as in section V.3.4 and 
the protein concentration was measured in the same method as in section 
V.3.5. The microsome incubation method was the same as in section V.3.6. 
and the extraction method was the same as in section V.3.7. After that, the 
optimised methods in section V.3.9 were used to separate and identify 
palmitic acid and a prospective metabolite (hydroxypalmitic acid) (Scheme 
5.1). 
 
OH
O C16H32O2
256.43
256.240230
C 74.94% H 12.58% O 12.48%  
HO OH
O
C16H32O3
272.43
272.235145
C 70.54% H 11.84% O 17.62%  
Scheme 5.1: The structure of (A) palmitic acid FW 256.43 and (B) hydroxypalmitic acid         
FW 272.43. 
 
V.4.1.1. Identification of palmitic acid and hydroxypalmitic acid 
The optimised method in section V.3.9 was used to determine the optimum 
absorbance and mass to charge of both palmitic acid (PA) and 
hydroxypalmitic acid (HPA). 
A 
B 
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V.4.1.1.1. Separation of hydroxypalmitic acid using HPLC  
HPA was scanned across the wavelength range 200-400nm. The detection of 
HPA was confirmed by making a scan of 10µM HPA and the λ max being 
shown to be 225nm. The retention time was 4.02min (Figure 5.1.). 
pmltest
Time
5.00 10.00 15.00 20.00 25.00 30.00
A
U
0.0
5.0e-3
1.0e-2
1.5e-2
2.0e-2
2.5e-2
3.0e-2
3.5e-2
4.0e-2
4.5e-2
1.95
4.02
 
   
Figure 5.1: Detection of 10µM hydroxypalmitic acid in HPLC. Reverse-phase LC was used 
for the separation of hydroxypalmitic acid. A, chromatogram of hydroxypalmitic acid using 
diode array detection (DAD) at wavelength 225nm and Rt. 4.02min. B, spectrum of 
hydroxypalmitic acid in DAD at wavelength 225nm. 
 
V.4.1.1.2. Separation of palmitic acid and hydroxypalmitic acid using  
LC-MS 
Identification of PA and HPA was confirmed by MS scanning of PA (100µM) 
and HPA (10µM) in the range 220-520 (Figure 5.2). The spectrum was m/z 
271.5 for HPA and m/z 255.4 for PA then the SIR channel was set up at m/z 
271.5 and m/z 255.4. These parameters were used as controls for further 
studies of PA metabolism. 
A 
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Figure 5.2: Detection of palmitic acid (100µM) and hydroxypalmitic acid (10µM) by LC-MS. 
Reverse-phase LC was used for the separation of palmitic acid and hydroxypalmitic acid. A, 
B MS trace supporting correct identification in MS detector. A, SIR in specific [ES-] m/z 271.5 
with Rt. 4.81min. This matches hydroxypalmitic acid FW (272.43). B, SIR in specific [ES-] 
m/z 255.4 with Rt. 18.31min. This matches palmitic acid FW (256.43). C, spectral 
characteristics of hydroxypalmitic acid at m/z 271.5 and D, spectral characteristics of palmitic 
acid at m/z 255.4. 
 
V.4.1.2. Metabolism of palmitic acid by CYP 4F11 
The in vitro metabolism of 50µM PA by CYP 4F11 was examined to 
investigate the influence of this enzyme on palmitic acid.  
The incubation was in duplicate in two separate samples of HEK293_4F11 
transfected cells and one of HEK293_Mock transfected cells supplemented 
with NADPH. The reaction was incubated for 60min. The protein 
concentration was 1mg/ml for all microsomes. The optimised method in 
section V.3.9 was used to separate and identify all metabolites (Figure 5.2). 
(B) Palmitic acid SIR m/ z 255.4 
 
(A) Hydroxypalmitic acid SIR m/ z 271.5 
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In the HEK293_Mock transfected cells no metabolite was separated in SIR 
(m/z 271.5) from incubation of PA (Figure 5.3). 
pmltest
Time
5.00 10.00 15.00 20.00 25.00 30.00
%
3
1.64
24.59
 
Figure 5.3: Metabolites of 50µM palmitic acid in microsomes (1mg/ml) of HEK293_Mock 
transfected cells + NADPH (2mM) for 1hr. No LC-MS trace for any potential metabolite was 
separated using SIR at m/z 271.5. 
 
 
In the HEK293_4F11 transfected cells there was likely to be a potential 
hydroxylation separated in SIR m/z 271.5 from incubation of PA (Figure 5.4).  
 
t= 30 min 
 
t= 60 min 
SIR m/z 271.5  
t= 0 min 
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pmltest
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Figure 5.4: Metabolites of 50µM palmitic acid in microsomes (1mg/ml) of HEK293_4F11 
transfected cells + NADPH (2mM) for 1hr. One LC-MS trace for potential metabolite at Rt. 
4.36min was separated using SIR at m/z 271.5. There was no peak at min. 0 then the peak 
area increased over time until 60min. This figure shows one of 2 replicates of HEK293_4F11 
incubation (with the same metabolite result). 
 
The results show that a palmitic acid (ω-1) hydroxylation is likely to be 
catalyzed in the HEK293_4F11 transfected cells while no potential 
metabolism was found in HEK293_Mock cells. 
V.4.1.3. Metabolism of palmitic acid by mouse liver microsomes  
The in vitro metabolism of 50µM PA in MLiM, the main location of CYP 
families in mammals, was performed to investigate the metabolism of PA in 
the presence of 1mg/ml MLiM supplemented with NADPH. The reaction was 
incubated for 60min.  
All the methods were the same as those in section V.4.1.2. All metabolites 
were separated and identified (Figure 5.5).   
 
t= 0 min 
t= 30 min 
t= 60 min 
HPA 
SIR m/z 271.5  
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Figure 5.5: Metabolites of 50µM palmitic acid in MLiM (1mg/ml) + NADPH (2mM) for 1 hour. 
Two main peaks for potential metabolites at Rt. 4.14 and 4.36min were separated using SIR 
at m/z 271.5. There was no peak in min. 0 then the peak area increased over time until 
60min. This figure shows one of 2 replicates of MLiM (with the same metabolite result). 
 
This is likely to be the result of a potential hydroxylation catalyzed in the 
MLiM at different places in palmitic acid.  
V.5. Discussion 
Palmitic acid is one of the most common saturated fatty acids. This fatty acid 
was verified as a substrate of CYP 4F11 as the enzyme catalyzed an          
ω-hydroxylation reaction (Tang et al., 2010). The CYP 4F subfamily shares 
about 74% of its amino acid sequence (Nelson, 2006). CYP 4F11 is the 
principal catalyst of long-chain -OH fatty acids in the human liver (Dhar et al., 
2008) (Scheme 5.2). 
 
 
SIR m/z 271.5  
HPA 
t= 0 min 
t= 30 min 
t= 60 min 
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     CYPs                                                 
Palmitic Acid                                     (ω-1) Hydroxylation                 16-Hydroxypalmitic acid           
FW256.42                                                                                                           FW 272.42 
 
Scheme 5.2: Palmitic acid (ω-1) hydroxylation reaction. CYP 4F11 catalyzes the metabolism 
of palmitic acid. 
The enzymatic assay in this study involved providing microsomal fractions of 
mouse liver containing the CYP 4F enzymes with palmitic acid and the 
NADPH-regenerating system.  
 
In the ICT, it has been shown that the expression of CYP 4F11 is very high in 
bladder cancer tissues and high in both lung and colon cancer tissues (J. Gill, 
ICT; see Appendix L). 
 
In this study palmitic acid was successfully utilised to assess CYP activity in 
both HEK293_4F11 and mouse liver microsomes. The results in Figures 5.4 
and 5.5 show that the product hydroxypalmitic acid increased in both MLiM 
and HEK293_4F11. However there was no activity in the wild type of HEK293 
cell line.  
 
The incubation of palmitic acid in microsomes of  HEK293_4F11 transfected 
cells for 1 hour demonstrated one potential metabolite (hydroxylation) but 
there was no metabolism when incubated in HEK293_Mock transfected cells 
(Figures 5.3 and 5.4).  
 
The mass to charge result of the metabolite matched the mass to charge of 
HPA (m/z 271.5) (see Figure 5.2).  
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The incubation of palmitic acid in MLiM demonstrated 2 main peaks at m/z 
271.5. It is possible to explain the peaks of products with mouse liver 
microsomes because there was more than one enzyme from the CYP 4F 
subfamily converting the palmitic acid, and the hydroxylation was in different 
places in the palmitic acid chain. This suggests that the CYP 4F subfamily 
can catalyze metabolism of palmitic acid in mouse liver microsomes. 
 
Erythromycin metabolism has been studied extensively. (Kalsotra et al., 2004) 
suggested erythromycin is a suitable substrate for CYP 4F11 however this 
was contradicted by (Tang et al., 2010) who suggested erythromycin is a 
poor substrate for CYP 4F11. Pilot studies using HEK293_4F11 transfected 
cells in this thesis also suggested erythromycin was a poor substrate 
indicated by slow demethylation however extensive metabolism was shown in 
mouse liver microsomes (data not shown). The main CYP isoform catalyzing 
the metabolism of erythromycin in human liver microsomes is known to be 
CYP 3A4, the major CYP isoform in human liver (Williams et al., 2002; 
Zaigler et al., 2000).     
 
Palmitic acid ,as suggested by (Tang et al., 2010), was therefore used as 
suitable substrate for CYP 4F11. 
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V.6. Conclusion  
From the findings in this chapter, we can conclude it is possible to use 
palmitic acid as a metabolic probe to evaluate the catalytic activity of        
CYP 4F11 in tumours.   
 
However further studies undertaken elsewhere in the ICT have indicated that 
CYP 4F11 did not generate any cytotoxic metabolites with any of the ICT 
compounds hence ruling out CYP 4F11 as a suitable target for the 
development of chloromethylindolines. The work on the cytotoxicity of 
chloromethylindolines activated by CYP 4F11 was undertaken by Dr Shnyder 
et al. and the data is shown in Appendix k. 
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VI.1. General conclusions 
 
CYPs and drug metabolism 
CYPs metabolise multiple substrates and catalyze multiple reactions. They 
are the major enzymes involved in drug metabolism, especially in the liver, 
where they metabolise drugs, toxic compounds and bilirubin (Guengerich, 
2008).  
 
The metabolism of a drug or toxin is an example of a biotransformation. 
Usually, the body deals with a foreign compound by making it more water 
soluble, to increase the rate of its excretion through the kidney or to facilitate 
conjugation for kidney and liver excretion. These reactions often act to 
detoxify toxic compounds, but in some cases the intermediates in xenobiotic 
metabolism can be the cause of toxic effects. 
 
It has been suggested that CYP-mediated activation of prodrugs could lead to 
the formation of reactive metabolites. These reactive metabolites are often 
electrophilic in nature and they are also capable of causing covalent 
modiﬁcation of nucleic acids, protein or other nucleophiles (Park et al., 1995). 
Tumour specific bio-activation of prodrugs by CYPs will help in reducing 
cytotoxicity to the normal cells and tissues which is often associated with the 
activation of chemotherapeutic agents. 
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CYPs and cancer 
The CYP superfamily is known to have a role in cancer development and 
therapeutic strategies against cancer progression. Members of the CYP1 
family are known to activate procarcinogens into carcinogens and toxic 
products, and CYP 1B1 is expressed in high frequency in many tumour types 
(Murray et al., 1997).  
 
Hormone dependent cancers such as breast cancer can be associated with 
expression of CYPs, like the CYP 19 family, the inhibition of which can be a 
successful treatment option (Brodie et al., 1977). The CYP 24 family is 
concerned in lung and colon cancer because it acts to deactivate an active 
vitamin D metabolite, which is an important endogenous anticancer agent 
(Skowronski et al., 1993).  
 
CYPs are involved in the metabolism of an inactive prodrug to an anticancer 
agent such as cyclophosphamide and dacarbazine (Patterson and Murray, 
2002). 
 
Despite the importance of discovering the similarities and differences 
between normal cells and cancer cells, little attention has been given to this 
matter. 
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CYP 1A1 and cancer 
CYP 1A1 is an extra- hepatic enzyme expressed mainly in tissues that 
exposed to procarcinogens such as tobacco, occupational exposure and 
environmental pollutants and the expression level in the liver is low see 
section I.2.3.1. The examples of extra- hepatic tissues are lung, small 
intestine, breast and bladder, In addition, this enzyme is expressed in high 
frequency during the development phase of cancer cell starting from a benign 
form to a highly metastatic malignant phenotype (Sissung et al., 2006; 
Wenzlaff et al., 2005). 
 
CYP 1A1 is the major enzyme involved in the metabolic activation of          
procarcinogens. The human carcinogen can induce gene expression of  CYP 
1A1. A high frequency of expression of CYP 1A1 in lung tissue in smokers 
has been found as compared to non-smokers (Anttila et al., 2003; Oyama et 
al., 2004). 
 
Moreover, CYP 1A1 plays a role in the development of breast cancer by 
metabolising environmental pollutants which are able to induce significant 
changes in gene expression in specific target cells (Li et al., 2005). The 
activation of PAHs from cigarette smoke can also increase the risk of breast 
cancer among women (Li et al., 2004).  
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CYP 1A1 and bladder cancer 
In men, bladder cancer is the third most frequent form of cancer in the United 
States and fourth most frequent in the UK. Transitional cell carcinoma (TCC) 
accounts for approximately 90% of all bladder cancer cases and is classified 
as either superficial or muscle invasive. Muscle invasive disease is 
particularly difficult to treat and is associated with a poor prognosis. In 
contrast, superficial TCC is usually managed well with intravescal therapy, 
with a much better prognosis. However, approximately 70% of superficial 
tumours will recur, with about 20% of these presenting as aggressive invasive 
disease (Jemal et al., 2009) (Cancer Research UK, 2010).Therefore, there is 
a clear need for better treatment for TCC, especially muscle invasive disease.   
 
RT-112 (human bladder cancer cell line) naturally expresses CYP 1A1, so 
this cell line can be selected as a model for CYP 1A1 activated prodrugs. 
Moreover a statistically significant association between the genetic 
polymorphism of CYP 1A1 and the development of bladder cancer has also 
been shown (Figueroa et al., 2008; Grando et al., 2009). 
 
Elevated CYP 1A1 has been shown in human bladder cancer relative to 
normal human tissues. RT-112 cells, CYP 1A1 positive, have selective 
chemosensitivity to ICT 2700 whereas EJ-138 cells, CYP 1A1 negative, are 
significantly less responsive. Introduction of CYP 1A1 into EJ-138 cells 
results in a 75-fold increase in chemosensitivity to ICT 2700 relative to        
wild type EJ-138. Negligible chemosensitivity is observed with ICT 2700 in 
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EJ-138 cells expressing CYP 1A2, or with exposure of EJ-138 cells to      
CYP 1B1 generated metabolites of ICT 2700 (Sutherland et al., 2012). 
 
In this study the in vitro results of ICT 2700 show that it is selectively 
metabolised to the active drug by CYP 1A1 as compared to CYP 2D6,      
CYP 3A4, MLiM, MKM, MLuM and HLM. This signifies that ICT 2700 can be 
used in tumours showing high frequency in expression of CYP 1A1. Hence 
ICT 2700 is a novel anticancer agent which can be utilised for the treatment 
of cancers with CYP 1A1 over-expression (Figure 6.1). 
 
Figure 6.1: Activation of chloromethylindoline (ICT 2700) 
 
ICT 2705, similarly to ICT 2700, was predictive of the potential toxic 
metabolite when incubated with CYP 1A1 bactosomes, but not with CYP 2D6, 
CYP 3A4 bactosomes and mouse liver microsomes. 
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Chloromethylindolines (ICT 2700 in particular) have been shown to have   
activity in vivo against high frequency expressed of CYP 1A1 in tumours 
(Sutherland et al., 2012). 
 
The work described in this  thesis has shows that ICT 2700 and other 
chloromethylindolines are metabolised by CYP 1A1 to a highly potent 
metabolite within the tumour environment. The active  metabolites have been 
identified by a combination of LC/MS and LC MS/MS techniques. Several 
metabolites are created by other highly expressed CYPs in the liver 
though there is no indication that these would cause toxicity in vivo   
confirming the potential for this class of agent to be used as a CYP activated 
prodrug. 
 
All this evidence supports the further development of ICT 2700 and ICT 2705 
as tumour-selective treatments for human cancers with high frequency 
expression in CYP 1A1. 
 
CYP 2W1 and cancer 
It has been established that CYP 2W1 is particularly high frequency 
expressed in human tumours. Hence CYP 2W1 is one of the potential drug 
targets for cancer therapy (Li et al., 2009b). 
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There was no significant expression in adult human liver, kidney, intestine, 
trachea, lung, stomach, or small intestine tissues, or in foetal brain, heart, 
kidney, liver, spleen, thymus or lung tissues (Karlgren et al., 2005). 
  
The lack of expression of hepatic CYP 2W1 would reduce unwanted 
metabolism in the liver for potential prodrugs that are designed to be 
selectively activated by CYP 2W1 only in the tumour site. This approach 
would depend on high levels of active CYP 2W1 enzyme in tumour cells 
(Karlgren and Ingelman-Sundberg, 2007).  
 
The expression of CYP 2W1 might be used as a prognostic marker for 
survival and malignancy in colorectal cancers (Edler et al., 2009) or as an 
alternative mechanism to activate anticancer prodrugs. 
 
CYP 2W1 is considered as one of the most specific CYPs expressed in 
gastrointestinal tumours.  
 
CYP 2W1 and colon cancer 
Today, colorectal cancer is one of the most common cancers worldwide with 
approximately 1 million new cases and half a million deaths annually (Parkin 
et al., 2005).  This type of cancer is the second most common cause of death 
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from cancer in the UK (CRUK, 2008). At the point of diagnosis, if the disease 
is localised there is a 90% 5-year survival rate which decreases to 11% if 
metastatic disease is present (Howlader et al., 2011). The most common 
sites of metastasis of colorectal cancer in the clinic are the liver, lungs and 
lymphatics (NCI, 2011). 
 
Over recent years treatment for colorectal cancer has improved. However, 
advanced or recurrent colon cancer remains incurable by conventional 
approaches, requiring the development of novel therapeutics.  
 
The expression of the enzyme was seen in 54% of human tumour colon and 
adrenal tumours but no expression was detected in normal adult or foetal 
human colon tissues. Moreover CYP 2W1 is highly expressed in colorectal 
cancer tissues and there are relatively low levels of both mRNA and protein in 
normal human adult tissues (Gomez et al., 2007; Karlgren et al., 2006). 
 
Selective expression of CYP 2W1 in colon tumours and their metastasis 
makes this enzyme not only a valuable prognostic biomarker but also a 
possible drug target in colon cancer therapy. So far several groups have 
reported the metabolism of few candidate substrates for CYP 2W1 using 
bacterial membranes and stably transfected HEK293 cells (Aflatoxin B1) 
although at a very low rate (Karlgren et al., 2006; Wu et al., 2006; Yoshioka 
et al., 2006, Gomez et al., 2010). Due to this lack of specific high affinity 
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ligands the targeting of CYP 2W1 in cancer could not have been explored to 
date.  
 
In vitro results have shown that ICT 2705 and ICT 2706 are cytotoxic for two 
types of human transfected cell lines (SW480_2W1 and HEK293_2W1). 
Moreover, ICT 2705 and ICT 2706 induced DNA damage in SW480_2W1 
transfected cells. These observations correspond to mock transfected cells 
(unpublished observations, Karolinska Institutet, Sweden; see Appendix N). 
 
The work described In this thesis showed that CYP 2W1 catalyzed the 
metabolism of ICT 2724, ICT 2726 and ICT 2727 though mass spectrometry 
data suggest the metabolites produced were not those anticipated to be 
cytotoxic i.e . did not resulting in spirocylisation. This finding was supported 
by the lack of cytotoxicity of these prodrugs when incubated in                  
HEK293_ 2W1 transfected cells. Moreover, these molecules can be usefully 
used as metabolic probes to monitor substrate- target interaction in tumours 
without causing toxicity. 
 
In contrast ICT 2706 showed a clear indication of a potential toxic metabolite 
when incubated in HEK293_ 2W1 cells transfected with CYP 2W1. This 
finding was explained by the high cytotoxicity of this prodrug in vitro when 
incubated in the presence of CYP 2W1. Pharmacokinetics results in this 
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thesis showed that ICT 2706 was well distributed in the plasma and tissues of 
mice and delivered significantly to the tumour.  
 
CYP 4F11 and cancer 
it has been shown that the expression of CYP 4F11 is very high in bladder 
cancer tissues and high in both lung and colon cancer tissues (J. Gill, see 
Appendix L). 
 
CYP 4F11 mRNA is principally expressed in the human liver followed by the 
kidneys, heart, skeletal muscle and brain. This gene encodes the CYP 4F11 
enzyme (Kalsotra et al., 2004). Compared to normal tissues, the expression 
of CYP 4F11 is not detected in colorectal cancer or in ovarian cancer, but it is 
expressed in prostate cancer. (F S Esaú, 2012)    
 
Human CYP 4F11 is known as one of 13 ‘orphans’ because of its unknown 
function (Tang et al., 2010). In this context, the findings regarding the 
selective substrate catalysed by a specific CYP isoform, first to monitor 
substrate-target interaction, second to determine therapeutic activity and 
pharmacokinetics, and third to monitor therapeutic responses in ‘clinically 
relevant’ tumour settings, are of the upmost importance for preclinical cancer 
pharmacology.  
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Other fatty acids have also been shown to suitable substrates for CYP 4F11 
(palmitic, oleic, arachidonic, and docosahaxaenoic acids) though palmitic acid 
was shown to be the substrate of choice (Tang et al 2010). 
 
VI.2. Future prospective 
Conventional chemotherapies rarely lack extremely unpleasant side-effects 
due to their poor selectivity for tumour cells. It must be kept in mind that the 
development of truly tumour-selective chemotherapeutic agents is an urgently 
needed improvement in the treatment of cancer patients. Additionally, the 
development of chemotherapeutic agents with indiscriminate toxicity is 
unacceptable in the future.  
As a result of the research performed in this project, further studies can be 
proposed which would strengthen the promising findings seen here.  
1) Further development of chloromethylindoline prodrugs 
 The compounds identified in this work could be viewed as lead 
compounds that require further optimisation to improve their 
pharmacokinetic profile and, more importantly, their water/lipophile 
balance since they are poorly water soluble and hence difficult to 
administer i.p. or i.v. 
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2)The work in this thesis investigated racemic chloromethylindolines 
 Further studies are required to explore whether enantiomeric forms (R 
& S) are preferentially metabolised, if so, this is relevant to the 
cytotoxic potential of these compounds. 
 Chiral columns are available to separate enantiomeric forms of the 
chloromethylindolines and it is now possible to investigate the 
influence of chirality on the metabolism, stability, pharmacokinetics 
and cytotoxicity of these agents, in particular ICT 2700. 
3) Regarding the CYP enzymes 
 Further investigations of the effect of chloromethylindolines on CYP 
enzyme induction and the effect of this on the metabolism of other 
agents that may be co-administered in a clinical setting. There is no 
current evidence to suggest chloromethylindolines have the ability to 
induce CYPs but drug interactions involving CYP induction with others 
agents are well know such as aminoflavone and phortress which able 
to induce CYP 1A1 expression by binding to AhR. 
4) The use of GSH forming adducts as a screen for future 
chloromethylindolines cytotoxicity 
 The ability of the cytotoxic metabolites to bind to GSH (as shown in 
this thesis) opens up the possibility of using this reaction in future 
studies to develop a relatively straight forward screen to detect the 
appearance of cytotoxic metabolites following incubations with CYPs. 
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Appendices 
 
Appendix A: Details of Human liver samples 
 
 ID Number Tissue 
Weight of 
specimen Sex Age Ethnicity 
1 ET-3124 Liver - Normal 1.0g Male n/a Caucasian 
2 ET-3127 Liver - Normal 1.2g Male 79 Caucasian 
3 ET-3136 Liver - Normal 1.0g Female 25 Caucasian 
4 ET-3274 Liver - Normal 1.1g Female 48 Caucasian 
5 ET-3275 Liver - Normal 1.1g Male 51 Caucasian 
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Appendix B: The experiments' incubation time 
 
 
 
 
 
 
 
 
 
 
 
Substrate Type of CYPs Incubation 
period 
Source of the 
enzyme 
ICT2700 CYP1A1, CYP1A2, CYP2D6, 
CYP3A4, MLiM, MLuM, MKM, 
HLM 
2hrs Bactosomes, 
Microsomes 
ICT2705 CYP1A1, CYP2D6, CYP3A4, 
MLiM 
2hrs Bactosomes, 
Microsomes 
ICT2726 CYP1A1, CYP2D6, CYP3A4, 
MLiM 
2hrs Bactosomes, 
Microsomes 
ICT2706 CYP2W1 7hrs SW480_2W1 
ICT2723 CYP2W1 7hrs HEK293_2W1 
ICT2724 CYP2W1 7hrs HEK293_2W1 
ICT2725 CYP2W1 7hrs HEK293_2W1 
ICT2726 CYP2W1 7hrs HEK293_2W1, 
SW480_2W1,  
ICT2727 CYP2W1 7hrs HEK293_2W1 
ICT2728 CYP2W1 7hrs HEK293_2W1 
Palmitic acid MLiM, CYP4F11 2hrs Microsomes, 
HEK293_4F11 
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Appendix C: MTT assay 
 
 
In vitro cytotoxicity studies for testing of anticancer drugs require an assay for 
determining cell viability. This can be achieved by for example counting cells 
after staining with a dye  (trypan blue) or by measuring the incorporation of 
radioactive nucleotides ([3H]thymidine) during DNA synthesis. In this thesis a 
colorimetric assay was used at which MTT (3-(4, 5-dimethyl-2-thiazolyl)-2,5-
diphenyl-2H-tetrazolium bromide) is transformed to crystal purple formazan in 
living cells by mitochondrial reductase (Mosmann, 1983).  
 
N
N
NN
S
N
Br
mitochondrial
reductase
N
N
N
S
N
NH
   
MTT      Formazan 
Chemical structures of MTT and formazan: MTT is water soluble molecule 
that is yellow. Formazan is a water insoluble product and has a purple colour. 
This purple crystal dissolved in DMSO, a deep purple solution is formed, the 
absorbance of which can be read on a spectrophotometer at 540 nm. 
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Discard 
Hanks 
Appendix D: Drug uptake experimental design in human lung 
adenocarcinoma cell lines (A- 549) 
 
 
                                                                40µl 
1X107 cells / ml                                                                                   MeCN 
   (5X106 cells)               
   + Substrate                                             
                                                                                                                                                      
   
                                                                                                            Inject  
 
                                         
                           
 
                              
                        
 
 
 
20µl 
Supernatant 
Discard supernatant 
Wash cells in 50 µl Hanks 
Spin 
Resuspend in  
50 µl MeCN 
Spin 
Inject supernatant 
Spin 
Sample A 
Sample B 
Sample 50 µM 
Spin 
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Appendix E: potential metabolites of ICT 2700 
 
HN
CH3O
Cl
O
N
NH
C21H18ClN3O2
379.85
379.108755
C 66.40% H 4.78% Cl 9.33% N 11.06% O 8.42% 
 
 
HN
CH3O
Cl
O
N
NH
OH C21H18ClN3O3
395.85
395.103669
C 63.72% H 4.58% Cl 8.96% N 10.62% O 12.13% 
 
HN
CH3O
O
N
NH
Cl
HO
C21H18ClN3O3
395.85
395.103669
C 63.72% H 4.58% Cl 8.96% N 10.62% O 12.13% 
 
HN
N
Cl
O
NH
O CH3
OH
OH
C21H18ClN3O4
411.84
411.098584
C 61.24% H 4.41% Cl 8.61% N 10.20% O 15.54%  
Meta1 Hydroxylation1 
Meta3 Hydroxylation2 
ICT 2700 
Meta2 (ICT 2740) 
 Hydroxylation1 
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HN
CH3O
O
N
NH
O
C21H17N3O3
359.38
359.126992
C 70.18% H 4.77% N 11.69% O 13.36% 
 
HN
N
OH
O
NH
O CH3
C21H19N3O3
361.40
361.142642
C 69.79% H 5.30% N 11.63% O 13.28% 
 
 
HN
OH
Cl
O
N
NH
C20H16ClN3O2
365.82
365.093105
C 65.67% H 4.41% Cl 9.69% N 11.49% O 8.75% 
 
 
 
 
 
 
 
 
 
 
 
 
Meta4 Toxic 
Meta5 Non- toxic 
Meta6 Demethylation 
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Appendix F: potential metabolites of ICT 2705 
HN
N
Cl
O
NH
F
C20H15ClFN3O
367.81
367.088768
C 65.31% H 4.11% Cl 9.64% F 5.17% N 11.42% O 4.35% 
 
    
   
HN
N
Cl
O
NH
F
OH
C20H15ClFN3O2
383.81
383.083683
C 62.59% H 3.94% Cl 9.24% F 4.95% N 10.95% O 8.34%       
  
N
O
NH
HN
F
Cl
OH
OH
C20H15ClFN3O3
399.81
399.078597
C 60.08% H 3.78% Cl 8.87% F 4.75% N 10.51% O 12.01%                         
 
HN
N
O
NH
F
O
C20H14FN3O2
347.35
347.107005
C 69.16% H 4.06% F 5.47% N 12.10% O 9.21% 
 
HN
N
OH
O
NH
F
C20H16FN3O2
349.36
349.122655
C 68.76% H 4.62% F 5.44% N 12.03% O 9.16% 
 
 
ICT 2705 
Meta9 Toxic 
Meta10 Non-toxic 
 
Meta7 Hydroxylation1 
Meta8 Hydroxylation2 
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  Appendix G: potential metabolites of ICT 2726 
O
F
Cl
O
N
NH
C20H14ClFN2O2
368.79
368.072784
C 65.14% H 3.83% Cl 9.61% F 5.15% N 7.60% O 8.68% 
 
 
O
F
Cl
O
N
NH OH
C20H14ClFN2O3
384.79
384.067698
C 62.43% H 3.67% Cl 9.21% F 4.94% N 7.28% O 12.47% 
 
 
 
O
N
Cl
O
NH
F
OH
OH
C20H14ClFN2O4
400.79
400.062613
C 59.94% H 3.52% Cl 8.85% F 4.74% N 6.99% O 15.97%                         
 
  
O
O
N
NH
F
O
C20H13FN2O3
348.33
348.091021
C 68.96% H 3.76% F 5.45% N 8.04% O 13.78% 
 
O
N
OH
O
NH
F
C20H15FN2O3
350.35
350.106671
C 68.57% H 4.32% F 5.42% N 8.00% O 13.70% 
 
ICT 2726 
Meta11 Hydroxy1 
Meta12 Hydroxylation2 
Meta13 Toxic 
Meta14 Non-toxic 
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Appendix H: weight of mice tumour samples  
 
Samples set 1: 
 
Time of incubation Weight (g) 
Pre-drug 0.0125 
5 min 0.0377 
30 min 0.0273 
1 hour 0.0215 
4 hours 0.0775 
24 hours 0.0121 
 
Samples set 2: 
 
Time of incubation Weight (g) 
Pre-drug 0.0297 
5 min 0.0042 
30 min 0.0133 
1 hour 0.0418 
4 hours 0.0212 
24 hours 0.0283 
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Appendix I: Calibration curves of ICT 2706 in MeOH, blank 
plasma of mouse and random mouse tumour.  
 
In MeCN        
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
2706 Conc. In MeCN µg/ml peak area (AU) at DAD 322nm 
0 < 10 
0.2 320 
0.4 691 
0.6 887 
0.8 1191 
1 1218 
2 2887 
4 5642 
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In blank plasma of mouse        
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
2706 Conc. In plasma µg/ml  peak area (AU) at DAD 322 nm 
0 < 10 
0.2 304 
0.4 604 
0.6 964 
0.8 1177 
1 1376 
2 3044 
4 6049 
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In random mouse tumour       
 
 
2706 Conc. In tumour µg/ml peak area (AU) at DAD (320nm 
0 < 10 
0.2 371 
0.4 713 
0.6 864 
0.8 1176 
1 1530 
2 3001 
4 5389 
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Appendix J: the expression of CYP1A1, 1A2 and 1B1 in clinical 
bladder samples, normal human tissues and bladder cancer cell 
lines. (Sutherland et al., 2012) 
 
 
A-C, constitutive expression of the aryl hydrocarbon receptor regulated CYP1A1, 1A2 and 1B1, 
respectively, in clinical bladder tumours and corresponding normal bladder tissue measured by real-
time RT-PCR (qRT-PCR). D, expression of CYP1A1, 1A2 and 1B1 in a panel of 20 different normal 
tissues and the bladder cell lines RT112 and EJ138 measured by qRT-PCR. E, elevated expression of 
CYP1A1 in EJ138-CYP1A1 relative to mock-transfected EJ-138 cells.  
 
Undetected             Low           Moderate          High              Very High 
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Appendix K: In vitro chemosensitivity test of selected 
chloromethylindoline prodrugs in HEK293 cells expressing 
CYP2W1 or CYP4F11 compared to wild type (Shnyder et al., 
unpublished) 
 
 
 
 
Figure A shows significant difference between the toxicity of some chloromethylindoline prodrugs 
including (2700, 2705 and 2706) in cells expressing CYP2W1 compared to wild type. Figure B shows 
no significant difference between the toxicity of the chloromethylindoline prodrugs in cells 
expressing CYP4F11 compared to wild type. 
A 
B 
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Appendix L: Expression of CYP4F11 in Bladder, Colon, Lung 
tumours comparing to normal tissues (Gill et al., unpublished)) 
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Appendix M: Expression levels of the CYP1 family in the cell 
lines RT-112, EJ-138 and A-549 (Sutherland et al., unpublished) 
 
 
 
Relative CYP1 expression levels in the cell lines RT112, EJ138 and A549. Total RNA was reverse 
transcribed and CYP1A1, 1A2 and 1B1 amplified using specific primers. The samples were 
analysed by agarose gel electrophoresis and the intensity of bands compared to the control 
GAPDH. Level of expression: negative < 0.5, low 0.5 – 1.5, moderate 1.5 – 2.5 and high  2.5 
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Appendix N: in vitro cytotoxicity of ICT2705, ICT2706 and 
ICT2726 in two types of human transfected cell lines 
(SW480_2W1 and HEK293_2W1) and the DNA damage in 
SW480_2W1 transfected cells comparing to mock-transfected 
cells (M. Ingelman-Sundberg et al., unpublished) 
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Figure 1: CYP2W1- mediated cytotoxicity of ICT2705, ICT2706 and ICT2726 in SW480_2W1 and 
HEK293_2W1 transfected cells comparing to wiled types 
 
 
 
 
Figure 2: dsDNA breaks formation in SW480_2W1 transfected cells comparing to mock-
transfected cells (immunodetection of phosphor-H2A-X) 
 
